

Clinical Study Protocol

NCT Number: NCT03283085

Title: A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Study Number: SHP647-304

Document Version and Date: Amendment 4, 21 September 2020

Certain information within this document has been redacted (ie, specific content is masked irreversibly from view) to protect either personally identifiable information or company confidential information.

Fornon-commercial US



PROTOCOL: SHP647-304

TITLE:	A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
DRUG:	Ontamalimab (SHP647)
IND:	100,222
EUDRACT NO.:	2017-000574-11
SPONSOR:	Shire Human Genetic Therapies, Inc. ("Shire"), a wholly owned subsidiary of Takeda Pharmaceutical Company Limited 300 Shire Way, Lexington, MA 02421 US
PRINCIPAL/ COORDINATING INVESTIGATOR:	, MD, PhD
PROTOCOL	Protocol Amendment 4: 21 Sep 2020
HISTORY:	Protocol Amendment 3: 07 Nov 2019
	Protocol Amendment 2:17 Sep 2018
	Protocol Amendment): 18 Dec 2017
	Original Protocol: 13 Jul 2017

This document contains confidential and proprietary information of Shire and is disclosed pursuant to confidentiality and nondisclosure obligations. This information should be used solely for the purposes for which it was provided and should not be copied, shared with, or disclosed to any third party without the express written consent of Shire.

21 Sep 2020

PROTOCOL SIGNATURE PAGE

Sponsor's (Shire) Approval DocuSigned by:				
Signature:	(Date:		
		22-Sep-2020 19:05:54 JST		
, MD				

Investigator's Acknowledgement

I have read this protocol for Shire Study SHP647-304.

Title: A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA).

I have fully discussed the objective(s) of this study and the contents of this protocol with the sponsor's representative.

I understand that the information in this protocol is confidential and should not be disclosed, other than to those directly involved in the execution of the scientific/ethical review of the study, without written authorization from the sponsor. It is, however, permissible to provide the information contained herein to a subject in order to obtain their consent to participate.

I agree to conduct this study according to this protocol and to comply with its requirements, subject to ethical and safety considerations and guidelines, and to conduct the study in accordance with International Council for Harmonisation guidelines on Good Clinical Practice and with the applicable regulatory requirements.

I understand that failure to comply with the requirements of the protocol may lead to the termination of my participation as an investigator for this study.

I understand that the sponsor may decide to suspend or prematurely terminate the study at any time for whatever reason; such a decision will be communicated to me in writing. Conversely, should I decide to withdraw from execution of the study, I will communicate my intention immediately in writing to the sponsor.

(please hand print or type)	
Investigator Name and Address:	

SUMMARY OF CHANGES FROM PREVIOUS VERSION

	Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number Amendment Date Global/Region/Country/Site Spe			
4	21 Sep 2020	Global	
Protocol Amendment Summary and	l Rationale:		
The main purpose of SHP647-304 An	nendment 4 is to allow subjects with m	oderate to severe ulcerative colitis (UC)	
or Crohn's disease (CD) to enter this s	study following discontinuation of the	Phase 3 maintenance studies	
	e already enrolled in this study (SHP6		
active treatment to receive ontamalim	ab treatment under a reduced schedule	of assessments to minimize subject	
burden, as it is expected that this study	y will be completed in no more than 3	years (ie, by December 2023) if not	
terminated early. Certain types of pha	rmacodynamic assessments have been	reduced, and efficacy and	
pharmacokinetic assessments have be	en removed. Response to ontamalimab	treatment will be assessed throughout	
the study, and safety will continue to l	be monitored closely. The safety follow	v-up period has been reduced from	
16 weeks to 12 weeks, based on emerged	gent data on the half-life of ontamalim	ab (16 days).	
	^O		
If an efficacious dose is determined ba		• •	
	chosen after the analysis of data from	-	
double-blind and will continue as such until the induction study results become available (ie, unblinding will not			
occur until the final analysis of the induction studies is completed and the lowest effective dose determined), as it is			
planned that subjects will receive the lowest effective dose based on the results of the induction studies. In the			
occurrence that the analysis of these results demonstrates the efficacy of at least one of the doses investigated, this			
	ed open label in this study. If both dose		
· ·	ne lowest effective dose will be selecte	d. However, if no efficacious dose is	
found, then the study will be terminate	ed.		

Amendment 4 removes the planned direct-entry of new subjects with UC that was added with Amendment 3 (dated 07 Nov 2019). No subject new to the program had been enrolled directly prior to, nor since, the company decision to close the ontamalimab clinical development program.

This amendment also provides clarification around home administration of investigational product, a provision that has been implemented in response to the World Health Organization (WHO) officially declaring the novel Coronavirus a pandemic on 11 March 2020. This amendment incorporates changes to provide flexibility in timing of site visits, to identify home healthcare solutions as permitted by local regulations, and to maintain subject safety and confidentiality and study integrity in the context of healthcare delivery challenges presented by the COVID-19 pandemic.

The significant changes in SHP647-304 Protocol Amendment 4 relative to the previous edition, SHP647-304 Protocol Amendment 3, are captured below.

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Protocol Signature Page	Updated sponsor signatory.	Administrative change.	
Product Quality Complaints	Updated the email address for product quality complaints.	Administrative change.	
Global	Replaced electronic diary with memory aid throughout the document.	Memory aid can be applicable for this type of long-term study for practical reasons.	
Global	Removed direct-entry of subjects with UC.	Due to the discontinuation of the ontamalimab clinical trial program and because no subjects had been enrolled directly prior to this decision.	
Global	Changed the safety follow-up period from 16 weeks to 12 weeks.	Due to the emergent data on the half-life of ontamalimab (16 days).	
Global	Updated the term 'MAdCAM' to 'MAdCAM-1' throughout the document.	As per the latest version of the ontamalimab Investigator's Brochure, Edition 9.0.	
Study Synopsis, Number of Subjects (total and for each treatment arm)	Revised total sample size	Due to the early discontinuation of the induction (SHP647-301, SHP647-302, SHP647-305, and SHP647-306) and maintenance (SHP647-303 and SHP647-307) studies and the removal of the criteria for direct-entry of subjects with UC in Study SHP647-304.	
Study Synopsis, Site(s) and Region(s) Section 3.3, Sites and Regions	Updated the number of sites and the countries in which the study will be conducted.	To reflect the changes due to discontinuation of the induction and maintenance studies.	
Study Synopsis, Objectives Section 2.2, Study Objectives	Added a secondary objective to evaluate the maintenance of response to long-term treatment with ontamalimab as measured by the clinical composite score (for subjects with UC) or CDAI score (for subjects with CD) and biomarkers, with or without endoscopy.	The study drug will be available for those who have been benefiting from it.	

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
	Added text to report the discontinuation of the ontamalimab Phase 3 clinical development program and the intention to continue this long-term safety extension study, which is expected to be completed in no more than 3 years (ie, by December 2023) if not terminated early, to provide active treatment to subjects already enrolled who are responding to treatment and to subjects entering who have responded to active treatment.	of efficacy over placebo, this study will be terminated.	
Study Synopsis, Rationale Study Synopsis, Methodology Section 2.1, Rationale for the Study Section 3.1, Study Design Section 6.1.1, Blinding the Treatment Assignment	Added text to describe the unblinding of the study following the completion of the final analysis of the induction studies.	To reflect the discontinuation of ontamalimab Phase 3 clinical development program.	
Section 6.2.4, Unblinding the Treatment Assignment			

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number	Amendment Date	Global/Region/Country/Site Specific
4	21 Sep 2020	Global
Section(s) Affected by Change	Description of Change	Rationale
Study Synopsis, Methodology Section 3.1, Study Design and Flowchart	Addition of details about Direct to Patient [DTP] program/provision for home administration of investigational product. Added text that no additional subjects from the induction studies will be enrolled in Study SHP647-304.	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.
	Revised the criteria for enrollment from maintenance studies SHP647-303 and SHP647-307 into Study SHP647-304.	To reflect that the induction studies will no longer have active subjects due to the discontinuation of the program. To enable the subjects to continue active treatment who had ever responded to active treatment in the Phase 3 clinical development program.
	Removed pharmacokinetic and health outcome assessments. Updated randomization details.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program. To reflect the discontinuation of ontamalimab Phase 3 clinical development program.

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number	Amendment Date	Global/Region/Country/Site Specific
4	21 Sep 2020	Global
Section(s) Affected by Change	Description of Change	Rationale
Study Synopsis, Rationale Study Synopsis, Methodology Study Synopsis, Maximum duration of subject involvement in the study Section 3.1, Study Design and Flowchart Section 3.2, Duration and Study Completion Definition	Updated the subject's maximum duration of study participation from approximately 7 years to no more than 3 years (ie, a subject's participation is not planned to extend beyond 2023).	To more accurately reflect the expected maximum duration of study participation.
Study Synopsis, Maximum duration of subject involvement in the study Section 3.2, Duration and Study Completion Definition	Updated the time of study completion from approximately 7 years to no more than 3 years (ie, a subject's participation is not expected to extend beyond 2023).	To more accurately reflect the expected duration of the study based on changes to study plans.
Study Synopsis, Inclusion and exclusion criteria Section 4, Study Population	Revised inclusion criterion 3 describing the milestones that subjects who rollover from maintenance studies to Study SHP647-304 must meet. Reduced inclusion/exclusion criteria for subjects with CD.	To align with the change in study design and as per the early discontinuation of induction and maintenance studies and the removal of criteria for direct-entry of subjects with UC.
Study Synopsis, Endpoints and statistical analysis Section 9.7, Study Population	Reduced analysis sets.	Due to the early discontinuation of the study and limited sample size, previously planned analyses will no longer be conducted.
Study Synopsis, Safety Endpoints Study Synopsis, Secondary Endpoints	Updated endpoints to reflect the inclusion of maintenance discontinuation rollover subjects.	To align with the change in study entry criteria.
Section 9.8.1.1, Secondary Endpoints (Subjects with UC) Section 9.8.2.1, Secondary Endpoints (Subjects with CD) Section 9.9, Safety Analyses	Removed secondary and exploratory endpoints and assessments that are no longer applicable under Amendment 4.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Table 1, Schedule of Assessments –Treatment Year 1 (Subjects withUC)Table 2, Schedule of Assessments –	Updated the visit window for all study procedures (including safety follow-up) from ± 7 days to ± 10 days.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.	
Treatment Year 2 Through Year 3 and End of Study (Subjects with UC)	Specified that laboratory assessments will be performed by	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19])	
Table 3, Schedule of Assessments –Treatment Year 1 (Subjects withCD)	the central laboratory and 12-lead electrocardiogram will be read by the local reader.	or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Table 4, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with CD)	Added treatment response	To determine if subjects are receiving benefit from active treatment.	
Table 1, Schedule of Assessments – Treatment Year 1 (Subjects with UC), footnote "f"	Added footnote that in case of a DTP situation, some procedures will be performed by remote visits	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19])	
Table 2, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC), footnote "e"	via virtual communications.	or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Table 3, Schedule of Assessments – Treatment Year 1 (Subjects with CD), footnote "f"	st non		
Table 4, Schedule of Assessments Treatment Year 2 Through Year 3 and End of Study (Subjects with CD), footnote "e"	0		
Table 1, Schedule of Assessments –Treatment Year 1 (Subjects withUC), footnote "g"	Added footnote to allow clinical laboratory assays (liver function testing) to be done by local	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19])	
Table 2, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC), footnote "f"	laboratory in case of issues related to COVID-19 (or other similar pandemic).	or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Table 3, Schedule of Assessments – Treatment Year 1 (Subjects with CD), footnote "g"			
Table 4, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with CD), footnote "f"			

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Table 1, Schedule of Assessments – Treatment Year 1 (Subjects with UC), footnote "h"	Added footnote to specify that subjects performing home administrations consecutively for	To comply with the FDA requirements.	
Table 2, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC), footnote "g"	3 months will need to perform liver function testing per FDA requirement, which may be done locally if it is not possible to collect samples at the central		
Table 3, Schedule of Assessments – Treatment Year 1 (Subjects with CD), footnote "h"	laboratory.		
Table 4, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with CD), footnote "g"			
Table 1, Schedule of Assessments –Treatment Year 1 (Subjects withUC), footnote "m"	Updated language to specify that endoscopy (flexible sigmoidoscopy or colonoscopy for subjects with	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.	
Table 2, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC), footnote "k"	UC)/colonoscopy (for subjects with CD) is optional; that, if performed, the results are to be recorded; and that if more than 2 endoscopies/colonoscopies are		
Table 3, Schedule of Assessments –Treatment Year 1 (Subjects withCD), footnote "m"	needed in a year, the subject should be discontinued.		
Table 4, Schedule of Assessments Treatment Year 2 Through Year 3 and End of Study (Subjects with CD), footnote "k"	0		
Section 7.3.2.1, Endoscopy			
Section 7.3.3.1, Colonoscopy			

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Table 1, Schedule of Assessments – Treatment Year 1 (Subjects with UC), footnote "p"	Added footnote to report the assessment of treatment response and also to clarify that it is applicable only after the	To align with the change in study design as per the early discontinuation of induction and maintenance studies.	
Table 2, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC), footnote "n"	implementation of Amendment 4.		
Table 3, Schedule of Assessments – Treatment Year 1 (Subjects with CD), footnote "p"			
Table 4, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with CD), footnote "n"			
Table 1, Schedule of Assessments –Treatment Year 1 (Subjects withUC), footnote "q"	Updated the duration for the entry of subject data from 10 days (for subjects with UC) before each	To adopt for memory aid data collection.	
Table 2, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC), footnote "o"	specified visit and 14 days (for subjects with CD) before each specified visit (using diaries) to 7 days (for all subjects) before		
Table 3, Schedule of Assessments – Treatment Year 1 (Subjects with CD), footnote "q"	each specified visit (using memory aids).		
Table 4, Schedule of Assessments Treatment Year 2 Through Year 3 and End of Study (Subjects with CD), footnote "o"	0		
Section 7.3.2.2, Mayo Score			
Section 7.3.2.3, Ulcerative Colitis Memory Aid			
Section 7.3.3.3, Crohn's Disease Activity Index			
Section 7.3.3.4, Crohn's Disease Memory Aid			

Protocol Amendment				
Summary of Change(s) Since the Last Version of the Approved Protocol				
Amendment Number	Amendment Date	Global/Region/Country/Site Specific		
4	21 Sep 2020	Global		
Section(s) Affected by Change	Description of Change	Rationale		
Table 1, Schedule of Assessments – Treatment Year 1 (Subjects with UC), footnote "t" Table 2, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC), footnote "q"	Addition of details around DTP program/provision for home administration of investigational product.	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.		
Table 3, Schedule of Assessments – Treatment Year 1 (Subjects with CD), footnote "t"				
Table 4, Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with CD), footnote "q"				
Table 2, Schedule of Assessments –Treatment Year 2 Through Year 3and End of Study (Subjects withUC)Table 4, Schedule of Assessments –Treatment Year 2 Through Year 3and End of Study (Subjects withCD)	Revised tables to reflect duration of treatment. Added note on study participation extending beyond Year 3.	To reflect the discontinuation of ontamalimab Phase 3 clinical development program.		
Section 2.2, Study Objectives	Removed the secondary and exploratory objectives that are no longer applicable under Amendment 4.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.		
Section 3.1, Study Design and Flow Chart	Added study design flow chart for subjects enrolling under Amendment 4 (Figure 1).	To show the change in study design and treatment allocation of subjects entering from the discontinued maintenance studies.		
Section 3.2, Duration and Study Completion Definition Section 7.2, Study Schedule	Updated subject's expected maximum study duration and overall study duration to no more than 3 years.	To reflect the discontinuation of ontamalimab Phase 3 clinical development program.		
	Added text on allowing EOT and 12-week safety follow-up visits to be conducted at subject's home due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.		

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Study Synopsis, Methodology Section 4.4.1, Loss of Response	Added the steps to be performed if the response criteria are not satisfied.	To facilitate correct clinical judgment.	
Section 4.4.2, Subject Withdrawal Criteria	Removed information around treatment failure assessment and stopping criteria.	An even stricter criterion (treatment response/loss of treatment response) will guide study drug and study discontinuation.	
	Added text regarding subject withdrawal from the study due to personal concerns related to COVID-19 (or other similar pandemic).	To address the situation if the subject withdraws from the study due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Section 4.4.3, Reason for Withdrawal	Replaced the term 'treatment failure' with 'loss of response'. Added text regarding subject withdrawal from the study due to personal concerns related to COVID-19 (or other similar pandemic).	To reflect the discontinuation of ontamalimab Phase 3 clinical development program. To address the situation if the subject withdraws from the study due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Section 5, Prior and Concomitant Treatment	Added text around change in permitted treatment when the subject is known to have been infected with the COVID-19 virus (Section 5.3). Updated details on permitted glucocorticoid use and prior treatments.	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Section 6.2.2, Allocation of Subjects to Treatment	Added text to specify dose allocation in subjects who withdrew from Studies SHP647-303 or SHP647-307.	To provide the dose allocation for the maintenance discontinuation rollover subjects with the change in study entry criteria.	

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Section 6.2.3, Dosing	Addition of details around DTP program/provision for home administration of investigational product, which has been implemented due to the COVID-19 pandemic situation. Added the criteria of delayed dosing and missed dosing due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Section 6.3.2, Packaging	Updated the packaging of pre-filled syringe from tray to foam insert.	To accurately describe study drug packaging.	
Section 6.3.3, Storage	Added the storage condition for the investigational product in case of DTP program/provision for home administration of investigational product.	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Section 6.3.4, Special Handling	Added the special handling of the investigational product in case of DTP program/provision for home administration of investigational product.	To comply with study procedures of as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Section 6.4, Drug Accountability	Added text related to the documentation of investigational product administration in case of DTP program/provision. Added text related to shipping of used investigational product to the site in case of DTP.	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Section 7.1, Changes to Study Procedures Due to a Pandemic	Added new section to address the changes to study procedures due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Section 7.2, Study Schedule	Updated details regarding the study baseline visit.	To reflect the discontinuation of ontamalimab Phase 3 clinical development program.	
	Updated the window for the safety follow-up visit to ± 10 days from ± 7 days for subjects with UC (Section 7.2.1.3) and subjects with CD (Section 7.2.2.3).	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.	
Section 7.3.2, Treatment Response Assessments – Subjects with Ulcerative Colitis	Added note that Mayo composite score will be computed only if an endoscopy is performed. Reduced signs and symptoms to be collected from subjects.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.	
Section 7.3.3.4, Crohn's Disease Memory Aid	Added information to be collected from subjects with the option of a memory aid.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.	
Section 7.3.4.3, Targeted Neurological Assessment	Added text on the assessment of potential PML following unblinding of the study. Added figure on post-unblinding process for quarterly neurological assessments.	To reflect the discontinuation of ontamalimab Phase 3 clinical development program.	
Section 7.3.4.6, Clinical Laboratory Evaluations	Added text to allow clinical laboratory assays to be done by local laboratory in case of issues related to COVID-19 (or other similar pandemic). Added liver function test (local laboratory) for subjects performing	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
	home administration consecutively for 3 months.	To comply with the FDA requirements.	

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Section 7.3.4.8, Electrocardiogram	Changed the ECG reading from central to local. Added details on performance of ECG in case of COVID-19-related or other pandemic-related issues.	To comply with study procedures as per the protocol due a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Section 7.3.4.11, Colonoscopy in Subjects at Elevated Risk of Colorectal Cancer	Added language to specify that colonoscopy is not required by the protocol.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.	
Section 7.3.5, Others	Removed the sections on health-related quality-of-life assessments and healthcare resource utilization assessments.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.	
Section 7.3.5.1, Pharmacodynamic Assessments Section 7.3.6, Volume of Blood to	Removed laboratory assessments for serum soluble MAdCAM-1 and blood β_7^+ T cells.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.	
be Drawn from Each Subject	Removed antidrug antibody and neutralizing antibody sampling. Updated volume of blood to be		
Section 9.4, Statistical Analysis Process	drawn. Added text to clarify that changes to analysis will be described in the statistical analysis plan.	To address the impact of COVID-19 (or other similar pandemic) on data analysis.	
Section 9.5, Planned Interim Analysis, Adaptive Design, Data Monitoring Committee, and Hypersensitivity Adjudication Committee	Updated text regarding the use of a DMC until the time of unblinding. Removed text describing interim analyses and the use of a hypersensitivity adjudication committee.	To reflect the discontinuation of ontamalimab Phase 3 clinical development program.	
Section 9.6, Sample Size Calculation and Power Considerations	Added text to report the discontinuation of the ontamalimab Phase 3 clinical development program. Updated sample size projection for the enrollment of subjects from induction and maintenance studies and removal of planned projection of direct-entry of subjects with UC.	Revised projections due to plan of early discontinuation of induction and maintenance studies and the removal of criteria for direct-entry of subjects with UC.	
Section 9.8, Efficacy Analyses	Removed the efficacy endpoints that are no longer applicable after the implementation of Amendment 4.	To minimize the subject burden due to discontinuation of ontamalimab Phase 3 clinical development program.	

Protocol Amendment			
Summary of Cha	Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
4	21 Sep 2020	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Section 9.10, Other Analyses	Removed the section on PK and PD analyses.	As there will be no PK or PD analyses due to discontinuation of ontamalimab Phase 3 clinical development program.	
Section 10.2.3.2, Recording, Access, and Retention of Source Data and Study Documents	Added sentence on document retention requirement in case of DTP provision.	To comply with study procedures as per the protocol due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.	
Appendices	Added Summary of Changes of Protocol Amendment 3. Removed scales and assessments no longer applicable under Amendment 4.	Administrative change.	
	Removed Appendix 5, Determination of Failure or Intolerance to Prior Treatment for Ulcerative Colitis.		

See Appendix 1 for protocol history, including all amendments.

Page 18

EMERGENCY CONTACT INFORMATION

In the event of a serious adverse event (SAE), the investigator must fax or email the Shire "Clinical Study Serious Adverse Event and Nonserious AE as Required by the Protocol Form" within 24 hours to the Shire Global Drug Safety Department. The fax number and email address are provided on the form (sent under separate cover). A copy of this form must also be sent to the contract research organization (CRO)/Shire medical monitor using the details below.

Fax +1 484 595 8155 (Global)

Email drugsafety@shire.com

For protocol- or safety-related issues, the investigator must contact the medical monitor via the appropriate regional safety hotline (24 hours): cialus

North America:

PPD 24 Hour Safety Hotline: RTP +1 888 483 7729; Wilmington +1 800 201 8725

PPD 24 Hour Safety Hotline Fax: RTP +1 888 529 3580 or +1 919 654 3836; Wilmington +1 888 488 9697 or +1 919 654 3849

Latin America:

PPD 24 Hour Safety Hotline: +55 11 4504 4801

PPD 24 Hour Safety Hotline Fax: +55 11 3958 0983

Europe, the Middle East, and Africa; and Asia-Pacific:

PPD 24 Hour Safety Hotline: +44 1223 374 240

PPD 24 Hour Safety Hotline Fax: +44 1223 374 102

Page 19

PRODUCT QUALITY COMPLAINTS

Investigators are required to report investigational product quality complaints or nonmedical complaints to Shire within 24 hours. If requested, defective product(s) will be returned to the sponsor for inspection and analysis.

A product quality complaint includes any instances where there is an allegation or report relating to Shire licensed or investigational products, received in writing, electronically, or orally, which indicates an impact to a product's strength, identity, safety, purity, or quality, or which suggests that a product did not meet the criteria defined in the regulatory applications, licenses, or marketing authorizations for the product. Examples of investigational product quality complaints include, but are not limited to, the following:

Unit	 Capsule fill empty or overage Syringe leakage
issues	Bottle/vial fill shortage or overage Missing components
	Capsule/tablet damaged/broken Product discoloration
	Syringe/vial cracked/broken Oevice malfunction
Labeling	Label missing Incomplete, inaccurate, or
	• Leaflet or Instructions For Use (IFU) misleading labeling
	missing • Lot number or serial number missing
	Label illegible
Packaging	• Damaged packaging (eg, secondary, • Missing components within package
	primary, bag/pouch)
	• Tampered seals
_	Inadequate or faulty closure
Foreign	Contaminated product
material	Particulate in bottle/vial
	Particulate in packaging

Please report the product quality complaint using the "Product Complaint Data Collection Form" via the email address below:

ctmcomplaint@takeda.com

Telephone number (provided for reference if needed):

1 800 828 2088

Shire, Lexington, MA (USA)

For instructions on reporting AEs related to product complaints, see Section 8.2.2.

TABLE OF CONTENTS

PROTOCOL SIGNATURE PAGE	2
SUMMARY OF CHANGES FROM PREVIOUS VERSION	3
EMERGENCY CONTACT INFORMATION	18
PRODUCT QUALITY COMPLAINTS	19
TABLE OF CONTENTS	20
LIST OF TABLES	25
LIST OF FIGURES	
LIST OF APPENDICES	25
ABBREVIATIONS	26
STUDY SYNOPSIS	28
STUDY SCHEDULES	
1. BACKGROUND INFORMATION	51
 BACKGROUND INFORMATION	51
1.1.1 Ulcerative Colitis	51
1.1.2 Crohn's Disease	51
1.2 Product Background and Clinical Information	52
1.3 Benefit/Risk Assessment	53
2. STUDY OBJECTIVES AND PURPOSE	55
 1.2 Product Background and Chinear Information 1.3 Benefit/Risk Assessment. 2. STUDY OBJECTIVES AND PURPOSE 2.1 Rationale for the Study. 2.2 Study Objectives 2.2.1 Primary Objective . 	55
2.2 Study Objectives	57
2.2.1 Primary Objective	57
2.2.2 Secondary Objectives – Subjects with Ulcerative Colitis	57
2.2.3 Secondary Objectives – Subjects with Crohn's Disease	57
3. STUDY DESIGN	58
3.1 Study Design and Flow Chart	58
3.2 Duration and Study Completion Definition	62
3.3 Sites and Regions	62
4. STUDY POPULATION	
4.1 Eligibility Criteria – Subjects with Ulcerative Colitis	63
4.1.1 Inclusion Criteria	63
4.1.2 Exclusion Criteria	64
4.2 Eligibility Criteria – Subjects with Crohn's Disease	65
4.2.1 Inclusion Criteria	65
4.2.2 Exclusion Criteria	66
4.3 Reproductive Potential	67
4.3.1 Contraceptive Methods for Female Study Subjects	68

Shi		Page 21
	amalimab 647-304 Protocol Amendment 4 2	1 Sep 2020
	4.3.2 Contraceptive Methods for Male Study Subjects	70
	4.4 Withdrawal of Subjects	
	4.4.1 Loss of Response	71
	4.4.2 Subject Withdrawal Criteria	72
	4.4.3 Reasons for Withdrawal	72
	4.4.4 Subjects "Lost to Follow-up" Prior to Last Scheduled Visit	73
5.	PRIOR AND CONCOMITANT TREATMENT	74
	5.1 Prior and Concomitant Treatment – Subjects with Ulcerative Colitis	74
	5.1.1 Prior Treatment	74
	5.1.2 Concomitant Treatment	74
	5.1.2.1 Permitted Treatment	74
	5.1.2.2 Prohibited Treatment	75
	5.2 Prior and Concomitant Treatment – Subjects with Crohn's Disease	
	5.2.1 Prior Treatment	76
	5.2.2 Concomitant Treatment	76
	5.2.2.1 Permitted Treatment	76
	5.2.2.2 Prohibited Treatment	
	5.3 COVID-19	79
6.	5.2.2 Conconnent Treatment 5.2.2.1 Permitted Treatment 5.2.2.2 Prohibited Treatment 5.3 COVID-19 INVESTIGATIONAL PRODUCT Concentration 6.1 Identity of Investigational Product	80
	6.1 Identity of Investigational Product	80
	6.1.1 Blinding the Treatment Assignment	80
	6.2 Administration of Investigational Product(s)	80
	6.2.1 Interactive Response Technology for Investigational Product Management	nt80
	6.2.2 Allocation of Subjects to Treatment	81
	6.2.3 Dosing	82
	6.2.4 Unblinding the Treatment Assignment	83
	6.3 Labeling, Packaging, Storage, and Handling	84
	6.3.1 Labeling	84
	6.3.2 Packaging	85
	6.3.3 Storage	85
	6.3.4 Special Handling	86
	6.4 Drug Accountability	86
	6.5 Subject Compliance	
7.	STUDY PROCEDURES	
	7.1 Changes to Study Procedures Due to a Pandemic	88
	7.2 Study Schedule	
	7.2.1 Subjects with Ulcerative Colitis	90
	7.2.1.1Baseline Visit (Week 0/Day 1)	90

	7.2	.1.2	Treatment Period	90
	7.2	.1.3	Follow-up Period	91
	7.2.2	Subjects	with Crohn's Disease	91
	7.2	.2.1	Baseline Visit (Week 0/Day 1)	91
	7.2	.2.2	Treatment Period	92
	7.2	.2.3	Follow-up Period	93
	7.2.3	Addition	al Care of Subjects After the Study	93
	7.3 S	tudy Eva	luations and Procedures	93
	7.3.1	Demogra	phic and Other Baseline Characteristics	94
	7.3.2	Treatmen	nt Response Assessments – Subjects with Ulcerative Colitis	94
	7.3	.2.1	Endoscopy	94
	7.3	.2.2	Mayo Score	94
	7.3	.2.3	Ulcerative Colitis Memory Aid	96
	7.3.3	Treatmen	nt Response Assessments – Subjects with Crohn's Disease	96
	7.3	.3.1	Colonoscopy	96
	7.3	.3.2	Simple Endoscopic Activity Score for Crohn's Disease	97
		.3.3	Crohn's Disease Activity Index	98
	7.3	.3.4	Crohn's Disease Memory Aic	98
	7.3.4	Safety		99
	7.3	.4.1	Medical and Medication History	99
	7.3	.4.2	Physical Examination (Including Weight)	99
	7.3	.4.3	Targeted Neurological Assessment	100
	7.3	.4.4	Adverse Event Collection	102
	7.3	.4.5	Vital Signs	103
	7.3	.4.6	Clinical Laboratory Evaluations	103
	7.3	.4.7	Pregnancy Test and Follicle-stimulating Hormone Test	105
	7.3	.4.8	Electrocardiogram	106
	7.3	.4.9	Monitoring for Type I and Type III Immune Reactions	106
	7.3	.4.10	Evaluation of Increased Gastrointestinal Symptoms	107
	7.3	.4.11	Colonoscopy in Subjects at Elevated Risk of Colorectal Cancer	107
	7.3.5	Others		108
	7.3	.5.1	Pharmacodynamic Assessments	108
	7.3.6	Volume	of Blood to Be Drawn from Each Subject – All Subjects	108
8.	ADVERS	E AND S	ERIOUS ADVERSE EVENTS ASSESSMENT	110
	8.1 E	Definition	of Adverse Events, Period of Observation, Recording of Adverse	
	E			
	8.1.1	Severity	Categorization	110
	8.1.2	Relations	ship Categorization	111

8.1.3.1 Hypersensitivity 112 8.1.4 Outcome Categorization 114 8.1.5 Symptoms of the Disease Under Study 114 8.1.6 Clinical Laboratory and Other Safety Evaluations 114 8.1.7 Pregnancy 115 8.1.8 Abuse, Misuse, Overdose, and Medication Error 116 8.1.9 Unexpected Adverse Event 117 8.1.10 Suspected Unexpected Serious Adverse Reaction 117 8.2 Serious Adverse Event Procedures 117 8.2.1 Reference Safety Information 117 8.2.2 Reporting Procedures 117 8.2.3 Serious Adverse Event Definition 118 8.2.4 Serious Adverse Event Collection Time Frame 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 20 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9.1 Data Collection 123 9.1 Data Collection <	8.1.3 Adverse Events of Special Interest	112
8.1.5 Symptoms of the Disease Under Study 114 8.1.6 Clinical Laboratory and Other Safety Evaluations 114 8.1.7 Pregnancy. 115 8.1.8 Abuse, Misuse, Overdose, and Medication Error. 116 8.1.9 Unexpected Adverse Event. 117 8.1.10 Suspected Unexpected Serious Adverse Reaction 117 8.2.1 Reference Safety Information 117 8.2.2 Reporting Procedures 117 8.2.3 Serious Adverse Event Definition 118 8.2.4 Serious Adverse Event Collection Time Frame. 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9.1 Data Collection 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Adaptiv	8.1.3.1 Hypersensitivity	112
8.1.6 Clinical Laboratory and Other Safety Evaluations 114 8.1.7 Pregnancy	8.1.4 Outcome Categorization	114
8.1.7 Pregnancy 115 8.1.8 Abuse, Misuse, Overdose, and Medication Error 116 8.1.9 Unexpected Adverse Event 117 8.1.10 Suspected Unexpected Serious Adverse Reaction 117 8.2 Serious Adverse Event Procedures 117 8.2.1 Reference Safety Information 117 8.2.2 Reporting Procedures 117 8.2.3 Serious Adverse Event Definition 117 8.2.4 Serious Adverse Event Collection Time Frame 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9.1 Data Collection 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitor	8.1.5 Symptoms of the Disease Under Study	114
8.1.8 Abuse, Misuse, Overdose, and Medication Error 116 8.1.9 Unexpected Adverse Event 117 8.1.10 Suspected Unexpected Serious Adverse Reaction 117 8.2 Serious Adverse Event Procedures 117 8.2.1 Reference Safety Information 117 8.2.2 Reporting Procedures 117 8.2.3 Serious Adverse Event Definition 118 8.2.4 Serious Adverse Event Collection Time Frame 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125	8.1.6 Clinical Laboratory and Other Safety Evaluations	114
8.1.9 Unexpected Adverse Event 117 8.1.10 Suspected Unexpected Serious Adverse Reaction 117 8.2 Serious Adverse Event Procedures 117 8.2.1 Reference Safety Information 117 8.2.2 Reporting Procedures 117 8.2.3 Serious Adverse Event Definition 118 8.2.4 Serious Adverse Event Collection Time Frame 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126	8.1.7 Pregnancy	115
8.1.10 Suspected Unexpected Serious Adverse Reaction 117 8.2 Serious Adverse Event Procedures 117 8.2.1 Reference Safety Information 117 8.2.2 Reporting Procedures 117 8.2.3 Serious Adverse Event Definition 118 8.2.4 Serious Adverse Event Collection Time Frame 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9.1 Data Collection 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126 9.8 Efficacy Analyses 126 9.8.1 Trea		
8.2 Serious Adverse Event Procedures 117 8.2.1 Reference Safety Information 117 8.2.2 Reporting Procedures 117 8.2.3 Serious Adverse Event Definition 118 8.2.4 Serious Adverse Event Collection Time Frame 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 125 9.7 Study Population 126 9.8.1 Treatment Response Analyses – Subjects with Ulcerative Colitis 126 <t< td=""><td>8.1.9 Unexpected Adverse Event</td><td>117</td></t<>	8.1.9 Unexpected Adverse Event	117
8.2.1 Reference Safety Information 117 8.2.2 Reporting Procedures 117 8.2.3 Serious Adverse Event Definition 118 8.2.4 Serious Adverse Event Collection Time Frame 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9.1 Data Collection 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126 9.8 Efficacy Analyses 126 9.8.1 Treatment Response Analyses – Subjects with Ulcerative Colitis 126 9.8.2.1 Secondary Endpoints 127 9.9 <td< td=""><td>8.1.10 Suspected Unexpected Serious Adverse Reaction</td><td>117</td></td<>	8.1.10 Suspected Unexpected Serious Adverse Reaction	117
8.2.2 Reporting Procedures 117 8.2.3 Serious Adverse Event Definition 118 8.2.4 Serious Adverse Event Collection Time Frame. 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126 9.8 Efficacy Analyses 126 9.8.1 Treatment Response Analyses – Subjects with Ulcerative Colitis 126 9.8.2.1 Secondary Endpoints 126 9.8.2.1 Secondary Endpoints 127 9	8.2 Serious Adverse Event Procedures	117
8.2.3 Serious Adverse Event Definition 118 8.2.4 Serious Adverse Event Collection Time Frame 119 8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126 9.8.1 Treatment Response Analyses – Subjects with Ulcerative Colitis 126 9.8.2 Treatment Response Analyses – Subjects with Crohn's Disease 127 9.8.2.1 Secondary Endpoints 127 9.9 Safety Analyses 127 9.9 Safety Analyses 127	8.2.1 Reference Safety Information	117
8.2.4 Serious Adverse Event Collection Time Frame	8.2.2 Reporting Procedures	117
8.2.5 Serious Adverse Event Onset and Resolution Dates 119 8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting. 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126 9.8 Efficacy Analyses 126 9.8.1 Treatment Response Analyses – Subjects with Ulcerative Colitis 126 9.8.2.1 Secondary Endpoints 126 9.9 Safety Analyses 127 9.9 Safety Analyses 127 9.9 Safety Analyses 127 9.9 Safety Analyses 127 9.9 Safety Analyses 127 </td <td></td> <td></td>		
8.2.6 Fatal Outcome 119 8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126 9.7 Study Population 126 9.8 Efficacy Analyses 126 9.8.1.1 Secondary Endpoints 126 9.8.2.1 Secondary Endpoints 126 9.8.2.1 Secondary Endpoints 127 9.9 Safety Analyses		
8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting. 120 8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury 120 9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126 9.8 Efficacy Analyses 126 9.8.1 Treatment Response Analyses – Subjects with Ulcerative Colitis 126 9.8.2.1 Secondary Endpoints 126 9.8.2.1 Secondary Endpoints 127 9.9 Safety Analyses 127 9.9 Safety Analyses 127 9.1 Sponsor's Responsibilities 129	8.2.5 Serious Adverse Event Onset and Resolution Dates	119
9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126 9.7 Study Population 126 9.8 Efficacy Analyses 126 9.8.1 Treatment Response Analyses – Subjects with Ulcerative Colitis 126 9.8.2 Treatment Response Analyses – Subjects with Crohn's Disease 127 9.9 Safety Analyses 127 9.9 Safety Analyses 127 9.1 Sponsor's Responsibilities 129	8.2.6 Fatal Outcome	119
9. DATA MANAGEMENT AND STATISTICAL METHODS 123 9.1 Data Collection 123 9.2 Clinical Data Management 123 9.3 Data Handling Considerations 123 9.4 Statistical Analysis Process 124 9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee 125 9.6 Sample Size Calculation and Power Considerations 126 9.7 Study Population 126 9.8 Efficacy Analyses 126 9.8.1 Treatment Response Analyses – Subjects with Ulcerative Colitis 126 9.8.2 Treatment Response Analyses – Subjects with Crohn's Disease 127 9.9 Safety Analyses 127 9.9 Safety Analyses 127 9.1 Sponsor's Responsibilities 129	8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committe Reporting	e, and Site 120
9.1Data Collection1239.2Clinical Data Management1239.3Data Handling Considerations1239.4Statistical Analysis Process1249.5Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee1259.6Sample Size Calculation and Power Considerations1269.7Study Population1269.8Efficacy Analyses1269.8.1Treatment Response Analyses – Subjects with Ulcerative Colitis1269.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Inju	ry120
9.1Data Collection1239.2Clinical Data Management1239.3Data Handling Considerations1239.4Statistical Analysis Process1249.5Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee1259.6Sample Size Calculation and Power Considerations1269.7Study Population1269.8Efficacy Analyses1269.8.1Treatment Response Analyses – Subjects with Ulcerative Colitis1269.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9. DATA MANAGEMENT AND STATISTICAL METHODS	
9.3Data Handling Considerations1239.4Statistical Analysis Process1249.5Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee1259.6Sample Size Calculation and Power Considerations1259.7Study Population1269.8Efficacy Analyses1269.8.1Treatment Response Analyses – Subjects with Ulcerative Colitis1269.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.1 Data Collection	
9.4Statistical Analysis Process1249.5Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee1259.6Sample Size Calculation and Power Considerations1259.7Study Population1269.8Efficacy Analyses1269.8.1Treatment Response Analyses – Subjects with Ulcerative Colitis1269.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints1279.9Safety Analyses1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.2 Clinical Data Management	
9.5Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee1259.6Sample Size Calculation and Power Considerations	9.3 Data Handling Considerations	
9.6Sample Size Calculation and Power Considerations.1259.7Study Population1269.8Efficacy Analyses.1269.8.1Treatment Response Analyses – Subjects with Ulcerative Colitis1269.8.1.1Secondary Endpoints.1269.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints.1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.4 Statistical Analysis Process	
9.7Study Population1269.8Efficacy Analyses1269.8.1Treatment Response Analyses – Subjects with Ulcerative Colitis1269.8.1.1Secondary Endpoints1269.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring C	Committee 125
9.8Efficacy Analyses1269.8.1Treatment Response Analyses – Subjects with Ulcerative Colitis1269.8.1.1Secondary Endpoints1269.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.6 Sample Size Calculation and Power Considerations	
9.8.1Treatment Response Analyses – Subjects with Ulcerative Colitis1269.8.1.1Secondary Endpoints1269.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.7 Study Population	
9.8.1.1Secondary Endpoints1269.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.8 Efficacy Analyses	
9.8.2Treatment Response Analyses – Subjects with Crohn's Disease1279.8.2.1Secondary Endpoints1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.8.1 Treatment Response Analyses – Subjects with Ulcerative Colitis.	
9.8.2.1Secondary Endpoints1279.9Safety Analyses12710.SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.8.1.1 Secondary Endpoints	
9.9Safety Analyses12710. SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES12910.1Sponsor's Responsibilities129	9.8.2 Treatment Response Analyses – Subjects with Crohn's Disease	
10. SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES 129 10.1 Sponsor's Responsibilities 129	9.8.2.1 Secondary Endpoints	
10.1Sponsor's Responsibilities	9.9 Safety Analyses	
	10. SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES	
10.1.1. Good Clinical Practice Compliance 129	10.1 Sponsor's Responsibilities	
	10.1.1 Good Clinical Practice Compliance	
10.1.2 Indemnity/Liability and Insurance	10.1.2 Indemnity/Liability and Insurance	130
	10.1.3 Public Posting of Study Information	130
	10.1.3 Public Posting of Study Information	

Shire	
Ontamalimab	
SHP647-304 P	rotocol Amendment 4

10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities of Member States Concerned and Ethics Committees	
10.1.5 Study Suspension, Termination, and Completion	
10.1.5Study Suspension, Termination, and Completion10.2Investigator's Responsibilities	
10.2.1 Good Clinical Practice Compliance	
10.2.2 Protocol Adherence and Investigator Agreement10.2.3 Documentation and Retention of Records	
10.2.3.1 Case Report Forms	132
10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents	122
10.2.3.3 Audit/Inspection	
10.2.3.4 Financial Disclosure	
10.2.3.4 Financial Disclosure	
10.3.1 Informed Consent.10.3.2 Institutional Review Board or Ethics Committee	134
10.3.2 Institutional Review Board or Ethics Committee	134
10.4 Privacy and Confidentiality	135
10.5 Study Results/Publication Policy	136
11. REFERENCES	138
10.3.2 Institutional Review Board or Ethics Committee 10.4 Privacy and Confidentiality 10.5 Study Results/Publication Policy 11. REFERENCES	

LIST OF TABLES

Table 1	Schedule of Assessments – Treatment Year 1 (Subjects with UC)
Table 2	Schedule of Assessments – Treatment Year 2 Through Year 3 and End
	of Study (Subjects with UC)41
Table 3	Schedule of Assessments – Treatment Year 1 (Subjects with CD)44
Table 4	Schedule of Assessments – Treatment Year 2 Through Year 3 and End
	of Study (Subjects with CD)
Table 5	Glucocorticoid Tapering – Subjects with Ulcerative Colitis
Table 6	Glucocorticoid Tapering – Subjects with Crohn's Disease77
Table 7	Quarterly Neurological Assessments
Table 8	Volume of Blood to Be Drawn from Each Subject – Treatment Year 1
	(All Subjects)
Table 9	Volume of Blood to Be Drawn from Each Subject – Treatment Year 2
	Through Year 3 (All Subjects)
Table 10	Clinical Criteria for Diagnosing Anaphylaxis (Type 1
	Hypersensitivity)
Table 11	Safety Monitoring Rules for Treatment-emergent Elevated ALT and/or
	Bilirubin

LIST OF FIGURES

Figure 1	Study Design Flow Chart for Subjects who Enter SHP647-304 Under Amendment 4	
-	Amendment 4	61
Figure 2	Flow Diagram for Quarterly Neurological Assessments	101
Figure 3	Post-unblinding Flow Diagram for Quarterly Neurological	
	Assessments	102
Figure 4	Potential Immunogenicity of Therapeutic Monoclonal Antibodies	112

LIST OF APPENDICES

Appendix 1	Protocol History	140
Appendix 2	Scales and Assessments	199
Appendix 3	Glucocorticoid Equivalent Doses	207
Appendix 4	Guidance for Diagnosis and Treatment of Increased Gastrointestinal	
	Symptoms	208

21 Sep 2020

ABBREVIATIONS

5-ASA	5-aminosalicylic acid
6-MP	6-mercaptopurine
ADA	antidrug antibody
AE	adverse event
AESI	adverse event of special interest
ALT	alanine aminotransferase
AUC	area under the concentration-time curve
AZA	azathioprine
β-hCG	beta-human chorionic gonadotropin
CD	Crohn's disease
CDAI	Crohn's Disease Activity Index
CNS	Crohn's Disease Activity Index central nervous system clinical research associate contract research organization C-reactive protein data monitoring committee ethics committee
CRA	clinical research associate
CRO	contract research organization
CRP	C-reactive protein
DMC	data monitoring committee
EC	ethics committee
ECCO	European Crohn's and Colitis Organisation
ECG	electrocardiogram
eCRF	electronic case report form
EMA	European Medicines Agency
EOT	end of treatment
ET	early termination
EU	European Union
FAS	full analysis set
FDA	Food and Drug Administration
FSH	follicle-stimulating hormone
GCP	Good Clinical Practice
GI	gastrointestinal
HIPAA	Health Insurance Portability and Accountability Act
hsCRP	high-sensitivity C-reactive protein
IB	Investigator's Brochure
IBD	inflammatory bowel disease
ICH	International Council for Harmonisation

21 Sep 2020

CONFIDENTIAL

IgG _{2κ}	immunoglobulin G2 kappa
IRB	Institutional Review Board
IRT	interactive response technology
MAdCAM-1	mucosal addressin cell adhesion molecule-1
MTX	methotrexate
NAb	neutralizing antibody
PFS	prefilled syringe
PGA	physician global assessment
РК	pharmacokinetic(s)
PML	progressive multifocal leukoencephalopathy
RB	rectal bleeding
RSI	reference safety information
SAE	serious adverse event
SAP	statistical analysis plan
SC	serious adverse event statistical analysis plan subcutaneous Simple Endoscopic Score for Crohn's Disease
SES-CD	Simple Endoscopic Score for Crohn's Disease
SMT	Safety Management Team
SOC	Safety Management Team system organ class
SUSAR	suspected unexpected serious adverse reaction
ТВ	Mycobacterium tuberculosis
TEAE	treatment-emergent adverse event
TNF	tumor necrosis factor
UC	ulcerative colitis
ULN	upper limit of normal

STUDY SYNOPSIS

Protocol number: SHP647-304	Drug: Ontamalimab (SHP647)	
Title of the study: A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects with Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)		
Number of subjects (total and for each A maximum of 451 subjects are projected		
Investigator(s): Multicenter study		
Site(s) and Region(s): This study will be conducted in approxim	nately 225 sites in approximately 33 countries.	
Study period (planned): 2018 – 2023	Clinical phase: 3	
Objectives:		
 Primary: To evaluate the safety and tolerability of long-term treatment with ontamalimab in subjects with moderate to severe ulcerative colitis (UC) or Crohn's disease (CD). Secondary - Subjects with Ulcerative Colitis: 		
 To evaluate the maintenance of response to long-term treatment with ontamalimab as measured by clinical composite score and biomarkers, with or without endoscopy. 		
Secondary - Subjects with Crohn's Disease:		
• To evaluate the maintenance of response to long-term treatment with ontamalimab as measured by Crohn's Disease Activity Index (CDAI) score and biomarkers, with or without endoscopy.		
the closure of the ontamalimab Phase 3 of studies for subjects with moderate to sev Per the announcement, the induction and recognition that this could potentially ca treatment (ie, fulfilling treatment respon- safety extension study, which is expected continue to provide active treatment to s entering from a maintenance study who	quired Shire, the sponsor of this study. On 29 May 2020, Takeda announced clinical development program, which included induction and maintenance vere inflammatory bowel disease who had failed at least 1 prior treatment. I maintenance studies will be closed earlier than originally planned. In use hardships for subjects who were benefiting from this investigational se criteria as defined in Section 9.8.1.1 and Section 9.8.2.1), this long-term d to be completed in no more than 3 years (ie, by December 2023), may ubjects already enrolled who are responding to treatment and to subjects have responded to treatment (ie, in the induction or maintenance studies and f the results of the induction or maintenance studies show that ontamalimab placebo, this study will be terminated.	
Originally, this extension study was desi	gned to evaluate the safety and efficacy of long-term treatment with	

Originally, this extension study was designed to evaluate the safety and efficacy of long-term treatment with ontamalimab in subjects with moderate to severe UC or CD who: (1) completed one of the 4 multicenter, randomized, double-blind, placebo-controlled, parallel-group studies evaluating ontamalimab as an induction therapy (SHP647-301, SHP647-302, SHP647-305, or SHP647-306) and did not meet the response criteria (clinical and/or endoscopic response/remission as appropriate) required for entry into a maintenance study (SHP647-303 or SHP647-307), or (2) were treatment failures (as defined in the respective protocols) and/or completers in one of the 2 multicenter, double-blind, randomized, placebo-controlled, parallel-group studies evaluating ontamalimab as maintenance therapy (SHP647-303 or SHP647-307). This study has been double-blind and will continue as such until the induction study results become available (ie, unblinding will not occur until the final analysis of the induction studies is completed and the lowest effective dose determined), as it is planned that subjects will receive

the lowest effective dose based on the results of the induction studies. It is expected that the analysis of these results will demonstrate the efficacy of at least one of the doses and allow for the selection of a single dose, at which time this study will be open label. If both doses are effective and the difference compared to placebo is similar, then the lowest effective dose will be selected. However, if the results of the induction or maintenance studies show that ontamalimab does not have evidence of efficacy over placebo, this study will be terminated.

Subjects in the induction studies SHP647-301 or SHP647-302:

• As of September 2020, no subjects remain in the induction studies who would be eligible to participate in this study (SHP647-304); therefore, no additional subjects from the induction studies will enter this study under Amendment 4.

Subjects in the maintenance studies SHP647-303 or SHP647-307:

- Subjects who received and responded to active treatment in either or both of the induction or maintenance studies may be eligible to enter this study.
- Subjects who have not received ontamalimab yet (ie, received placebo in both the induction and maintenance studies) will not be eligible to enter this study.
- Subjects eligible to enter this study will be assessed for treatment response criteria according to the revised study schedule in Study SHP647-304.

Subjects currently in Study SHP647-304 (ie, enrolled prior to Amendment 4) will be assessed for treatment response as follows:

- Subjects who have already entered Study SHP647-304 may continue and will be assessed for treatment response according to the revised study schedule. If they show response to ontamalimab treatment, they may continue further in this study.
- If the results of the induction or maintenance studies show that ontamalimab does not have evidence of efficacy over placebo, this study will be terminated.

All subjects will be evaluated periodically and in case of clinical worsening at an unscheduled visit during the study for treatment response. If a subject shows response to ontamalimab treatment, he or she may continue in this study either until he or she shows a loss of treatment response (ie, no longer meets response criteria) or elects to seek another treatment option, or until the end of the study.

Investigational product, dose, and mode of administration:

The test product is ontamalimab, which will be provided as a sterile aqueous buffered solution for subcutaneous (SC) administration in a glass prefilled syringe (PFS) with a fixed needle. Each PFS contains 1 mL of ontamalimab solution for injection at an appropriate concentration to provide the intended dose of drug (25 mg or 75 mg). Additional information is provided in the current ontamalimab Investigator's Brochure.

Methodology:

This is a Phase 3 multicenter extension study designed to evaluate the long-term safety of ontamalimab in subjects with moderate to severe UC or CD. The study has enrolled subjects from 6 separate Phase 3 studies to date: 4 multicenter, randomized, double-blind, placebo-controlled, parallel-group studies evaluating ontamalimab as an induction therapy in subjects with moderate to severe UC (SHP647-301 and SHP647-302) or CD (SHP647-305 and SHP647-306); and 2 multicenter, double-blind, randomized, placebo-controlled, parallel-group studies evaluating ontamalimab as maintenance therapy in subjects with moderate to severe UC (SHP647-303) or CD (SHP647-307). As the induction and maintenance studies will be closed earlier than planned, the study will enroll

subjects with moderate to severe UC and CD from the 2 maintenance studies (at the time of their closure) who have responded to active treatment. As the 4 induction studies do not have any subjects eligible for rollover to the SHP647-304 study, no additional subjects will enter from those studies.

This study is planned to become a single-dose study, with the dose to be determined after the analysis of data from the induction studies. This study has been double-blind and will continue as such until the induction study results become available (ie, unblinding will not occur until the final analysis of the induction studies is completed and the lowest effective dose determined), as it is planned that subjects will receive the lowest effective dose based on the results of the induction studies. It is expected that the analysis of these results will demonstrate the efficacy of at least one of the doses and allow for the selection of a single dose, at which time this study will be open label. If both doses are effective and the difference compared to placebo is similar, then the lowest effective dose will be selected. However, if the results of the induction or maintenance studies show that ontamalimab does not have evidence of efficacy over placebo, this study will be terminated.

All subjects will receive active drug in this study. Eligible subjects entering Study SHP647-304 will be assigned to continue their present dose of ontamalimab (if currently receiving active drug) or to return to the dose of active drug associated with previous response (if on placebo). Ongoing subjects in this study will remain on the dose to which they have been previously assigned. Once the final dose has been determined, all subjects will continue on that dose only.

Subjects will come to the investigational site every 4 weeks (unless unable to participate on site due to the ongoing COVID-19 pandemic [or other similar pandemic], in which case they may qualify for the "Direct to Patient" [DTP] program) for investigational product administration and appropriate assessments.

The eligibility of a subject for this study will be assessed from study data collected at the following time points:

- For subjects with UC, the Week 12 visit of the induction study (SHP647-301 or SHP647-302) OR the Week 52 or Early Termination (ET) visit of the maintenance study (SHP647-303), which are considered and recorded as the baseline visit for this extension study (with the exception of the treatment response evaluation, for which baseline of the induction study will be used as baseline of this extension study). No additional subjects from the induction studies will be enrolling into Study SHP647-304. Subjects from the maintenance study (SHP647-303) will have the opportunity to enroll into this study at the time of the approval of Amendment 4 if they have benefited from active treatment in the induction or maintenance study.
- For subjects with CD, the Week 16 visit of the induction study (SHP647-305 or SHP647-306), OR the ET or Week 52 visit of the maintenance study (SHP647-307), which will be considered and recorded as the baseline visit for this extension study (with the exception of the treatment response evaluation, for which baseline of the induction study will be used as baseline of this extension study), with an additional window of 1 week for subjects whose treatment failure status is still under evaluation at the time of the Week 52 visit of the maintenance study. No additional subjects from the induction studies will be enrolling into Study SHP647-304. Subjects from the maintenance study (SHP647-307) will have the opportunity to enroll into this study at the time of the approval of Amendment 4 if they have benefited from active treatment in the induction or maintenance study.

Subjects enrolled in this study will receive treatment every 4 weeks, in the form of SC injections using PFSs. Subjects will undergo treatment response and safety assessments.

At every third visit, subjects with UC will be assessed for ongoing benefit (treatment response) using the clinical composite score or composite score. To facilitate data collection and reliability, subjects will have the option to use a memory aid. Endoscopies are not required, but if performed (eg, for routine surveillance), it is recommended that

the Mayo endoscopic subscore be recorded by the endoscopist for assessment. The total Mayo score will be calculated only when endoscopy data are available. The partial Mayo score consists of the Mayo score without the endoscopic subscores. The composite score is a recommended measure consisting of the Mayo score without the physician global assessment (PGA) subscore. The clinical composite score is a measure consisting of rectal bleeding (RB) plus stool frequency without the endoscopic and PGA subscore. The data for Mayo scores and composite score will be collected from subjects, who have the option of using a memory aid, for 7 days before each specified visit as in the schedules of assessments. Biomarkers (C-reactive protein [CRP] and fecal calprotectin) will be assessed every 3 months or in case there is a necessity to confirm the loss of clinical treatment response.

At every third visit, subjects with CD will be assessed for ongoing benefit (treatment response) using the CDAI score (treatment response defined as CDAI-100). Data on CDAI components (abdominal pain severity, very soft stool/liquid stool frequency, general well-being) will be collected from the subjects by the investigators. To facilitate data collection and reliability, subjects will have the option to use a memory aid. Endoscopies are not required, but if performed (eg, for routine surveillance), it is recommended that the Simple Endoscopic Score for Crohn's Disease (SES-CD) be recorded by the endoscopist for assessment. The CDAI is a composite measure with 8 components. Five components will be captured at the visits, and 3 components (abdominal pain severity, very soft stool/liquid stool frequency, and general well-being) will be collected from subjects, who have the option of using a memory aid, for 7 days before each specified visit as in the schedules of assessments. Biomarkers (CRP and fecal calprotectin) will be assessed every 3 months or in case there is a necessity to confirm the loss of clinical treatment response.

Treatment response will be assessed at every third visit for all subjects to allow monitoring of clinical benefit derived and evaluation of loss of response throughout the study. At these assessment visits, subjects' response will be evaluated and compared to the value of clinical composite score (for subjects with UC) or CDAI (for subjects with CD) determined at entry into the induction studies. As long as response criteria are satisfied, subjects may remain in the study. If there is a concern regarding loss of response between scheduled assessment visits, assessments may be performed at any scheduled or, if necessary, unscheduled visit to evaluate response. To ensure that placebo-treated subjects from a feeder study (SHP647-301, SHP647-302, SHP647-303, SHP647-305, SHP647-306, or SHP647-307) have sufficient exposure to active drug to permit assessment of treatment response, treatment response will be assessed according to the revised study schedule. Subjects may discontinue participation at any time, for any reason. If response to investigational product is lost, based on clinical criteria, or if there is an unexplained clinical exacerbation or unacceptably low level of clinical response the investigator may assess biomarkers and perform other investigations to exclude other potential causes like *Clostridium difficile* infection or an appropriate ad-hoc endoscopy to determine whether the loss of response is confirmed or not at an unscheduled visit. The totality of available data will be used to determine ongoing response status and subjects whose loss of response is confirmed.

If clinical response criteria are no longer satisfied and alternative explanations for clinical worsening (eg, infection) can be excluded, the subject will be discontinued. If necessary for assessment in the opinion of the investigator (eg, borderline treatment response results), the following evaluations may be considered:

1) Have subject return in 2 to 4 weeks for repeat assessment if loss of response criteria is still met:

a) Perform endoscopy to determine if there is an objective benefit despite clinical symptoms; if the composite of clinical and endoscopic data meets response criteria, continue the study.

Endoscopic response criterion for UC is Mayo endoscopic subscore decreased by
≥1 point as compared to the baseline value recorded upon entry into the induction studies.

- Endoscopic response criterion for CD is SES-CD improved by >25% as compared to the 2. baseline value recorded upon entry into the induction studies.
- b) Biomarkers may be used to determine overall response criteria at the discretion of the investigator; serum CRP < upper limit of normal or fecal calprotectin <250 μ g/g is considered indicative of clinical benefit.

Upon termination from the study, subjects must return for a safety visit 12 weeks after the last dose of investigational product.

Subjects who have experienced loss of response should be withdrawn from active treatment once other possible etiologies have been ruled out and appropriate clinical evaluation has been performed as suggested above. While these response criteria are offered as general guidance to the investigator, there may be additional criteria that warrant withdrawal from active treatment and the ultimate decision of withdrawal from active treatment is left to the investigator based on the assessment of disease activity, subject's clinical benefit and tolerance of the investigational product.

For subjects who are tolerating investigational product and receiving clinical benefit in the judgment of the investigator (ie, fulfilling treatment response criteria as defined in Section 9.8.1.1 and Section 9.8.2.1), study participation may continue until the subject withdraws from the study, or the investigator or sponsor decide to withdraw the subject (eg, in the interest of subject safety), or the sponsor decides to close the study, or the program is stopped completely. A subject's maximum duration of participation in this study under the current amendment is expected to be no more than 3 years (ie, a subject's participation is not planned to extend beyond 2023), subject to local or country requirements. Subjects will enter a 12-week safety follow-up period following the last dose of investigational product. omin

Inclusion and exclusion criteria:

Inclusion Criteria – Subjects with UC:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

- Subjects and/or their parent or legally authorized representative must have an understanding, ability, and 1 willingness to fully comply with study procedures and restrictions.
- 2. Subjects must be able to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent and/or assent, as applicable, to participate in the study.
- 3. Subjects must have been enrolled previously in Study SHP647-301 or SHP647-302 and are in the treatment period of Study SHP647-303, completed the ET or Week 52 visit in the maintenance study SHP647-303, had responded to ontamalimab treatment (in the induction and/or maintenance studies), and meet one of the following criteria:
 - o Subjects are on placebo at the maintenance study ET or Week 52 visit: they received ontamalimab in the induction studies and fulfilled the maintenance study response entry criteria, OR
 - Subjects have received ontamalimab at the maintenance study ET or Week 52 visit: 0
 - Clinical composite score that has decreased by ≥ 2 points and $\geq 30\%$, with an accompanying decrease in the subscore for $RB \ge 1$ point or a subscore for $RB \le 1$, compared to the baseline value for induction studies, AND/OR
 - Composite score that has decreased by $\geq 30\%$ and ≥ 3 points compared to the baseline value for induction studies.

4. Subjects receiving any treatment(s) for UC described in Section 5.2.1 are eligible provided they have been on a stable dose for the designated period of time.

Exclusion Criteria – Subjects with UC:

Subjects are excluded from the study if any of the following criteria are met:

- 1. Subjects who had major protocol deviation(s) (as determined by the sponsor) in Study SHP647-301, SHP647-302, or SHP647-303.
- 2. Subjects who permanently discontinued investigational product because of an adverse event (AE), regardless of relatedness to investigational product, in Study SHP647-301, SHP647-302, or SHP647-303.
- 3. Subjects who are likely to require major surgery for UC.
- 4. Subjects are females who became pregnant during Study SHP647-301, SHP647-302, or SHP647-303, females who are lactating, females who are planning to become pregnant during the study period, or males or females of childbearing potential not agreeing to continue using appropriate contraception methods (ie, highly effective methods for female and medically appropriate methods for male study subjects) through the conclusion of study participation.
- 5. Subjects who do not agree to postpone donation of any organ or tissue, including male subjects who are planning to bank or donate sperm and female subjects who are planning to harvest or donate eggs, for the duration of the study and through 16 weeks after last dose of investigational product.
- 6. Subjects who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
- 7. Subjects who have a newly-diagnosed malignancy or recurrence of malignancy (other than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
- 8. Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, gastrointestinal [GI] [except disease under study], endocrine, cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.
- 9. Subjects with any other severe acute or chronic medical or psychiatric condition or laboratory or electrocardiogram (ECG) abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- 10. Subjects with known exposure to *Mycobacterium tuberculosis* (TB) since testing at screening in Study SHP647-301 or SHP647-302 and who have been advised to require treatment for latent or active disease, but who are without a generally accepted course of treatment.
- 11. Subjects who are investigational site staff members or relatives of those site staff members or subjects who are sponsor employees directly involved in the conduct of the study.
- Subjects who are participating in other investigational studies (other than SHP647-301, SHP647-302, or SHP647-303) or plan to participate in other investigational studies during long-term extension study SHP647-304.

Inclusion Criteria – Subjects with CD:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

- 1. Subjects and/or their parent or legally authorized representative must have an understanding, ability, and willingness to fully comply with study procedures and restrictions.
- 2. Subjects must be able to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent and/or assent, as applicable, to participate in the study.
- 3. Subjects must have been enrolled previously in Study SHP647-305 or SHP647-306 and are in the treatment period of Study SHP647-307, completed the ET or Week 52 visit in maintenance study SHP647-307, had responded to ontamalimab treatment (in the induction and/or maintenance studies), and meet one of the following criteria:
 - Subjects are on placebo at the maintenance study ET or Week 52 visit: they received ontamalimab in the induction study and fulfilled the maintenance study response criteria, OR
 - o Subjects have received ontamalimab at the maintenance study ET or Week 52 visit:
 - CDAI score that has decreased by ≥100 points at the end of treatment visit compared to the baseline value for induction studies, AND/OR
 - SES-CD that has decreased by $\geq 25\%$ compared to the baseline value for induction studies.
- 4. Subjects receiving any treatment(s) for CD described in Section 5.3.1 are eligible provided they have been on a stable dose for the designated period of time.

Exclusion Criteria – Subjects with CD:

Subjects are excluded from the study if any of the following criteria are met:

- 1. Subjects who had major protocol deviation(s) (as determined by the sponsor) in Study SHP647-305, SHP647-306, or SHP647-307.
- 2. Subjects who permanently discontinued investigational product because of an AE, regardless of relatedness to investigational product, in Study SHP647-305, SHP647-306, or SHP647-307.
- 3. Subjects who are likely to require major surgery for CD or developed acute severe complications of CD (with or without fulfilling the treatment failure criteria in the maintenance study) that required immediate intervention (eg, need for immediate biologic treatment with proven effect) and/or CDAI score >450.
- 4. Subjects are females who became pregnant during Study SHP647-305, SHP647-306, or SHP647-307, females who are lactating, females who are planning to become pregnant during the study period, or males or females of childbearing potential not agreeing to continue using appropriate contraception methods (ie, highly effective methods for female and medically appropriate methods for male study subjects) through the conclusion of study participation.
- 5. Subjects who do not agree to postpone donation of any organ or tissue, including male subjects who are planning to bank or donate sperm and female subjects who are planning to harvest or donate eggs, for the duration of the study and through 16 weeks after last dose of investigational product.
- 6. Subjects who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
- 7. Subjects who have a newly-diagnosed malignancy or recurrence of malignancy (other than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix that has been treated

with no evidence of recurrence).

- 8. Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, GI [except disease under study], endocrine, cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.
- 9. Subjects with any other severe acute or chronic medical or psychiatric condition or laboratory or ECG abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- 10. Subjects with known exposure to TB since testing at screening in Study SHP647-305 or SHP647-306, and who have been advised to require treatment for latent or active disease, but who are without a generally accepted course of treatment.
- 11. Subjects who are investigational site staff members or relatives of those site staff members or subjects who are sponsor employees directly involved in the conduct of the study.
- 12. Subjects who are participating in other investigational studies (other than SHP647-305, SHP647-306, or SHP647-307) or plan to participate in other investigational studies during long-term extension study SHP647-304.

Maximum duration of subject involvement in the study:

For subjects who are tolerating investigational product and receiving clinical benefit in the judgment of the investigator (ie, fulfilling treatment response criteria as defined in Section 9.8.1.1 and Section 9.8.2.1), study participation may continue until the subject withdraws from the study, or the investigator or sponsor decide to withdraw the subject (eg, in the interest of subject safety), or the sponsor decides to close the study, or the program is stopped completely. Subjects will enter a 12-week safety follow-up period following the last dose of investigational product. A subject's maximum duration of participation in this study under the current amendment is expected to be no more than 3 years (ie, a subject's participation is not planned to extend beyond 2023), subject to local or country requirements. It is expected that the study will be completed in no more than 3 years (ie, by December 2023).

Endpoints and statistical analysis:

Analysis Sets:

The full analysis set (FAS) will consist of all subjects in the randomized set who receive at least 1 dose of investigational product in the SHP647-304 study.

The safety set will consist of all subjects who receive at least 1 dose of investigational product in the SHP647-304 study.

Primary Endpoint: The primary endpoint is the assessment of safety as measured by: incidence and severity of AEs; incidence and nature of serious infections; and actual values and change from baseline, as well as incidence of abnormalities, in laboratory tests, ECGs, and vital signs.

Safety Endpoints: All safety analyses will be performed using the safety set. Subjects will be analyzed according to the treatment they actually received. Adverse events will be coded using the Medical Dictionary for Regulatory Activities. Summaries will be presented by indication separately and also overall. Summaries may be presented by the status at entry into this study (eg, induction nonresponder, maintenance ontamalimab completer, maintenance discontinuation rollovers, etc.).

Treatment-emergent AEs (TEAEs) are defined as AEs with start dates or worsening dates at the time of or following the first exposure to investigational product in the SHP647-304 study. The number of events, incidence, and percentage of TEAEs will be calculated overall, by system organ class, by preferred term, and by treatment group. Treatment-emergent AEs will be further summarized by severity and relationship to investigational product. Adverse events leading to withdrawal, serious AEs, and deaths will be similarly summarized/listed. Adverse events of special interest will be summarized by treatment group.

Clinical laboratory tests, vital signs, and ECG findings will be summarized by indication, treatment group, and visit. Potentially clinically important findings will also be summarized or listed.

Secondary Endpoints - Subjects with Ulcerative Colitis:

The secondary endpoint is as follows:

Treatment response over time, with response defined as clinical composite score that has decreased by ≥ 2 points and $\geq 30\%$, with an accompanying decrease in the subscore for RB ≥ 1 point or a subscore for $RB \ge 1$, and/or composite score that has decreased by $\ge 30\%$ and ≥ 3 points compared to the baseline value USE ONIT for induction studies.

Secondary Endpoints – Subjects with Crohn's Disease:

The secondary endpoint is as follows:

Treatment response over time, with response defined as CDAI score that has decreased by ≥100 points compared to the baseline value for induction studies and/or SES-CD that has decreased by \geq 25% compared to the baseline value for induction studies.

All analyses will be performed using the FAS.

Secondary endpoints will be summarized by treatment group using descriptive statistics at each assessment visit. Summaries may be presented by the status at entry into the study (eg, induction nonresponder, maintenance ontamalimab completer, maintenance early discontinuation rollovers, etc.). Statistical summaries will include number of subjects and percentages, and 95% confidence intervals.

STUDY SCHEDULES

Table 1 Schedule of Assessments – Treatment Year 1 (Subjects with UC)

Study Procedure	Baseline ^a						Treatme	ent – Yea	r 1				
	W0/ Day 1	W4	W8	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48
Visit Number	1	2	3	4	5	6	7	8	9	10	11	12	13
Visit Window	None						±1() days					
Informed consent/assent	Х						Ľ						
Eligibility assessment ^b	X					0							
Medical history ^c	IDT or MNT					S							
Complete physical examination ^d	IDT or MNT					5	Х						
Targeted physical examination ^d	IDT or MNT												Х
Targeted neurological assessment ^{e,f}	IDT or MNT			X	5		X			X			Х
Vital signs	IDT or MNT	Х		X			Х			Х			Х
Weight	IDT or MNT	Х	C	х			Х			Х			Х
12-lead ECG (local)	IDT or MNT		0	Х			Х						Х
Laboratory (Central) ^g		2											
Hematology	IDT or MNT	X		Х			Х			Х			Х
Serum chemistry ^h	IDT or MNT	X		Х			Х			Х			Х
Urinalysis	IDT or MNT	Х		X			X			X			Х
Urine β-hCG ⁱ	IDT or MNT	Х	Х	Х	Х	Х	X	Х	Х	X	Х	Х	Х
FSH ^j	X												
Contraception check ^k		X	X	X	X	Х	X	Х	X	X	Х	Х	Х
Stool sample for fecal calprotectin	IDT or MNT						Х						Х
Serum CRP ¹	IDT or MNT						Х						Х

Table 1 Schedule of Assessments – Treatment Year 1 (Subjects with UC)

Study Procedure	Baseline ^a						Treatme	nt – Yea	r 1				
	W0/ Day 1	W4	W8	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48
Visit Number	1	2	3	4	5	6	7	8	9	10	11	12	13
Visit Window	None						±1() days					
Endoscopic Procedure													
OPTIONAL endoscopy (flexible sigmoidoscopy or colonoscopy) ^m	IDT or MNT	0	0	0	0	0	Ho	0	0	0	0	0	0
UC Assessments ⁿ						0							
OPTIONAL Total Mayo score ^o	IDT or MNT	0	0	0	0	50	0	0	0	0	0	0	0
Partial Mayo score	IDT or MNT					5	X						Х
Treatment response assessment ^{p,q}	IDT			Х	,Clo		Х			Х			Х
Treatment Procedures				. ~ ~	5								
Administration of ontamalimab ^{r,s,t}	Х	Х	X	X	Х	Х	X	Х	Х	X	Х	Х	Х
Hypersensitivity monitoring ^u	Х	Х	x,C	x	Х	Х	Х	Х	Х	Х	Х	Х	Х
Adverse events	Х	Х	OX	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Concomitant medication and procedures	Х	X	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	X
Dispense stool collection kit for stool sample ^{v}		¢0.				Х						Х	

Page 39

Table 1 Schedule of Assessments – Treatment Year 1 (Subjects with UC)

Study Procedure	Baseline ^a					,	Treatme	nt – Yea	r 1				
	W0/ Day 1	W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48											
Visit Number	1	2	3	4	5	6	7	8	9	10	11	12	13
Visit Window	None						±1() days					

β-hCG=beta-human chorionic gonadotropin; CLIA=Clinical Laboratory Improvement Amendments; CRP=C-reactive protein; DTP=Direct-To-Patient; ECG=electrocardiogram; ET=early termination; FDA=Food and Drug Administration; FSH=follicle-stimulating hormone; GI=gastrointestinal; IDT=induction study (SHP647-301 or SHP647-302); LTT=liver function terting; MNIT=meintenenee etudy SHP647-303; O=entional; LIC=ulcereting; ention terting; MNIT=meintenenee etudy SHP647-303; O=entional; LIC=ulcereting; ention terting; MNIT=meintenenee; etudy SHP647-303; O=entional; LIC=ulcereting; ention terting; MNIT=meintenenee; etudy SHP647-304; O=entional; LIC=ulcereting; etudy states etudy; etudy etudy; etudy

LFT=liver function testing; MNT=maintenance study SHP647-303; O=optional; UC=ulcerative colitis; W=Week.

^a Baseline = Week 0 (Day 1). For subjects previously enrolled in induction study SHP647-301 or SHP647-302, the baseline visit is the Week 12 study visit (with the exception of treatment response assessment). For subjects entering from maintenance study SHP647-303, the baseline visit is the Week 52 visit (for subjects who completed the study) or the ET visit (for subjects who withdrew early), with the exception of treatment response assessment.

^b Eligibility will be assessed after the consent form is signed and after procedures are completed at Visit 6, Part 2 in Study SHP647-301 or SHP647-302, or at Visit 14, Part 2 or the ET or Week 52 visit in Study SHP647-303.

^c Medical history from Studies SHP647-301, SHP647-302, and SHP647-303 will be used as the baseline medical history data for Study SHP647-304.

^d Complete physical examination includes the review of the following body systems: general appearance; skin; head, eyes, ears, nose, and throat; heart; lungs; breast (optional); abdomen; external genitalia (optional); extremities; neurologic function; back; and lymph nodes. Targeted physical examination includes the review of the following body systems: skin, heart, lungs, eyes, abdomen, and examination of body systems where there are symptom complaints by the subject.

^e Subjects will be evaluated to reveal any potential abnormalities in the following neurologic domains: vision, motor, tactile sensation, coordination/cerebellar function, speech, verbal comprehension, and cognition/behavior. Subjects with any unexplained positive item at screening that is suggestive of progressive multifocal leukoencephalopathy should be excluded. See Section 7.3.4.3 for further details.

^f In case of a DTP situation, to be performed by remote visits via virtual communications (eg, TeleHealth application).

^g Clinical laboratory assays (LFT) can also be performed by the local laboratory in case of issues related to COVID-19 (or other similar pandemic) and if deemed necessary by the investigator to confirm the subject's safety. In such a case, the investigative site must obtain the local laboratory's normal ranges as well as a CLIA certificate and the investigator must add the local laboratory as appropriate.

^h Subjects performing home administrations consecutively for 3 months will need to perform LFT per FDA requirement. It may be done locally if it is not possible to collect samples at the central laboratory.

ⁱ The urine pregnancy test will be performed at the site using test kits supplied by the central laboratory.

^j For confirmation of postmenopausal status in women who have had 12 consecutive months of spontaneous amenorrhea and are ≥51 years of age. This does not need to be performed if postmenopausal status was confirmed by FSH in induction study SHP647-301 or SHP647-302 or maintenance study SHP647-303.

^k Contraception check should be made for female subjects of childbearing potential and male subjects who are with a partner of childbearing potential; see Section 4.3.

¹ Samples must be collected before administration of investigational product.

^m Flexible sigmoidoscopy or colonoscopy (if preferred). Endoscopy is optional for treatment response evaluation after the implementation of Amendment 4; if performed (eg, due to routine cancer surveillance required by GI guidelines or due to local clinical practice), the results should be recorded. If more than 2 endoscopies/colonoscopies are needed in a year, the subject should be discontinued.

ⁿ Mayo score will be based on subject self-report, with the assistance of a memory aid.

• The total Mayo score will be calculated based on the locally read endoscopic subscore (if endoscopy is performed). The total Mayo score will be calculated only when endoscopy data are available.

^p Measured by clinical composite score and biomarkers, with or without endoscopy. Applicable only after the implementation of Amendment 4.

21 Sep 2020

Page 40

Table 1 Schedule of Assessments – Treatment Year 1 (Subjects with UC)

Study Procedure	Baseline ^a						Treatme	nt – Yea	r 1				
	W0/ Day 1												
Visit Number	1 1	2	3	4	5	6	7	8	9	10	11	12	13
Visit Window	None						±1() days					

^q Subjects will have the option to fill in a memory aid to collect data at least 7 days before each specified visit. See Section 7.3.2.3 for further details.

^r Interactive response technology will be used for dispensation of study treatment.

^s Investigational product is to be administered after all other visit assessments have been performed.

^t In a situation in which a subject is not able to visit the study site due to the COVID-19 public health emergency (or other similar pandemic), DTP investigational product administration options may be available, in accordance with local regulations (refer to DTP guidance document).

^u At each visit, the subject will be assessed for the presence of Type I and Type III hypersensitivity reactions since the prior visit. If a suspected hypersensitivity reaction has occurred, the next dose of investigational product should be withheld if necessary until the precise ettology (investigational product related or not) has been determined. If a Type III reaction is suspected, appropriate samples for testing will be collected and stored.

^v Stool sample collection kit will be dispensed to the subject to take home at the visit prior to the one at which testing will be done.

Note: See Section 7.3 for the order in which assessments should be performed. Timing of visits is relative to SHP647-304 baseline.

For non-conner

21 Sep 2020

Table 2 Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC)

Study Procedure				ſ	reatmen	it – Year	2 Throu	gh Year	3					Follow-up
	W52/ W100	W56/ W104	W60/ W108	W64/ W112	W68/ W116	W72/ W120	W76/ W124	W80/ W128	W84/ W132	W88/ W136	W92/ W140	W96ª/ W144	EOT Visit	12 Weeks Post-EOT ^b
Visit Number	14/ 26	15/ 27	16/ 28	17/ 29	18/ 30	19/ 31	20/ 32	21/ 33	22/ 34	23/ 35	24/ 36	25/ 37		
Visit Window						±10	days							
Complete physical examination ^c													Х	х
Targeted physical examination ^c									on	3		Х		
Targeted neurological assessment ^{d,e}			Х			Х		y.	У х			Х	Х	х
Vital signs						Х		3				Х	Х	Х
Weight						Х	al al	5				Х	Х	
12-lead ECG (local)							n					Х	Х	
Laboratory (Central) ^f						~0								
Hematology			Х			X			Х			Х	Х	Х
Serum chemistry ^g						Уx						Х	Х	Х
Urinalysis					0	Х						Х	Х	Х
Urine β-hCG ^h	Х	Х	Х	Х	X	Х	Х	Х	Х	Х	Х	Х	X	Х
Contraception check ⁱ	Х	Х	Х	Х	X	Х	Х	Х	Х	Х	Х	Х	Х	Х
Stool sample for fecal calprotectin						Х						Х		
Serum CRP ^j						Х						Х		
Endoscopic Procedure	5												•	
OPTIONAL endoscopy (flexible sigmoidoscopy or colonoscopy) ^k	О	О	О	О	О	О	О	0	О	0	О	О	0	О

Table 2 Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC)

Study Procedure				1	reatmen	it – Year	2 Throu	gh Year	3					Follow-up
	W52/ W100	W56/ W104	W60/ W108	W64/ W112	W68/ W116	W72/ W120	W76/ W124	W80/ W128	W84/ W132	W88/ W136	W92/ W140	W96ª/ W144	EOT Visit	12 Weeks Post-EOT ^b
Visit Number	14/ 26	15/ 27	16/ 28	17/ 29	18/ 30	19/ 31	20/ 32	21/ 33	22/ 34	23/ 35	24/ 36	25/ 37		
Visit Window						±10	days							
UC Assessments ¹														
OPTIONAL Total Mayo score ^m	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Treatment response assessment ^{n,o}			X			Х		0	Ø X			Х	Х	Х
Partial Mayo score						Х		15				Х	Х	
Treatment Procedures	5							50.						
Administration of ontamalimab ^{p,q}	Х	Х	Х	Х	Х	Х	x	X	Х	Х	Х	Х		
Hypersensitivity monitoring ^r	X	Х	X	Х	X	xo	X	Х	X	Х	Х	X	Х	х
Adverse events	Х	Х	Х	Х	X	X	Х	Х	Х	Х	Х	Х	Х	Х
Concomitant medication and procedures	Х	Х	Х	X	, ox	x	х	Х	Х	Х	Х	Х	х	Х
Dispense stool collection kit for stool sample ^s					х						х			

β-hCG=beta-human chorionic gonadotropin; CLIA=Clinical Laboratory Improvement Amendments; CRP=C-reactive protein; DTP=Direct-To-Patient; ECG=electrocardiogram; EOT=end of treatment; FDA=Food and Drug Administration; GI=gastrointestinal; LFT=liver function testing; O=optional; UC=ulcerative colitis; W=Week.

^a After Treatment Year 1, assessments will be repeated on the subsequent year rotation from Week 52.

^b Subjects will enter a 12-week safety follow-up period, with a visit at the study site at 12 weeks following the EOT visit.

^c Complete physical examination includes the review of the following body systems: general appearance; skin; head, eyes, ears, nose, and throat; heart; lungs; breast (optional); abdomen; external genitalia (optional); extremities; neurologic function; back; and lymph nodes. Targeted physical examination includes the review of the following body systems: skin, heart, lungs, eyes, abdomen, and examination of body systems where there are symptom complaints by the subject.

^d Subject will be evaluated to reveal any potential abnormalities in the following neurologic domains: vision, motor, tactile sensation, coordination/cerebellar function, speech, verbal comprehension, cognition/behavior. See Section 7.3.4.3 for further details.

Table 2 Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with UC)

Study Procedure				Т	reatmen	t – Year	2 Throu	gh Year	3					Follow-up
	W52/ W100	W56/ W104	W60/ W108	W64/ W112	W68/ W116	W72/ W120	W76/ W124	W80/ W128	W84/ W132	W88/ W136	W92/ W140	W96ª/ W144	EOT Visit	12 Weeks Post-EOT ^b
Visit Number	14/	15/	16/	17/	18/	19/	20/	21/	22/	23/	24/	25/		
	26	27	28	29	30	31	32	33	34	35	36	37		
Visit Window						±10	days							
 f Clinical laboratory necessary by the in certificate and the g Subjects performin collect samples at h The urine pregnan i Contraception che Section 4.3. j Samples must be c k Flexible sigmoidor performed (eg, due 2 endoscopies/cold Mayo score will be m The total Mayo scowhen endoscopy di m Measured by clinic o Subjects will have p Investigational prof q In a situation in when product administration in the structure of the section has occurring been determined. I s Stool sample colle Note: For subjects who assessments will be rep 	isit Window ±10 days In case of a DTP situation, to be performed by remote visits via virtual communications (eg, TeleHealth application). Clinical laboratory assays (LFT) can also be performed by the local laboratory in case of issues related to COVID-19 (or other similar pander necessary by the investigator to confirm the subject's safety. In such a case, the investigative site must obtain the local laboratory's normal ra certificate and the investigator must add the local laboratory as appropriate. Subjects performing home administrations consecutively for 3 months will need to perform LFT per FDA requirement. It may be done locally collect samples at the central laboratory. The urine pregnancy test will be performed at the site using test kits supplied by the central laboratory. Contraception check should be made for female subjects of childbearing potential and male subjects who are with a partner of childbearing potential		y if it is n otential; mendme f more th ll be calcu 4. details. DTP invo d hyperso uct relate	well as a CLIA not possible to see nt 4; if an ulated only estigational ensitivity ed or not) has										

Table 3 Schedule of Assessments – Treatment Year 1 (Subjects with CD)

Study Procedure	Baseline ^a					7	Freatme	nt – Year	r 1				
	W0/ Day 1	W4	W8	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48
Visit Number	ĺ	2	3	4	5	6	7	8	9	10	11	12	13
Visit Window	None						±10	days					
Informed consent/assent	Х												
Eligibility assessment ^b	Х						1						
Medical history ^c	IDT or MNT					~	12						
Complete physical examination ^d	IDT or MNT					0	Х						
Targeted physical examination ^d	IDT or MNT			Х		S				X			Х
Targeted neurological assessment ^{e,f}	IDT or MNT			Х	. 0	Ŭ.	Х			Х			Х
Vital signs	IDT or MNT	Х		X	CIU		Х			Х			Х
Weight	IDT or MNT	Х		х	0		Х			Х			X
12-lead ECG (local)	IDT or MNT			x			Х						Х
Laboratory (Central) ^g				CO.									
Hematology	IDT or MNT	Х	0	Х			Х			Х			Х
Serum chemistry ^h	IDT or MNT	X	ζ	Х			Х			Х			Х
Urinalysis	IDT or MNT	$\langle X^{\circ} \rangle$		Х			Х			Х			Х
Urine β-hCG ⁱ	IDT or MNT	X	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
FSH ^j	X												
Contraception check ^k		Х	Х	Х	X	Х	Х	Х	Х	Х	Х	Х	Х
Stool sample for fecal calprotectin	IDT or MNT						Х						Х
Serum CRP ¹	IDT or MNT						Х						Х

Table 3 Schedule of Assessments – Treatment Year 1 (Subjects with CD)

Study Procedure	Baseline ^a]	Freatme	nt – Year	: 1				
	W0/ Day 1	W4	W8	W12	W16	W20	W24	W28	W32	W36	W40	W44	W48
Visit Number	1	2	3	4	5	6	7	8	9	10	11	12	13
Visit Window	None						±10	days					
Endoscopic Procedure													
OPTIONAL colonoscopy ^m	IDT or MNT	0	0	0	0	0	0	0	0	0	0	0	0
CD Assessments ⁿ						~	12						
OPTIONAL SES-CD°	IDT or MNT	0	0	0	0	_0	0	0	0	0	0	0	0
CDAI	IDT or MNT					5	Х						Х
Treatment response assessment ^{p,q}	IDT			Х	· ?	-	Х			Х			Х
Treatment Procedures					N.C.								
Administration of ontamalimab ^{r,s,t}	Х	Х	X	X	X	Х	Х	Х	Х	X	Х	Х	Х
Hypersensitivity monitoring ^u	Х	Х	X	x	Х	Х	Х	Х	Х	X	Х	Х	Х
Adverse events	Х	Х	X	υx	Х	Х	Х	Х	Х	Х	Х	Х	Х
Concomitant medication and procedures	Х	Х	X	Х	Х	Х	Х	Х	Х	X	Х	Х	Х
Dispense stool collection kit for stool sample ^{v}		50				Х						X	

Page 46

Table 3 Schedule of Assessments – Treatment Year 1 (Subjects with CD)

Study Procedure	Baseline ^a					r	Freatme	nt – Year	: 1				
	W0/ Day 1	W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48											
Visit Number	1	2	3	4	5	6	7	8	9	10	11	12	13
Visit Window	None						±10	days					

8-hCG=beta-human chorionic gonadotropin: CD=Crohn's disease: CDAI=Crohn's Disease Activity Index: CLIA=Clinical Laboratory Improvement Amendments: CRP=C-reactive protein; DTP=Direct-To-Patient; ECG=electrocardiogram; ET=early termination; FSH=follicle-stimulating hormone; GI=gastrointestinal; IDT=induction study (SHP647-305 or SHP647-306); LFT=liver function testing; MNT=maintenance study SHP647-307; O=optional; SES-CD=Simple Endoscopic Score for Crohn's Disease; W=Week.

Baseline = Week 0 (Day 1). For subjects previously enrolled in induction study SHP647-305 or SHP647-306, the baseline visit is the Week 16 study visit (with the exception а of treatment response assessment). For subjects entering from maintenance study SHP647-307, the baseline visit is the Week 52 visit (for subjects who completed the study) or the ET visit (for subjects who withdrew early), with the exception of treatment response assessment.

If results for confirmation of treatment failure are pending at the time of the end of study visit in Study SHP647-307, sites will have 1 additional week to confirm final status of the subject (treatment failure or not) before enrolling the subject in Study SHP647-304. Eligibility will be assessed after the consent form is signed and after procedures are completed at Visit 7, Part 2 in Study SHP647-305 or SHP647-306, or at Visit 14, Part 2 or

- the ET or Week 52 visit in Study SHP647-307.
- Medical history from Studies SHP647-305, SHP647-306, and SHP647-307 will be used as the baseline medical history data for Study SHP647-304. с
- Complete physical examination includes the review of the following body systems: general appearance; skin; head, eves, ears, nose, and throat; heart; lungs; breast (optional); abdomen; external genitalia (optional); extremities; neurologic function; back, and lymph nodes. Targeted physical examination includes the review of the following body systems: skin and mucosa (specifically including perianal for fistula and oral eavity for stomatitis), heart, lungs, eves, abdomen, and examination of body systems where there are symptom complaints by the subject.
- Subjects will be evaluated to reveal any potential abnormalities in the following neurologic domains: vision, motor, tactile sensation, coordination/cerebellar function, speech, verbal comprehension, and cognition/behavior. Subjects with any unexplained positive item at screening that is suggestive of progressive multifocal leukoencephalopathy should be excluded. See Section 7.3.4.3 for further details.
- In case of a DTP situation, to be performed by remote visits via virtual communications (eg, TeleHealth application). f
- Clinical laboratory assays (LFT) can also be performed by the local laboratory in case of issues related to COVID-19 (or other similar pandemic) and if deemed necessary by g the investigator to confirm the subject's safety. In such a case, the investigative site must obtain the local laboratory's normal ranges as well as a CLIA certificate and the investigator must add the local laboratory as appropriate.
- Subjects performing home administrations consecutively for 3 months will need to perform LFT per FDA requirement. It may be done locally if it is not possible to collect samples at the central laboratory.
- The urine pregnancy test will be performed at the site using test kits supplied by the central laboratory.
- For confirmation of postmenopausal status in women who have had 12 consecutive months of spontaneous amenorrhea and are \geq 51 years of age. This does not need to be performed if postmenopausal status was confirmed by FSH in induction study SHP647-305 or SHP647-306 or maintenance study SHP647-307.
- Contraception check should be made for female subjects of childbearing potential and male subjects who are with a partner of childbearing potential; see Section 4.3.
- Samples must be collected before administration of investigational product.
- Colonoscopy is optional for treatment response evaluation after the implementation of Amendment 4: if performed (eg, due to routine cancer surveillance required by GI guidelines or due to local clinical practice), the results should be recorded. If more than 2 colonoscopies are needed in a year, the subject should be discontinued.
- CDAI score will be calculated based on data reported by the subject, with the assistance of a memory aid, as well as data obtained at the site visit.

Page 47

Table 3 Schedule of Assessments – Treatment Year 1 (Subjects with CD)

Study Procedure	Baseline ^a]	Freatme	nt – Year	:1				
	W0/ Day 1	W4 W8 W12 W16 W20 W24 W28 W32 W36 W40 W44 W48											
Visit Number	1	2	3	4	5	6	7	8	9	10	11	12	13
Visit Window	None						±10	days					

Endoscopies are not required, but if performed, it is recommended that the SES-CD be recorded by the endoscopist for assessment. SES-CD total score will be calculated based on the locally read endoscopic subscores for each of the segments investigated.

Measured by CDAI score and biomarkers, with or without endoscopy. Applicable only after the implementation of Amendment 4.

q Subjects will have the option to fill in a memory aid to collect data at least 7 days before each specified visit. See Section 7.3.3.4 for further details.

r Interactive response technology will be used for dispensation of study treatment.

s

Investigational product is to be administered after all other visit assessments have been performed. In a situation in which a subject is not able to visit the study site due to the COVID-19 public health emergency (or other similar pandemic), DTP investigational product administration options may be available, in accordance with local regulations (refer to DTP guidance document).

u At each visit, the subject will be assessed for the presence of Type I and Type III hypersensitivity reactions since the prior visit. If a suspected hypersensitivity reaction has occurred, the next dose of investigational product should be withheld if necessary until the precise etiology (investigational product related or not) has been determined. If a Type III reaction is suspected, appropriate samples for testing will be collected and stored.

Stool sample collection kit will be dispensed to the subject to take home at the visit prior to the one at which testing will be done.

Note: See Section 7.3 for the order in which assessments should be performed. Timing of visits is relative to SHP647-304 baseline.

ormed. The COT

21 Sep 2020

Table 4 Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with CD)

Study Procedure				Т	reatmen	t – Year	2 Throu	gh Year	3					Follow- up
	W52/ W100	W56/ W104	W60/ W108	W64/ W112	W68/ W116	W72/ W120	W76/ W124	W80/ W128	W84/ W132	W88/ W136	W92/ W140	W96ª/ W144	EOT Visit	12 Weeks Post- EOT ^b
Visit Number	14/ 26	15/ 27	16/ 28	17/ 29	18/ 30	19/ 31	20/ 32	21/ 33	22/ 34	23/ 35	24/ 36	25/ 37		
Visit Window						±10	days							
Complete physical examination ^c									A				Х	Х
Targeted physical examination ^c			Х			Х		0	X			Х		
Targeted neurological assessment ^{d,e}			X			Х		S	Х			Х	Х	Х
Vital signs						Х						Х	Х	Х
Weight						X	5					Х	Х	
12-lead ECG (local)						UI.						Х	Х	
Laboratory (Central) ^f					Ç	Ģ.								
Hematology			X			Х			Х			Х	Х	Х
Serum chemistry ^g				2	(Х						Х	Х	Х
Urinalysis				K 0		Х						Х	Х	Х
Urine β-hCG ^h	Х	Х	X	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Contraception check ⁱ	Х	Х	X	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х	Х
Stool sample for fecal calprotectin						Х						Х		
Serum CRP ^j						Х						Х		
Endoscopic Procedure														
OPTIONAL colonoscopy ^k	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Page 48

21 Sep 2020

Table 4 Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with CD)

Study Procedure	Treatment – Year 2 Through Year 3													Follow- up
	W52/ W100	W56/ W104	W60/ W108	W64/ W112	W68/ W116	W72/ W120	W76/ W124	W80/ W128	W84/ W132	W88/ W136	W92/ W140	W96 ^a / W144	EOT Visit	12 Weeks Post- EOT ^b
Visit Number	14/ 26	15/ 27	16/ 28	17/ 29	18/ 30	19/ 31	20/ 32	21/ 33	22/ 34	23/ 35	24/ 36	25/ 37		
Visit Window				•	•	±10	days							
CD Assessments ¹								4	1					
OPTIONAL SES-CD ^m	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CDAI						Х		e O				Х	Х	
Treatment response assessment ^{n,o}			Х			Х		22	Х			Х	Х	
Treatment Procedures							, CIV							
Administration of ontamalimab ^{p,q}	Х	Х	х	Х	Х	X	X	Х	Х	Х	Х	Х		
Hypersensitivity monitoring ^r	Х	Х	Х	Х	X	X	Х	Х	Х	Х	Х	Х	Х	Х
Adverse events	Х	Х	х	Х	X	X	Х	Х	Х	Х	Х	Х	Х	Х
Concomitant medication and procedures	Х	Х	X	X	C X	Х	Х	Х	Х	Х	Х	Х	Х	Х
Dispense stool collection kit for stool sample ^s				<i>k</i> 0,	Х						Х			

β-hCG=beta-human chorionic gonadotropin; CD=Crohn's disease; CDAI=Crohn's Disease Activity Index; CLIA=Clinical Laboratory Improvement Amendments; CRP=C-reactive protein; DTP=Direct-To-Patient; ECG=electrocardiogram; EOT=end of treatment; FDA=Food and Drug Administration; GI=gastrointestinal; LFT=liver function testing; O=optional; SES-CD=Simple Endoscopic Score for Crohn's Disease; W=Week.

^a After Treatment Year 1, assessments will be repeated on the subsequent year rotation from Week 52.

^b Subjects will enter a 12-week safety follow-up period, with a visit at the study site at 12 weeks following the EOT visit.

^c Complete physical examination includes the review of the following body systems: general appearance; skin; head, eyes, ears, nose, and throat; heart; lungs; breast (optional); abdomen, external genitalia (optional); extremities; neurologic function, back, and lymph nodes. Targeted physical examination includes the review of the following body systems: skin and mucosa (specifically including perianal for fistula and oral cavity for stomatitis), heart, lungs, eyes, abdomen, and examination of body systems where there are symptom complaints by the subject.

^d Subject will be evaluated to reveal any potential abnormalities in the following neurologic domains: vision, motor, tactile sensation, coordination/cerebellar function, speech, verbal comprehension, cognition/behavior. See Section 7.3.4.3 for further details.

^e In case of a DTP situation, to be performed by remote visits via virtual communications (eg, TeleHealth application).

Table 4 Schedule of Assessments – Treatment Year 2 Through Year 3 and End of Study (Subjects with CD)

Study Procedure		Treatment – Year 2 Through Year 3												Follow-
												up		
	W52/ W100	W56/ W104	W60/ W108	W64/ W112	W68/ W116	W72/ W120	W76/ W124	W80/ W128	W84/ W132	W88/ W136	W92/ W140	W96ª/ W144	EOT Visit	12 Weeks Post- EOT ^b
Visit Number	14/ 26	15/ 27	16/ 28	17/ 29	18/ 30	19/ 31	20/ 32	21/ 33	22/ 34	23/ 35	24/ 36	25/ 37		
Visit Window		±10 days												

^f Clinical laboratory assays (LFT) can also be performed by the local laboratory in case of issues related to COVID-19 (or other similar pandemic) and if deemed necessary by the investigator to confirm the subject's safety. In such a case, the investigative site must obtain the local laboratory's normal ranges as well as a CLIA certificate and the investigator must add the local laboratory as appropriate.

^g Subjects performing home administrations consecutively for 3 months will need to perform LFT per FDA requirement. It may be done locally if it is not possible to collect samples at the central laboratory.

^h The urine pregnancy test will be performed at the site using test kits supplied by the central laboratory.

¹ Contraception check should be made for female subjects of childbearing potential and male subjects who are with a partner of childbearing potential; see Section 4.3. Samples must be collected before administration of investigational product.

^k Colonoscopy is optional for treatment response evaluation after the implementation of Amendment 4; if performed (eg, due to routine cancer surveillance required by GI guidelines or due to local clinical practice), the results should be recorded. If more than 2 colonoscopies are needed in a year, the subject should be discontinued.

¹ CDAI score will be calculated based on data reported by the subject, with the assistance of a memory aid, as well as data obtained at the site visit.

^m Endoscopies are not required, but if performed, it is recommended that the SES-CD be recorded by the endoscopist for assessment. SES-CD total score will be calculated based on the locally read endoscopic subscores for each of the segments investigated.

ⁿ Measured by CDAI and biomarkers, with or without endoscopy. Applicable only after the implementation of Amendment 4.

^o Subjects will have the option to fill in a memory aid to collect data at least 7 days before each specified visit. See Section 7.3.3.4 for further details.

^p Investigational product is to be administered after all other visit assessments have been performed.

^q In a situation in which a subject is not able to visit the study site due to the COVID-19 public health emergency (or other similar pandemic), DTP investigational product administration options may be available, in accordance with local regulations (refer to DTP guidance document).

^r At each visit, the subject will be assessed for the presence of Type I and Type III hypersensitivity reactions since the prior visit. If a suspected hypersensitivity reaction has occurred, the next dose of investigational product should be withheld if necessary until the precise etiology (investigational product related or not) has been determined. If a Type III reaction is suspected, appropriate samples for testing will be collected and stored.

^s Stool sample collection kit will be dispensed to the subject to take home at the visit prior to the one at which testing will be done.

Note: For subjects whose study participation extends beyond Year 3 (ie, subjects already enrolled in this study prior to the implementation of Amendment 4), assessments will be repeated on the subsequent year rotation beginning with Week 100.

See Section 7.3 for the order in which assessments should be performed. Timing of visits is relative to SHP647-304 baseline.

1. BACKGROUND INFORMATION

1.1 Indication and Current Treatment Options

1.1.1 Ulcerative Colitis

Ulcerative colitis (UC) is a chronic, relapsing disease marked by ulceration and inflammation of the colonic mucosa and submucosa. Initially it usually involves the rectum but may extend proximally to involve a portion of, or the entirety of, the colon. In the early stages, hemorrhagic and erythematous tissue is observed, progressing to mucosal ulceration with purulent exudates in severe cases. The ulceration pattern is continuous and may extend the entire length of the colon. Perforation of the bowel wall causing ileus and peritonitis can occur with transmural extension of the ulceration. Bloody diarrhea with or without mucus and lower abdominal pain with periods of remission and exacerbation are the most common symptoms.

The incidence of UC is estimated to be up to 24.3 cases per 100,000 persons per year in Europe and up to 19.2 cases per 100,000 persons per year in North America. No clear difference in incidence has been observed between men and women. Although UC can occur at any age, peak incidence has been observed in the second to fourth decades of life (Molodecky et al., 2012). Ulcerative colitis is a lifelong condition with a serious effect on the quality of life. Current treatment primarily consists of symptomatic management with dietary modifications and opiates (loperamide), as well as disease modifying agents such as 5-aminosalicylic acid (5-ASA), systemic glucocorticoids, immunosuppressive agents (azathioprine [AZA]/6-mercaptopurine [6-MP], cyclosporine), and biologic therapy with anti-tumor necrosis factor (TNF) or anti-integrin agents. Despite recent advances, there is still an unmet need for an effective pharmacological treatment that will induce and maintain remission.

1.1.2 Crohn's Disease

Crohn's disease (CD) is a chronic, relapsing disease marked by granulomatous inflammation of the gastrointestinal (GI) tract. Although the terminal ileum and right colon are the most commonly involved sites, CD can affect any part of the GI tract, from the mouth to the perianal region. Inflammation is typically transmural (full-thickness), segmental, and discontinuous, and symptoms are predominantly determined by the part of bowel or organ involved. Patients typically present with symptoms including abdominal pain, diarrhea, rectal bleeding (RB), which may be persistent and lead to anemia, and weight loss due to pain on eating and malabsorption. As the disease progresses, extraintestinal manifestations and associated conditions can develop, including bowel obstruction, fistulas, and stenosis, as well as painful skin ulcerations, eye pain, and arthritis.

The incidence of CD is estimated to be up to 12.7 cases per 100,000 persons per year in Europe and up to 20.2 cases per 100,000 persons per year in North America. No clear difference in incidence has been observed between men and women. Although CD can occur at any age, peak incidence has been observed in the second to fourth decades of life, with a second modest rise in incidence in the latter decades of life (Molodecky et al., 2012).

Crohn's disease is a lifelong condition with a serious effect on quality of life. The traditional approach to therapy of CD has been the step-up approach usually represented as a pyramid where, progressing from mild to severe disease, therapeutic choices proceed step by step from less potent drugs at the base of the pyramid to more potent but also more toxic drugs at the top. Current treatment primarily consists of symptomatic management with dietary modifications, 5-ASA, opiates (loperamide), systemic glucocorticoids, immunosuppressive agents (AZA/6-MP, methotrexate [MTX]), and biologic therapy with anti-TNF agents or anti-integrin agents. Despite recent advances, there is still an unmet need for a safe, effective, and durable pharmacological treatment that will induce and maintain remission.

1.2 Product Background and Clinical Information

The selectivity of lymphocyte homing to specialized lymphoid tissue and mucosal sites of the GI tract is influenced by the endothelial expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1). MAdCAM-1 is a member of the immunoglobulin super family of cell adhesion molecules and is mostly expressed on the cell surface of high endothelial venules of organized intestinal lymphoid tissue such as Peyer's patches and mesenteric lymph nodes (Briskin et al., 1997; Shyjan et al., 1996; Liaskou et al., 2011). MAdCAM-1 plays a role in gut immune surveillance, and also appears to facilitate excessive lymphocyte infiltration under conditions of chronic GI inflammation. The $\alpha_4\beta_7$ integrin is the recognized ligand for MAdCAM-1, and expression of this ligand on populations of CD4⁺ and CD8⁺ T cells, as well as on subsets of B cells, distinguishes them as unique gut homing lymphocytes.

Ontamalimab (previously known as PF-00547659 and SHP647) is a fully human immunoglobulin G₂ kappa (IgG₂) monoclonal antibody that binds to human MAdCAM-1 to reduce lymphocyte homing to the gut and GI inflammation. Ontamalimab binds MAdCAM-1 with high affinity and selectivity that prevents the binding of $\alpha_4\beta_7^+$ lymphocytes to MAdCAM-1-expressing sites in the high endothelial venules of the GI tract.

1.3 Benefit/Risk Assessment

Ontamalimab has been evaluated in Phase 1 and Phase 2 clinical studies in subjects with UC and CD. In UC study A7281009, induction with ontamalimab at doses of 7.5 mg, 22.5 mg, or 75 mg every 4 weeks resulted in statistically significantly higher proportions of subjects in remission at Week 12 based on total Mayo score (both local and central read) when compared with placebo treatment. In CD study A7281006, induction with ontamalimab did not meet the primary endpoint; no statistically significant differences were observed between the active treatment arms and the placebo arm in Crohn's Disease Activity Index [CDAI]-70 response rate at Week 8 or Week 12. Post hoc analyses suggested evidence of drug effect in subjects with more inflammation at baseline, as indicated by higher serum concentrations of C-reactive protein (CRP) or Simple Endoscopic Score for CD (SES-CD).

In UC induction study A7281009, decreases in fecal calprotectin were observed in all groups, including placebo; however, there were no statistically significant differences in the decrease in fecal calprotectin between any dose level of ontamalimab and placebo. Decreases in high-sensitivity CRP (hsCRP) were also observed in all 4 treatment groups; however, other than the 75 mg dose group at Week 12, no statistically significant differences were observed in active treatment versus placebo.

In the induction study A7281006 in subjects with CD, compared to placebo, nominally statistically significant decreases in feeal calprotectin were observed in the 75 mg group at Week 8 and in the 22.5 mg and 75 mg groups at Week 12. Generally, decreases from baseline in hsCRP were observed in all 4 treatment groups over the 12-week induction period. Compared to placebo, nominally statistically significant decreases in hsCRP were observed in all 3 active treatment groups (22.5 mg, 75 mg, and 225 mg) at Week 12. There was no evidence of a dose response for either of these parameters. A nominally statistically significant increase was observed in circulating β 7 + central memory T lymphocytes at Weeks 8 and 12, consistent with the predicted mechanism of action.

The most common serious adverse events (SAEs) across all studies were CD and UC. In Study A7281006, the randomized, placebo-controlled induction study in CD, treatment-emergent adverse events (TEAEs) were most commonly reported within the GI disorders system organ class (SOC) followed by the infections and infestations SOC. The most common all-causality TEAEs were CD (worsening and progression of underlying disease), followed by pyrexia, headache, and arthralgia, all of which had similar incidences in the placebo treatment group compared with the active treatment groups. In Study A7281009, the randomized, placebo-controlled induction study in UC, TEAEs were most commonly reported within the

GI disorders SOC followed by the infections and infestations SOC. The most common all-causality TEAE was headache, followed by abdominal pain, nasopharyngitis, UC (worsening and progression of underlying disease), and nausea, all with similar incidence between placebo- and drug-treated subjects.

The long-term, open-label safety studies (Studies A7281007 and A7281010) were not placebo-controlled, but permitted exposure to the investigational product at doses of 75 mg or 225 mg every 4 weeks for 18 and 36 months, respectively. In Study A7281007, the most common all-causality TEAE was CD (worsening or progression), arthralgia, nasopharyngitis, and abdominal pain. In Study A7281010, the most common all-causality TEAEs were UC (worsening or progression), arthralgia, and nasopharyngitis.

Ontamalimab appears to be generally well tolerated, with the majority of TEAEs distributed at similar frequencies among treatment arms with only peripheral edema, gastroenteritis, and arthralgia more frequently reported in ontamalimab- than placebo-treated subjects in the pooled induction studies. In the placebo-controlled induction studies, nasopharyngitis was not reported more frequently in ontamalimab- than placebo-treated subjects, but occurred at relatively high frequency during long-term safety studies. Ontamalimab does not appear to be associated with impaired central nervous system (CNS) immune surveillance. No case of progressive multifocal leukoencephalopathy (PML) or myocarditis has been reported. Ontamalimab, in doses of 7.5 mg, 22.5 mg, and 75 mg, appears to increase the rate of remission in subjects with UC, and may have an effect in patients with CD who have greater evidence of inflammation based on biomarker or endoscopic data.

Always refer to the latest version of the ontamalimab Investigator's Brochure (IB) for the overall benefit/risk assessment and the most accurate and current information regarding the pharmacokinetics (PK), efficacy, and safety of ontamalimab.

2. STUDY OBJECTIVES AND PURPOSE

2.1 Rationale for the Study

Ontamalimab, a fully human IgG_{2k} antihuman MAdCAM-1 monoclonal antibody, was under development for the treatment of UC and CD. Ontamalimab prevents the binding of $\alpha_4\beta_7^+$ lymphocytes to MAdCAM-1-expressing sites with high affinity and selectivity. Principal sites of the MAdCAM-1 expression on normal tissue include intestine, pancreas, stomach, esophagus, spleen, and to a lesser extent lung, liver, and bladder but not the CNS (Steffen et al., 1996; Pullen et al., 2009).

Although selective targeting of the MAdCAM-1 receptors is a novel approach, the basic interference of lymphocyte homing by preventing the binding of these $\alpha_4\beta_7^+$ lymphocytes to the MAdCAM-1 receptor and the resultant efficacy in UC is well established (Feagan et al., 2013). Ontamalimab is differentiated from other molecules used for the treatment of UC in that it blocks the interaction of $\alpha_4\beta_7^+$ lymphocytes to the MAdCAM-1 receptor by selectively binding to MAdCAM-1 in the gut (and related tissues) whereas other molecules only target the integrins on the infiltrating lymphocytes. Additionally, ontamalimab does not bind to the vascular cell adhesion molecule; therefore, ontamalimab is not expected to be an effective treatment for multiple sclerosis, or affect lymphocyte homing or surveillance in the CNS.

In 2019, Takeda formally acquired Shire, the sponsor of this study. On 29 May 2020, Takeda announced the closure of the ontamalimab Phase 3 clinical development program, which included induction and maintenance studies for subjects with moderate to severe inflammatory bowel disease (IBD) who had failed at least 1 prior treatment. Per the announcement, the induction and maintenance studies will be closed earlier than originally planned. In recognition that this could potentially cause hardships for subjects who were benefiting from this investigational treatment (ie, fulfilling treatment response criteria as defined in Section 9.8.1.1 and Section 9.8.2.1), this long-term safety extension study, which is expected to be completed in no more than 3 years (ie, by December 2023), may continue to provide active treatment to subjects already enrolled who are responding to treatment (ie, in the induction or maintenance studies and who meet the entry criteria). However, if the results of the induction or maintenance studies show that ontamalimab does not have evidence of efficacy over placebo, this study will be terminated.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

21 Sep 2020

Originally, this extension study was designed to evaluate the safety and efficacy of long-term treatment with ontamalimab in subjects with moderate to severe UC or CD who: (1) completed one of the 4 multicenter, randomized, double-blind, placebo-controlled, parallel-group studies evaluating ontamalimab as an induction therapy (SHP647-301, SHP647-302, SHP647-305, or SHP647-306) and did not meet the response criteria (clinical and/or endoscopic response/remission as appropriate) required for entry into a maintenance study (SHP647-303 or SHP647-307), or (2) were treatment failures (as defined in the respective protocols) and/or completers in one of the 2 multicenter, double-blind, randomized, placebo-controlled, parallel-group study evaluating ontamalimab as maintenance therapy (SHP647-303 or SHP647-307). This study has been double-blind and will continue as such until the induction study results become available (ie, unblinding will not occur until the final analysis of the induction studies is completed and the lowest effective dose determined), as it is planned that subjects will receive the lowest effective dose based on the results of the induction studies. It is expected that the analysis of these results will demonstrate the efficacy of at least one of the doses and allow for the selection of a single dose, at which time this study will be open label. If both doses are effective and the difference compared to placebo is similar, then the lowest effective dose will be selected. However, if the results of the induction or maintenance studies show that ontamalimab does not have evidence of efficacy over placebo, this study will be terminated.

Subjects in the induction studies SHP647-301 or SHP647-302:

• As of September 2020, no subjects remain in the induction studies who would be eligible to participate in this study (SHP647-304); therefore, no additional subjects from the induction studies will enter this study under Amendment 4.

Subjects in the maintenance studies SHP647-303 or SHP647-307:

- Subjects who received and responded to active treatment in either or both of the induction or maintenance studies may be eligible to enter this study.
- Subjects who have not received ontamalimab yet (ie, received placebo in both the induction and maintenance studies) will not be eligible to enter this study.
- Subjects eligible to enter this study will be assessed for treatment response criteria according to the revised study schedule in Study SHP647-304.

21 Sep 2020

Subjects currently in Study SHP647-304 (ie, enrolled prior to Amendment 4) will be assessed for treatment response as follows:

- Subjects who have already entered Study SHP647-304 may continue and will be assessed for treatment response according to the revised study schedule. If they show response to ontamalimab treatment, they may continue further in this study.
- If the results of the induction or maintenance studies show that ontamalimab does not have evidence of efficacy over placebo, this study will be terminated.

All subjects will be evaluated periodically and in case of clinical worsening at an unscheduled visit during the study for treatment response. If a subject shows response to ontamalimab treatment, he or she may continue in this study either until he or she shows a loss of treatment response (ie, no longer meets response criteria) or elects to seek another treatment option, or rcialuseor until the end of the study.

2.2 **Study Objectives**

2.2.1 **Primary Objective**

The primary objective of the study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in subjects with moderate to severe UC or CD.

Secondary Objectives - Subjects with Ulcerative Colitis 2.2.2

To evaluate the maintenance of response to long-term treatment with ontamalimab as • measured by clinical composite score and biomarkers, with or without endoscopy.

2.2.3 Secondary Objectives – Subjects with Crohn's Disease

To evaluate the maintenance of response to long-term treatment with ontamalimab as • measured by CDAI score and biomarkers, with or without endoscopy.

3. STUDY DESIGN

3.1 Study Design and Flow Chart

This is a Phase 3 multicenter extension study designed to evaluate the long-term safety of ontamalimab in subjects with moderate to severe UC or CD. The study has enrolled subjects from 6 separate Phase 3 studies to date: 4 multicenter, randomized, double-blind, placebo-controlled, parallel-group studies evaluating ontamalimab as an induction therapy in subjects with moderate to severe UC (SHP647-301 and SHP647-302) or CD (SHP647-305 and SHP647-306); and 2 multicenter, double-blind, randomized, placebo-controlled, parallel-group studies evaluating ontamalimab as maintenance therapy in subjects with moderate to severe UC (SHP647-303) or CD (SHP647-307). As the induction and maintenance studies will be closed earlier than planned, the study will enroll subjects with moderate to severe UC and CD from the 2 maintenance studies (at the time of their closure) who have responded to active treatment. As the 4 induction studies do not have any subjects eligible for rollover to the SHP647-304 study as of September 2020, no additional subjects will enter from those studies.

This study is planned to become a single-dose study, with the dose to be determined after the analysis of data from the induction studies. This study has been double-blind and will continue as such until the induction study results become available (ie, unblinding will not occur until the final analysis of the induction studies is completed and the lowest effective dose determined), as it is planned that subjects will receive the lowest effective dose based on the results of the induction studies. It is expected that the analysis of these results will demonstrate the efficacy of at least one of the doses and allow for the selection of a single dose, at which time this study will be open label. If both doses are effective and the difference compared to placebo is similar, then the lowest effective dose will be selected. However, if the results of the induction or maintenance studies show that ontamalimab does not have evidence of efficacy over placebo, this study will be terminated.

All subjects will receive active drug in this study. Eligible subjects entering Study SHP647-304 from the discontinued SHP647-303 and SHP647-307 studies will be assigned to continue their present dose of ontamalimab (if currently receiving active drug) or to return to the dose of active drug associated with previous response (if on placebo). Ongoing subjects in this study will remain on the dose to which they have been previously assigned. Once the final dose has been determined, all subjects will continue on that dose only.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

Page 59

21 Sep 2020

Subjects will come to the investigational site every 4 weeks (unless unable to participate on site due to a pandemic [eg, coronavirus disease (COVID-19)] or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits), in which case they may qualify for the "Direct to Patient" [DTP] program) for investigational product administration and appropriate assessments.

The eligibility of a subject for this study will be assessed from study data collected at the following time points:

- For subjects with UC, the Week 12 visit of the induction study (SHP647-301 or SHP647-302) OR the Week 52 or Early Termination (ET) visit of the maintenance study (SHP647-303), which are considered and recorded as the baseline visit for this extension study (with the exception of the treatment response evaluation, for which baseline of the induction study will be used as baseline of this extension study). No additional subjects from the induction studies will be enrolling into Study SHP647-304. Subjects from the maintenance study (SHP647-303) will have the opportunity to enroll into this study at the time of the approval of Amendment 4 if they have benefited from active treatment in the induction or maintenance study.
- For subjects with CD, the Week 16 visit of the induction study (SHP647-305 or SHP647-306), OR the ET or Week 52 visit of the maintenance study (SHP647-307), which will be considered and recorded as the baseline visit for this extension study (with the exception of the treatment response evaluation, for which baseline of the induction study will be used as baseline of this extension study), with an additional window of 1 week for subjects whose treatment failure status is still under evaluation at the time of the Week 52 visit of the maintenance study. No additional subjects from the induction studies will be enrolling into Study SHP647-304. Subjects from the maintenance study (SHP647-307) will have the opportunity to enroll into this study at the time of the approval of Amendment 4 if they have benefited from active treatment in the induction or maintenance study.

Subjects enrolled in this study will receive treatment every 4 weeks, in the form of subcutaneous (SC) injections using prefilled syringes (PFSs). Subjects will undergo treatment response and safety assessments as outlined in the Schedules of Assessments. Assessments for Year 1 are provided in Table 1 (for subjects with UC) and Table 3 (for subjects with CD). Assessments for Year 2 through end of study, are provided in Table 2 (for subjects with UC) and Table 4 (for subjects with CD).

Shire Ontamalimab SHP647-304 Protocol Amendment 4

21 Sep 2020

At every third visit, subjects with UC will be assessed for ongoing benefit (treatment response) using the clinical composite score or composite score. To facilitate data collection and reliability, subjects will have the option to use a memory aid. Endoscopies are not required, but if performed (eg, for routine surveillance), it is recommended that the Mayo endoscopic subscore be recorded by the endoscopist for assessment. The total Mayo score will be calculated only when endoscopy data are available. The partial Mayo score consists of the Mayo score without the endoscopic subscores. The composite score is a recommended measure consisting of the Mayo score without the physical global assessment (PGA) subscore. The clinical composite score is a measure consisting of RB plus stool frequency without the endoscopic and PGA subscore. The data for Mayo scores and composite score will be collected from subjects, who have the option of using a memory aid, for 7 days before each specified visit as in the schedules of assessments. Biomarkers (C-reactive protein and fecal calprotectin) will be assessed every 3 months or in case there is a necessity to confirm the loss of clinical treatment response.

At every third visit, subjects with CD will be assessed for ongoing benefit (treatment response) using the CDAI score (treatment response defined as CDAI-100). Data on CDAI components (abdominal pain severity, very soft stool/liquid stool frequency, general well-being) will be collected from the subjects by the investigators. To facilitate data collection and reliability, subjects will have the option to use a memory aid. Endoscopies are not required, but if performed (eg, for routine surveillance), it is recommended that the SES-CD be recorded by the endoscopist for assessment. The CDAI is a composite measure with 8 components. Five components will be captured at the visits, and 3 components (abdominal pain severity, very soft stool/liquid stool frequency, and general well-being) will be collected from subjects, who have the option of using a memory aid, for 7 days before each specified visit as in the schedules of assessments. Biomarkers (C-reactive protein and fecal calprotectin) will be assessed every 3 months or in case there is a necessity to confirm the loss of clinical treatment response.


Treatment response will be assessed at every third visit for all subjects to allow monitoring of clinical benefit derived and evaluation of loss of response throughout the study. At these assessment visits, subjects' response will be evaluated and compared to the value of clinical composite score (for subjects with UC) or CDAI (for subjects with CD) determined at entry into the induction studies. As long as response criteria are satisfied, subjects may remain in the study. If there is a concern regarding loss of response between scheduled assessment visits, assessments may be performed at any scheduled or, if necessary, unscheduled visit to evaluate response. To ensure that placebo-treated subjects from a feeder study (SHP647-301, SHP647-302, SHP647-303, SHP647-305, SHP647-306, or SHP647-307) have sufficient exposure to active drug to permit assessment of treatment response, treatment response will be assessed according to the revised study schedule. Subjects may discontinue participation at any time, for any reason.


Shire Ontamalimab SHP647-304 Protocol Amendment 4

21 Sep 2020

If response to investigational product is lost, based on clinical criteria, or if there is an unexplained clinical exacerbation or unacceptably low level of clinical response the investigator may assess biomarkers and perform other investigations to exclude other potential causes like *Clostridium difficile* infection or an appropriate ad-hoc endoscopy to determine whether the loss of response is confirmed or not at an unscheduled visit. The totality of available data will be used to determine ongoing response status and subjects whose loss of response is confirmed (see Section 4.4.1 for further details).

The overall study design is shown in Figure 1.





EOT=end of treatment; SC=subcutaneous; wks=weeks.

^a Prior to unblinding. Subjects enrolling after unblinding will continue on their selected dose.

^b Determined by active dose received in maintenance or induction study.

Maintenance studies are SHP647-303 and SHP647-307.

Induction studies are SHP647-301, SHP647-302, SHP647-305, and SHP647-306.

3.2 **Duration and Study Completion Definition**

For subjects who are tolerating investigational product and receiving clinical benefit in the judgment of the investigator (ie, fulfilling treatment response criteria as defined in Section 9.8.1.1 and Section 9.8.2.1), study participation may continue until the subject withdraws from the study, or the investigator or sponsor decide to withdraw the subject (eg, in the interest of subject safety), or the sponsor decides to close the study, or the program is stopped completely. A subject's maximum duration of participation in this study under the current amendment is expected to be no more than 3 years (ie, a subject's participation is not planned to extend beyond 2023), subject to local or country requirements. Subjects will enter a 12-week safety follow-up period following the last dose of investigational product. Both the end of treatment (EOT) and 12-week safety follow-up visits are preferred to be on-site visits; however, due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits, these visits may also be conducted at a subject's home, provided a qualified site staff member performs these evaluations following DTP guidance. It is expected that the study will be completed in no more than 3 years (ie, by December 2023).

The study completion date is defined as the date the final subject, across all sites, completes their final protocol-defined assessment. Please note that this includes the follow-up visit or contact, whichever is later. The study completion date is used to ascertain timing for study results posting Fornonc and reporting.

3.3 **Sites and Regions**

This study will be conducted in approximately 225 sites in approximately 33 countries.

4. STUDY POPULATION

Each subject must participate in the informed consent process and provide written informed consent/assent before any procedures specified in the protocol are performed. Subject eligibility should be reviewed and documented by an appropriately qualified member of the investigator's study team before subjects are included in the study.

4.1 Eligibility Criteria – Subjects with Ulcerative Colitis

4.1.1 Inclusion Criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

- 1. Subjects and/or their parent or legally authorized representative must have an understanding, ability, and willingness to fully comply with study procedures and restrictions.
- 2. Subjects must be able to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent and/or assent, as applicable, to participate in the study.
- 3. Subjects must have been enrolled previously in Study SHP647-301 or SHP647-302 and are in the treatment period of Study SHP647-303, completed the ET or Week 52 visit in maintenance study SHP647-303, had responded to ontamalimab treatment (in the induction and/or maintenance studies), and meet one of the following criteria:
 - Subjects are on placebo at the maintenance study ET or Week 52 visit: they received ontamalimab in the induction studies and fulfilled the maintenance study response criteria, OR
 - Subjects have received ontamalimab at the maintenance study ET or Week 52 visit:
 - Clinical composite score that has decreased by ≥2 points and ≥30%, with an accompanying decrease in the subscore for RB ≥1 point or a subscore for RB ≤1, compared to the baseline value for induction studies, and/or
 - Composite score that has decreased by ≥30% and ≥3 points compared to the baseline value for induction studies.
- 4. Subjects receiving any treatment(s) for UC described in Section 5.1.2.1 are eligible provided they have been on a stable dose for the designated period of time.

4.1.2 Exclusion Criteria

Subjects are excluded from the study if any of the following criteria are met:

- 1. Subjects who had major protocol deviation(s) (as determined by the sponsor) in Study SHP647-301, SHP647-302, or SHP647-303.
- 2. Subjects who permanently discontinued investigational product because of an AE, regardless of relatedness to investigational product, in Study SHP647-301, SHP647-302, or SHP647-303.
- 3. Subjects who are likely to require major surgery for UC.
- 4. Subjects are females who became pregnant during Study SHP647-301, SHP647-302, or SHP647-303, females who are lactating, females who are planning to become pregnant during the study period, or males or females of childbearing potential not agreeing to continue using appropriate contraception methods (ie, highly effective methods for female and medically appropriate methods for male study subjects) through the conclusion of study participation (see Section 4.3).
- 5. Subjects who do not agree to postpone donation of any organ or tissue, including male subjects who are planning to bank or donate sperm and female subjects who are planning to harvest or donate eggs, for the duration of the study and through 16 weeks after last dose of investigational product.
- 6. Subjects who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
- 7. Subjects who have a newly-diagnosed malignancy or recurrence of malignancy (other than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
- 8. Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, GI [except disease under study], endocrine, cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.
- 9. Subjects with any other severe acute or chronic medical or psychiatric condition or laboratory or electrocardiogram (ECG) abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.

- 10. Subjects with known exposure to *Mycobacterium tuberculosis* (TB) since testing at screening in Study SHP647-301 or SHP647-302 and who have been advised to require treatment for latent or active disease, but who are without a generally accepted course of treatment.
- 11. Subjects who are investigational site staff members or relatives of those site staff members or subjects who are sponsor employees directly involved in the conduct of the study.
- Subjects who are participating in other investigational studies (other than SHP647-301, SHP647-302, or SHP647-303) or plan to participate in other investigational studies during long-term extension study SHP647-304.

4.2 Eligibility Criteria – Subjects with Crohn's Disease

4.2.1 Inclusion Criteria

Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:

- 1. Subjects and/or their parent or legally authorized representative must have an understanding, ability, and willingness to fully comply with study procedures and restrictions.
- 2. Subjects must be able to voluntarily provide written, signed, and dated (personally or via a legally authorized representative) informed consent and/or assent, as applicable, to participate in the study.
- 3. Subjects must have been enrolled previously in Study SHP647-305 or SHP647-306 and are in the treatment period of Study SHP647-307, completed the ET or Week 52 visit in maintenance study SHP647-307, had responded to ontamalimab treatment (in the induction and/or maintenance studies), and meet one of the following criteria:
 - Subjects are on placebo at the maintenance study ET or Week 52 visit: they received ontamalimab in the induction study and fulfilled the maintenance study response criteria, OR
 - Subjects have received ontamalimab at the maintenance study ET or Week 52 visit:
 - CDAI score that has decreased by ≥100 points at EOT visit compared to the baseline value for induction studies, and/or
 - SES-CD that has decreased by ≥25% compared to the baseline value for induction studies.
- 4. Subjects receiving any treatment(s) for CD described in Section 5.2.2.1 are eligible provided they have been on a stable dose for the designated period of time.

4.2.2 Exclusion Criteria

Subjects are excluded from the study if any of the following criteria are met:

- 1. Subjects who had major protocol deviation(s) (as determined by the sponsor) in Study SHP647-305, SHP647-306, or SHP647-307.
- Subjects who permanently discontinued investigational product because of an AE, regardless of relatedness to investigational product, in Study SHP647-305, SHP647-306, or SHP647-307.
- 3. Subjects who are likely to require major surgery for CD, or developed acute severe complications of CD (with or without fulfilling the treatment failure criteria in the maintenance study) that required immediate intervention (eg, need for immediate biologic treatment with proven effect) and/or CDAI score >450.
- 4. Subjects are females who became pregnant during Study SHP647-305, SHP647-306, or SHP647-307, females who are lactating, females who are planning to become pregnant during the study period, or males or females of childbearing potential not agreeing to continue appropriate contraception methods (ie, highly effective methods for female and medically appropriate methods for male study subjects) through the conclusion of study participation (see Section 4.3).
- 5. Subjects who do not agree to postpone donation of any organ or tissue, including male subjects who are planning to bank or donate sperm and female subjects who are planning to harvest or donate eggs, for the duration of the study and through 16 weeks after last dose of investigational product.
- 6. Subjects who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
- 7. Subjects who have a newly-diagnosed malignancy or recurrence of malignancy (other than resected cutaneous basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
- 8. Subjects who have developed any major illness/condition or evidence of an unstable clinical condition (eg, renal, hepatic, hematologic, GI [except disease under study], endocrine, cardiovascular, pulmonary, immunologic [eg, Felty's syndrome], or local active infection/infectious illness) that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.

- 9. Subjects with any other severe acute or chronic medical or psychiatric condition or laboratory or ECG abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- 10. Subjects with known exposure to TB since testing at screening in Study SHP647-305 or SHP647-306, and who have been advised to require treatment for latent or active disease, but who are without a generally accepted course of treatment.
- 11. Subjects who are investigational site staff members or relatives of those site staff members or subjects who are sponsor employees directly involved in the conduct of the study.
- 12. Subjects who are participating in other investigational studies (other than SHP647-305, SHP647-306, or SHP647-307) or plan to participate in other investigational studies during USE ONLY long-term extension study SHP647-304.

4.3 **Reproductive Potential**

The potential effects of ontamalimab on embryofetal or postnatal development have not been assessed in humans. Preliminary results from an enhanced pre- and postnatal development toxicity study of ontamalimab in nonhuman primates indicated that, at the dose levels tested (30 and 60 mg/kg), infant losses were increased in ontamalimab-exposed animals when compared both to control animals in the study and to the historical control animal data from the testing facility. The relevance of this finding to humans is unknown but cannot be excluded. Based on the exposure in the Phase 2 clinical study A7281009 (area under the concentration-time curve [AUC] from 0 to 672 hours [AUC_{0-672h}] at 6140 µg·h/mL following repeated SC administration of 75 mg SHP647 once every 4 weeks), maternal exposure (AUC) in cynomolgus monkeys within a similar duration at 30 and 60 mg/kg once every 10 days is approximately 77 times and 172 times the clinical exposure, respectively.

To minimize the risk of unintentional exposure of the embryo or fetus in the clinical study, all sexually active male and female subjects who, in the opinion of the investigator, are biologically capable of having children and with their partners are at risk of pregnancy, must agree to use an appropriate form of contraception (ie, highly effective methods for female and medically appropriate methods for male study subjects), in accordance with the package instructions/leaflet, for the duration of the active treatment period and for at least 16 weeks after the last dose of investigational product.

21 Sep 2020

True abstinence is considered to be a highly effective contraception (ie, a method that results in a failure rate of <1% per year) when it is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, postovulation methods), declaration of abstinence for the duration of exposure to investigational product, and withdrawal are not appropriate methods of contraception.

During the induction studies (SHP647-301, SHP647-302, SHP647-305, and SHP647-306) or maintenance studies (SHP647-303 and SHP647-307), the investigator or designee in consultation with the subject will confirm the subject's childbearing potential status. For subjects of childbearing potential, it must be confirmed and documented that the subject has selected the most appropriate method of contraception (ie, highly effective methods for female and medically appropriate methods for male study subjects) from the permitted list of contraception methods. Subjects must affirm the consistent and correct use of at least one of these selected methods. Regular contraception check discussions will take place at the time points specified in Table 1 and Table 2 (for subjects with UC), Table 3 and Table 4 (for subjects with CD) (ie, at each site visit) and will be documented. In addition, the subject must be instructed to call the site immediately if the selected contraception method is discontinued or if pregnancy is known or suspected.

4.3.1 Contraceptive Methods for Female Study Subjects

For subjects entering from a maintenance study, at baseline in this study, the childbearing potential of subjects must be re-established and documented if the subject's status has changed since the induction studies (SHP647-301, SHP647-302, SHP647-305, or SHP647-306) or maintenance studies (SHP647-303 or SHP647-307) (see Section 7.3.4.7).

Sexually active females of childbearing potential must already be using an established highly effective form of contraception, and must be advised to use appropriate contraceptives throughout the study period and for 16 weeks following the last dose of investigational product. If hormonal contraceptives are used they should be administered according to the package insert. Contraception methods with low user dependency should preferably be used, in particular when contraception is introduced as a result of participation in the clinical study. The following highly effective contraceptive methods are considered to be methods with low user dependency:

- Intrauterine device
- Intrauterine hormone-releasing system
- Bilateral tubal occlusion

- Male sterilization/vasectomized partner
- Implantable progesterone-only hormonal contraception associated with inhibition of ovulation.

Female subjects should be in one of the following categories:

- Postmenopausal (12 consecutive months of spontaneous amenorrhea and ≥51 years of age); postmenopausal status should be confirmed by follicle-stimulating hormone (FSH) testing.
- Surgically sterile (having undergone one of the following surgical acts: hysterectomy, bilateral tubal ligation, bilateral oophorectomy or bilateral salpingectomy) and at least 6 weeks post-sterilization or has medically confirmed ovarian failure.
- Females of childbearing potential with a negative pregnancy test result at Study SHP647-304 baseline. Females of childbearing potential must agree to practice true abstinence (refrain from sexual activity that could result in pregnancy) or agree to use appropriate methods of highly effective contraception.

Highly effective contraception (ie, methods that result in a failure rate of <1% per year when used consistently and correctly) are:

- Combined (estrogen- and progestogen-containing) hormonal contraceptives associated with inhibition of ovulation (oral, intravaginal, transdermal) stabilized for at least 30 days before Study SHP647-304 baseline
- Progestogen-only hormonal contraception associated with inhibition of ovulation plus a barrier method
- Intrauterine device
- Intrauterine hormone-releasing system
- Bilateral tubal occlusion
- Male sterilization/vasectomized partner with documented absence of sperm in the postvasectomy ejaculate
- True abstinence (see Section 4.3).

4.3.2 Contraceptive Methods for Male Study Subjects

Contraception is required for all sexually active male subjects, who with their female sexual partners, must agree to use one of the following appropriate methods of contraception throughout the study period and for 16 weeks following the last dose of investigational product.

Appropriate methods of contraception for male subjects are:

- Male condom with spermicide; however, if spermicide is not available in the country, additional contraception (ie, one of those listed below) must be used in addition to a male condom
- Male sterilization with documented absence of sperm in the postvasectomy ejaculate.

Appropriate methods for female sexual partners of male subjects are (unless the female sexual partner is sterile [surgically or documented nonsurgical sterility])

- Use of a highly effective method of contraception listed in Section 4.3.1 OR an acceptable method of contraception (failure rate of >1% per year)
 - Female condom with spermicide (use by female sexual partner); however, if spermicide is not available in the country, additional contraception (ie, one of those listed below) must be used in addition to a female condom
 - Intrauterine device with spermicide
 - Contraceptive sponge with spermicide
 - Intravaginal system (eg, vaginal ring with spermicide, a diaphragm with spermicide, or a cervical cap with spermicide).

4.4 Withdrawal of Subjects

A subject may withdraw from the study at any time for any reason without prejudice to their future medical care by the physician or at the institution. The investigator or sponsor may withdraw the subject at any time (eg, in the interest of subject safety). The investigator is encouraged to discuss withdrawal of a subject from investigational product with the medical monitor when possible.

If investigational product is discontinued, regardless of the reason, the evaluations listed for the EOT visit are to be performed. All subjects who discontinue investigational product should also undergo the protocol-specified 12-week follow-up period. In the event that subjects are unable to

21 Sep 2020

attend in person for the follow-up visit, all efforts should be made to collect information on AEs and concomitant medications. Comments (spontaneous or elicited) or complaints made by the subject must be recorded. The reason for termination and date of stopping investigational product must be recorded.

Subjects who discontinue will not be replaced.

4.4.1 Loss of Response

If response to investigational product is lost, based on clinical criteria, or if there is an unexplained clinical exacerbation or unacceptably low level of clinical response, the investigator may assess biomarkers and perform other investigations to exclude other potential causes like *C. difficile* infection or an appropriate ad-hoc endoscopy to determine whether the loss of response is confirmed or not at an unscheduled visit. The totality of available data will be used to determine ongoing response status and subjects whose loss of response is confirmed.

If clinical response criteria are no longer satisfied and alternative explanations for clinical worsening (eg, infection) can be excluded, the subject will be discontinued. If necessary for assessment in the opinion of the investigator (eg, borderline treatment response results), the following evaluations may be considered:

 Have subject return in 2 to 4 weeks for repeat assessment if loss of response criteria is still met:

a) Perform endoscopy to determine if there is an objective benefit despite clinical symptoms; if the composite of clinical and endoscopic data meets response criteria, continue the study.

- Endoscopic response criterion for UC is Mayo endoscopic subscore decreased by ≥1 point as compared to the baseline value recorded upon entry into the induction studies.
- 2. Endoscopic response criterion for CD is SES-CD improved by >25% as compared to the baseline value recorded upon entry into the induction studies.

b) Biomarkers may be used to determine overall response criteria at the discretion of the investigator; serum CRP < upper limit of normal (ULN) or fecal calprotectin <250 μ g/g is considered indicative of clinical benefit.

Upon termination from the study, subjects must return for a safety visit 12 weeks after the last dose of investigational product.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

Subjects who have experienced loss of response should be withdrawn from active treatment once other possible etiologies have been ruled out and appropriate clinical evaluation has been performed as suggested above. While these response criteria are offered as general guidance to the investigator, there may be additional criteria that warrant withdrawal from active treatment, and the ultimate decision of withdrawal from active treatment is left to the investigator based on the assessment of disease activity, the subject's clinical benefit, and tolerance of the investigational product.

4.4.2 Subject Withdrawal Criteria

Additional reasons a subject may be withdrawn from active treatment include but are not limited to: AEs, SAEs, pregnancy, protocol deviations, and failure to return for visits.

A subject should be withdrawn from study treatment if the subject undergoes surgery for UC or CD.

Subjects who withdraw from active treatment due to an increase in disease symptoms may see nonstudy-related physicians for treatment, and may receive treatments prohibited during the treatment periods of this study.

If a subject chooses to withdraw from study participation due to personal concerns related to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits (other than a COVID-19-related or other pandemic-related AE), this should be specified as the reason for subject withdrawal in the electronic case report form (eCRF).

If a subject withdraws from the study, and also withdraws consent for disclosure of future information, no further evaluation should be performed, and no additional data should be collected. The sponsor may retain and continue to use any data collected before such withdrawal of consent.

4.4.3 Reasons for Withdrawal

The reason for withdrawal must be determined by the investigator and recorded in the subject's medical record and source document. This includes unavoidable circumstances, such as a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits.

Shire **Ontamalimab** SHP647-304 Protocol Amendment 4

Page 73

If a subject chooses to withdraw from study participation due to personal concerns related to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits (other than a COVID-19-related or other pandemic-related AE), this should be specified as the reason for subject withdrawal in the eCRF.

Other reasons for discontinuation may include but are not limited to:

- Adverse event (AE) •
- Protocol deviation
- Withdrawal by subject
- Lost to follow-up
- Loss of response ٠
- . m. m.commercialui Other (if "other" is selected, the investigator must specify the reason)
- Death
- Physician decision •
- Pregnancy •
- Screen failure
- Site terminated by sponsor
- Study terminated by sponsor. •

4.4.4 Subjects "Lost to Follow-up" Prior to Last Scheduled Visit

A minimum of 3 documented attempts must be made to contact any subject lost to follow-up at any time point before the last scheduled contact (office visit or telephone contact). At least one of these documented attempts must include a written communication sent to the subject's last known address via courier or mail (with an acknowledgement of receipt request) asking that they return to the site for final safety evaluations.

Page 74

PRIOR AND CONCOMITANT TREATMENT 5.

5.1 Prior and Concomitant Treatment – Subjects with Ulcerative Colitis

5.1.1 **Prior Treatment**

Prior treatment includes all treatment (including but not limited to herbal remedies and vitamins) that is ongoing at the time of the baseline visit. It is expected that prior treatment will have been recorded during the induction study.

5.1.2 **Concomitant Treatment**

Concomitant treatment refers to all treatment taken between the dates of the first dose of investigational product in this study and the end of the safety follow-up period, inclusive. Additional safety assessments may be required, according to concomitant therapy safety recommendations. only

5.1.2.1 **Permitted Treatment**

Any permitted treatment may be initiated or discontinued as clinically appropriate. The following treatments for UC are permitted as concomitant medication:

- 5-ASA (mesalamine) and sulfasalazine
- Immunosuppressants (AZA, 6-MP, MTX) •
- Concomitant oral glucocorticoids; however, tapering should start once subject achieves adequate treatment response and should be guided by investigator clinical judgment. The recommended tapering scheme, based on European Crohn's and Colitis Organisation (ECCO) guidelines, is shown in Table 5.

Note: If a new course of oral glucocorticoid treatment (for IBD) is required, the subject should be discontinued from the study.

	First Taper	Subsequent Taper
Timing	Prospectively define glucocorticoid-dependent subjects (ie, ECCO ^a)	When subject is stable
Increments	• If daily dose >10 mg: Taper by 5 mg/day each 1-2 weeks	 If daily dose is >5 mg: Taper by 2.5 mg/day each week
	• When daily dose is ≤10 mg: Taper by 2.5 mg/day each 1-2 weeks	 When daily dose is ≤5 mg: Taper by 1 mg/day each week
Action if unable to taper	Return to SHP647-304 baseline dose	

Table 5 Glucocorticoid Tapering – Subjects with Ulcerative Colitis

ECCO=European Crohn's and Colitis Organisation.

^a Glucocorticoid-dependent subjects are:

- Subjects who are unable to reduce glucocorticoids below the equivalent of prednisone 10 mg/day (or budesonide below 3 mg/day) within 3 months of starting glucocorticoids, without recurrent active disease OR
- Subjects who have a relapse within 3 months of stopping glucocorticoids (Dignass et al., 2012).

Medicinal marijuana (cannabis) under a physician's prescription, obtained from a licensed pharmacy or provider may be used.

Routine nonlive vaccinations are allowed during the study.

Dietary and herbal supplements and probiotics are allowed in the study and should be recorded as concomitant medications.

Use of nicotine-containing preparations should be recorded as concomitant medication.

5.1.2.2 Prohibited Treatment

The following common treatments are excluded medications for this study. As the subjects are transferred from Study SHP647-301, SHP647-302, or SHP647-303, during which these treatments were also prohibited, no washout period is applicable.

- Anti-integrin or antiadhesion molecule treatment (eg, natalizumab, vedolizumab, efalizumab, etrolizumab)
- Anti-TNF treatment and other biologics with immunomodulatory properties including biosimilars
- Live (attenuated) vaccines
- Any investigational product other than ontamalimab

- Nonbiologics with immunomodulatory properties (except for AZA, 6-MP, and MTX, which are permitted)
- Leukocyte apheresis or selective lymphocyte, monocyte, or granulocyte apheresis or plasma exchange.

Treatments not listed in this section may be considered allowable; see Section 5.1.2.1 for further details.

No new nonpharmacological therapies that might affect bowel habit or GI function should be started during the study.

Subjects who enter the 12-week safety follow-up period will no longer need to abstain from the medications that were prohibited during the treatment period. Other UC treatments will be allowed. Biologics or nonbiologic immunosuppressants should not be initiated without prior discussion with the sponsor study physician or designee, due to the long half-life of ontamalimab.

5.2 Prior and Concomitant Treatment – Subjects with Crohn's Disease

5.2.1 **Prior Treatment**

Prior treatment includes all treatment (including but not limited to herbal remedies and vitamins) that is ongoing at the time of the baseline visit. It is expected that prior treatment will have been recorded during the induction study.

5.2.2 Concomitant Treatment

Concomitant treatment refers to all treatment taken between the dates of the first dose of investigational product in this study and the end of the safety follow-up period, inclusive. Additional safety monitoring may be required, according to concomitant therapy safety recommendations.

5.2.2.1 Permitted Treatment

The following treatments for CD are permitted as concomitant medication:

- Oral 5-ASA (mesalamine) and sulfasalazine
- Immunosuppressants (AZA, 6-MP, MTX)

• Concomitant oral glucocorticoids; however, tapering should start once subject achieves adequate treatment response and should be guided by investigator clinical judgment. The recommended tapering scheme, based on ECCO guidelines, is shown in Table 6. Parenteral and rectally used glucocorticoids are permitted per discretion of the investigator.

Note: If a new course of oral glucocorticoid treatment (for IBD) is required, the subject should be discontinued from the study.

	First Taper	Subsequent Taper
Timing	Prospectively define glucocorticoid-dependent subjects (ie, ECCO ^a)	When subject is stable
Increments	 If daily dose >10 mg: Taper by 5 mg/day each 1-2 weeks When daily dose is <10 mm 	If daily dose is >5 mg: Taper by 2.5 mg/day each week
	• When daily dose is ≤10 mg: Taper by 2.5 mg/day each 1-2 weeks	 When daily dose is ≤5 mg: Taper by 1 mg/day each week
	 When daily dose of budesonide is up to a maximum of 9 mg/day: Taper by 3 mg every 3 weeks 	
Action if unable to taper	Return to SHP647-304 baseline dose	

Table 6 Glucocorticoid Tapering – Subjects with Crohn's Disease

ECCO=European Crohn's and Colitis Organisation.

^a Glucocorticoid-dependent subjects are:

- Subjects who are unable to reduce glucocorticoids below the equivalent of prednisone 10 mg/day (or budesonide below 3 mg/day) within 3 months of starting glucocorticoids, without recurrent active disease OR
- Subjects who have a relapse within 3 months of stopping glucocorticoids (Dignass et al., 2012).

Antidiarrheal opiate drugs such as IMODIUM[®] (loperamide), LOMOTIL[®] (diphenoxylate hydrochloride and atropine sulfate), tincture of opium, and codeine will be recorded.

Medicinal marijuana (cannabis) under a physician's prescription, obtained from a licensed pharmacy or provider may be used.

Routine nonlive vaccinations are allowed during the study.

Dietary and herbal supplements and probiotics are allowed in the study and should be recorded as concomitant medications.

Use of nicotine-containing preparations should be recorded as concomitant medication.

5.2.2.2 Prohibited Treatment

The following common treatments are excluded medications for this study. As the subjects are transferred from Study SHP647-305, SHP647-306, or SHP647-307, during which these treatments were also prohibited, no washout period is applicable.

- Off-label usage of immunosuppressants used in transplantation or other non-established therapies for CD (eg, mycophenolate mofetil, cyclosporine, rapamycin, thalidomide, tofacitinib, or tacrolimus)
- Rectally administered 5-ASA
- Bismuth subsalicylate products
- Anti-TNF treatment and other biologics with immunomodulatory properties, including biosimilars
- Anti-integrin or antiadhesion molecule treatment (eg, natalizumab, vedolizumab, efalizumab, etrolizumab)
- Nonbiologics with immunomodulatory properties (except for AZA, 6-MP, and MTX, which are permitted)
- Lymphocytes apheresis or selective monocyte granulocytes apheresis
- Live (attenuated) vaccines
- Fecal microbiota transplantation
- Any investigational product other than ontamalimab.

Treatments not listed in this section may be considered allowable; see Section 5.2.2.1 for further details.

No new nonpharmacological therapies that might affect bowel habit or GI function should be started during the study.

Parenteral nutrition is not permitted at any time during the study.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

Page 79

Subjects who enter the 12-week safety follow-up period will no longer need to abstain from the medications that were prohibited during the treatment period. Other CD treatments will be allowed. Biologics or nonbiologic immunosuppressants should not be initiated without prior discussion with the sponsor study physician or designee, due to the long half-life of ontamalimab.

5.3 COVID-19

In cases in which the subject is known to have been infected with the COVID-19 virus but does not have the disease, he or she should be actively moved to lower doses of prednisone (<20 mg/day) or transition to budesonide when feasible. Thiopurines and MTX should be temporarily withheld. The study drug should have dosing delayed for 2 weeks while the subject is monitored for the development of COVID-19.

Fornoncommercialuse only

6. INVESTIGATIONAL PRODUCT

6.1 Identity of Investigational Product

The test product is ontamalimab, which will be provided as a sterile aqueous buffered solution for SC administration in a glass PFS with a fixed needle. Each PFS contains 1 mL of ontamalimab solution for injection at an appropriate concentration to provide the intended dose of drug (25 mg or 75 mg). Additional information is provided in the current ontamalimab IB.

6.1.1 Blinding the Treatment Assignment

The fill volume for all syringes will be the same.

This study has been double-blind, as the purpose of the blinding was to maintain the blind in maintenance study SHP647-303 for UC subjects and SHP647-307 for CD subjects while these studies are ongoing. Due to the early discontinuation of the program, this study is planned to become unblinded after the completion of the analysis for the induction studies (SHP647-301, SHP647-302, SHP647-305, and SHP647-306) and prior to the completion of the SHP647-303 and SHP647-307 studies. Until the induction study results become available, this study will continue to be blinded (ie, unblinding will not occur until the final analysis of the induction studies is completed), as it is planned that subjects will receive the lowest effective dose based on the results of the induction studies. It is expected that the analysis of these results will demonstrate the efficacy of at least one of the doses and allow for the selection of a single dose, at which time this study will be open label. If both doses are effective and the difference compared to placebo is similar, then the lowest effective dose will be selected. If neither dose is deemed efficacious, this study will be terminated.

As the treatment assignment is planned to be unblinded after the completion of the analysis for the induction studies (SHP647-301, SHP647-302, SHP647-305, and SHP647-306) and prior to the completion of the SHP647-303 and SHP647-307 studies, these two studies will be considered unblinded, and the date of study unblinding will be recorded.

6.2 Administration of Investigational Product(s)

6.2.1 Interactive Response Technology for Investigational Product Management

An interactive response technology (IRT) system will be used for enrolling subjects, recording subject visits, investigational product supply dispensation and management, inventory management and supply ordering, and investigational product expiration tracking and management. Please refer to the Study Manual for additional details regarding the IRT system.

6.2.2 Allocation of Subjects to Treatment

Originally, subjects were to be randomized to treatment in this study. Under Amendment 4 of the protocol, randomization will not be performed, as the aim of the study is to provide subjects with the ontamalimab dose associated with their treatment response.

Following the confirmation of eligibility, subjects will be allocated to receive either 25 mg or 75 mg of ontamalimab SC every 4 weeks depending on which dose they had responded to in a prior study.

Eligible subjects who withdrew from Study SHP647-303 or SHP647-307 due to the early discontinuation of these studies, who received active treatment and showed treatment response at the EOT visit, will receive the dose of ontamalimab (that resulted in treatment response) in the previous maintenance study every 4 weeks. Eligible subjects currently receiving placebo in maintenance study SHP647-303 or SHP647-307 will receive the same dose of ontamalimab that they received in the previous induction study every 4 weeks.

Subject numbers are assigned to all subjects as they consent to take part in the study. The subject numbers will be different than the numbers assigned in SHP647-301, SHP647-302, SHP647-303, SHP647-305, SHP647-306, and SHP647-307 for subjects who enter from these studies. The randomization number represents a unique number corresponding to investigational product allocated to the subject, once eligibility has been determined.

If during the study, either the 25 mg or 75 mg dose of ontamalimab is determined to be the efficacious dose, based on emergent data from the induction studies, subjects may have their treatment assignment switched to that dose, and the study would continue as an open-label study at that dose level, unless neither dose is efficacious, in which case this study will be terminated.

To preserve blinding, all subjects will receive a randomization number, including those subjects who completed a maintenance study (SHP647-303 or SHP647-307) and are to receive the same ontamalimab dose in this study. Individual subject treatment is automatically assigned by the IRT system.

Investigational product packaging identification numbers, separate from randomization numbers/unique identifiers, may also be assigned to subjects for specific treatment assignment as dictated by the study, until the time of unblinding. In these cases, the same investigational product packing identification number may not be assigned to more than 1 subject.

6.2.3 Dosing

Investigational product (ontamalimab) will be administered subcutaneously every 4 weeks for the duration of the treatment period. See Section 7.3 for the timing of dosing relative to other procedures.

Investigational product should be administered in the anterolateral right or left thigh. The injection site should be rotated. If there are clinical reasons why the drug cannot be administered in the thigh, the drug may be administered in the deltoid area or abdomen with appropriate documentation.

As some subjects may enter this study having received placebo and not active treatment in the induction (SHP647-301, SHP647-302, SHP647-305, or SHP647-306) or maintenance (SHP647-303 or SHP647-307) study, after the first administration of investigational product, the subject must be observed by a member of the study staff for at least 30 minutes (the total duration should be determined at the discretion of the investigator). For subsequent administrations, observation of the subject is at the discretion of the investigator. Injection site and allergic reaction monitoring should be completed by a member of the study staff.

Principal investigators are responsible for ensuring that all study and nonstudy personnel identified to administer investigational product are qualified, with documented training and delegation of responsibilities prior to their first investigational product administration visit at subjects' homes.

In a situation in which a subject is not able to visit the study site due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits, DTP investigational product administration options may be available, in accordance with local regulations (refer to DTP guidance document).

All subjects and nonstudy personnel performing the investigational product administration must receive training in order to receive DTP shipments. Training will include how to identify hypersensitivity reactions, inject the IP, and properly dispose of IP after use. Training may be in person or via telephone call. All DTP shipments will require pre-administration and post-administration calls by the site staff to assess and monitor subject's health status and safety; to review any AEs, concomitant medications, and diary assessments; and to perform the neurological questionnaire assessment by the investigator. These calls must be appropriately recorded in the source document.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

The personnel that perform study procedures at the subjects' homes will be delegated, trained, and properly supervised by the principal investigator(s) of each site.

All study and nonstudy personnel will be trained on potential hypersensitivity reactions (Type I and Type III) and associated symptoms.

NOTE: DTP investigational product administration, except when performed by study personnel, is NOT ALLOWED for a subject's first dose of investigational product in this study.

Investigator-directed delays in dosing due to abnormal laboratory results or AEs or due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits should be discussed with the medical monitor to determine whether the subject should remain in the study. Dosing delays up to 8 weeks (2 doses) are allowed, and the subjects are allowed to miss a maximum of 2 doses due to COVID-related or other pandemic-related issues (see Section 5.3). Sites must receive Shire approvals for each subject meeting the missed/delayed dosing criteria.

The investigator, or an approved representative (eg, pharmacist), will ensure that all investigational product is dispensed by qualified staff members. During the COVID-19 public health emergency (or other similar pandemic), alternative investigational product delivery to study participants may be necessary to avoid unnecessary subject visits to sites while providing needed investigational product. Additional investigational product may be dispensed during a scheduled study visit or investigational product may be shipped directly from investigational sites to participants' residences by a contracted logistics provider or distributor (DTP shipment) in compliance with national laws or temporary national emergency measures and sponsor processes.

6.2.4 Unblinding the Treatment Assignment

This study has been double-blind and will continue as such until the induction study results become available (ie, unblinding will not occur until the final analysis of the induction studies is completed and the lowest effective dose determined), as it is planned that subjects will receive the lowest effective dose based on the results of the induction studies.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

Prior to the time of unblinding, whenever possible, the investigator or sub-investigator should contact the Shire physician and/or assigned medical monitor before breaking the blind. It is understood that in an emergency situation it may not be possible to communicate with the study team before breaking the blind. The safety of the subject should be of primary concern. When the blinding code is broken, the reasons must be fully documented.

In the event that the treatment assignment is broken, the date, the signature of the person who broke the code, and the reason for breaking the code are recorded on the IRT and the source documents. Upon breaking the blind, the subject is withdrawn from the study but should be followed up for safety purposes. The IRT will notify the relevant personnel in the event of any code break. Code-break information is held by the pharmacist/designated person at the site. Note: This is applicable only until the time of unblinding.

6.3 Labeling, Packaging, Storage, and Handling

6.3.1 Labeling

eonth The sponsor will provide the investigator with packaged investigational product labeled in accordance with specific country regulatory requirements. All investigational product is labeled with a minimum of the following: protocol number, medication identification number, dosage form (including product name and quantity in pack), directions for use, storage conditions, expiry date (if applicable), batch number and/or packaging reference, the statements "For clinical trial use only" and/or "CAUTION: New Drug – Limited by Federal (or US) Law to Investigational Use" and the sponsor's name and address.

Additional labels may be applied in order to meet local or institutional requirements, but must not:

- Contradict the clinical study label •
- Obscure the clinical study label
- Identify the study subject by name.

Additional labels may not be added without the sponsor's prior written agreement.

Page 85

6.3.2 Packaging

Investigational product is packaged in the following labeled containers: PFS with nominal fill volume of 1 mL. The PFS will be packaged in a foam insert and labelled carton.

Changes to sponsor-supplied packaging before dosing may not occur without full agreement in advance by the sponsor.

6.3.3 Storage

The investigator has overall responsibility for ensuring that investigational product is stored in a secure, limited-access location. Limited responsibility may be delegated to the pharmacy or member of the study team, but this delegation must be documented. Investigational products are distributed by the pharmacy or delegated member of the study team. The pharmacist or delegated team member will enter the unique subject identifier on the investigational product labels as they are distributed.

0,

Investigational product must be stored in accordance with labeled storage conditions. Temperature monitoring is required at the storage location to ensure that the investigational product is maintained within an established temperature range. In case of a DTP situation, the investigational product can be shipped to subject's home; please refer to DTP guidance for further details.

The investigator is responsible for ensuring that the temperature is monitored throughout the duration of the study and that records are maintained; the temperature should be monitored continuously by using either an in-house system, a mechanical recording device such as a calibrated chart recorder, or by manual means, such that both minimum and maximum thermometric values over a specific time period can be recorded and retrieved as required. Such a device (ie, certified min/max thermometer) would require manual resetting upon each recording. The sponsor must be notified immediately upon discovery of any excursion from the established range. Temperature excursions will require site investigation as to cause and remediation. The sponsor will determine the ultimate impact of excursions on the investigational product and will provide supportive documentation as necessary. Under no circumstances should the product be dispensed to subjects until the impact has been determined and the product is deemed appropriate for use by the sponsor.

The sponsor should be notified immediately if there are any changes to the storage area of the investigational product that could affect the integrity of the product(s), eg, fumigation of a storage room.

6.3.4 Special Handling

The investigational product should be protected from light and should not be frozen. Do not shake. In case of a DTP situation, the safety of the investigational product will be managed; it will be transported via a secured courier or study site personnel with temperature monitoring and tracking. Please refer to DTP guidance for further details.

6.4 Drug Accountability

Investigators will be provided with sufficient amounts of the investigational product to carry out this protocol for the agreed number of subjects. The investigator or designee will acknowledge receipt of the investigational product, documenting shipment content and condition. Accurate records of all investigational product dispensed, used, returned, and/or destroyed must be maintained as detailed further in this section.

The investigator has overall responsibility for administering/dispensing investigational product. Where permissible, tasks may be delegated to a qualified designee (eg, a pharmacist) who is adequately trained in the protocol and who works under the direct supervision of the investigator. This delegation must be documented in the applicable study delegation of authority form.

The investigator or his/her designee (as documented by the investigator in the applicable study delegation of authority form) will administer the investigational product only to subjects included in this study following the procedures set out in the study protocol. Each subject will be given only the investigational product carrying his/her treatment assignment. All administered investigational product will be documented in the subject's source document and/or other investigational product record. In case of a DTP situation, the investigational product administration will be documented in the drug administration visit report form (if nonstudy personnel administer the investigational product) and in the drug administration log (in case of self-administration by the subjects/caregivers/parents).

No investigational product stock or returned inventory from a Shire-sponsored study may be removed from the site where originally shipped without prior knowledge and consent by the sponsor. If such transfer is authorized by the sponsor, all applicable local, state, and national laws must be adhered to for the transfer. In case of a DTP situation, the process for shipping of used investigational product to the site is described in the DTP guidance.

The sponsor or its representatives must be permitted access to review the supplies storage and distribution procedures and records provided that the blind of the study is not compromised.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

Page 87

With the written agreement of the sponsor, at the end of the study all unused stock may be destroyed at the site or a local facility. In this case, destruction records identifying what was destroyed, when and how, must be obtained with copies provided to the sponsor. Destruction of investigational products must be in accordance with local, state, and national laws.

Based on entries in the site drug accountability forms, it must be possible to reconcile investigational products delivered with those used and returned. All investigational products must be accounted for and all discrepancies investigated and documented to the sponsor's satisfaction.

6.5 Subject Compliance

Drug accountability must be assessed at the container/packaging level for unused investigational product that is contained within the original tamper-evident sealed container (eg, bottles, vials, and cartons) or at the individual count level for opened containers/packaging. The pharmacist or delegated team member will record details on the drug accountability form.

- ane drug account

7. STUDY PROCEDURES

7.1 Changes to Study Procedures Due to a Pandemic

The following information provides guidance regarding changes to study procedures that may be implemented for study participants or study sites affected by a pandemic (eg, coronavirus disease [COVID-19] or other future similar unexpected public health concerns) that require physical distancing that may result in subjects missing their visits. This guidance takes references from the US Food and Drug Administration (FDA) Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency – Guidance for Industry, Investigators, and Institutional Review Boards, March 2020, updated 02 July 2020; the European Medicines Agency (EMA) Guidance on the Management of Clinical Trials During the COVID-19 (Coronavirus) Pandemic, Version 3 (28 April 2020); and the EMA Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials, dated 26 June 2020.

Because a pandemic (eg, COVID-19) may peak in different regions at different times and restrictions implemented by local laws and recommendations may vary, any decision on procedural changes should be made on a case-by-case basis by the principal investigator in consultation with the study team and the medical team as needed, while maintaining subject safety and confidentiality as the priority.

Procedural changes due to COVID-19 (or other similar pandemic) may include the following (refer to DTP guidance document for further details):

- Allow study sites to follow COVID-19 screening requirements per local regulations.
- Identify which study visits and procedures may be conducted in the clinic or by optional home healthcare and evaluations that may be done remotely (eg, Telehealth, Telemedicine). See Table 1, Table 2, Table 3, and Table 4 for details on subject visits that must be done with the subject present at the investigative site and visits that may be conducted at the clinic or by home healthcare visits to extend flexibility to patients during the COVID-19 public health emergency (or other similar pandemic). Home healthcare visits will be documented in the study records and eCRF.
- Allowance of more flexibility around scheduling of study visits and/or allowing some assessments to be conducted remotely (See Table 1, Table 2, Table 3, and Table 4).

- For home healthcare visits, collection of clinical laboratory samples (blood specimen collection or other diagnostic tests) may be performed by the investigator or qualified site staff who can visit the trial participant's residence, or at a local laboratory if necessary.
- Missed clinic visits or subject withdrawals due to COVID-19 (or other similar pandemic) must be recorded on the eCRF (See Section 4.4.3, Reasons for Withdrawal).
- ECG procedures: For home healthcare visits, ECGs may be performed by a qualified healthcare professional who is authorized/certified to perform such tests routinely.
- "Remote visits" via virtual communications (eg, TeleHealth application) may be performed as a safety check (AE assessment) on subject well-being, concomitant medication use, neurological assessments, etc.
- Allow transfer of study participants to investigational sites away from risk zones or closer to their home that are already participating in the trial or to new sites.
- Deviations from the protocol-specified procedures (eg, not collecting a protocol-specified specimen, such as postdose bloodwork) will be recorded as related to COVID-19 (or other similar pandemic).
- Alternative investigational product deliveries may include dispensing additional investigational product at clinic visits or DTP delivery of the investigational product from the investigational site to subjects in compliance with national laws or temporary national emergency measures (See Section 6.2.3, Dosing and Section 6.3, Labeling, Packaging, Storage, and Handling).

7.2 Study Schedule

The investigator may schedule visits (unscheduled visits) in addition to those listed on the schedules of assessments (Table 1 and Table 2 for subjects with UC and Table 3 and Table 4 for subjects with CD), in order to conduct evaluations or assessments required to protect the well-being of the subject.

7.2.1 Subjects with Ulcerative Colitis

7.2.1.1 Baseline Visit (Week 0/Day 1)

For subjects entering into Study SHP647-304 from maintenance study SHP647-303 and who completed the 52-week treatment period, procedures performed (with the exception of the treatment response evaluation) at the Week 52 visit will be used as the baseline visit (Week 0/Day 1) assessments for this extension study. For subjects entering from maintenance study SHP647-303 and who completed participation prior to Week 52, procedures performed (with the exception of the treatment response evaluation) at the ET visit will be used as the baseline visit (Week 0/Day 1) assessments for this extension study. The assessments and procedures performed during the baseline visit are specified in Table 1.

For subjects entering into Study SHP647-304 from a maintenance study, baseline of the induction study will be used as the baseline visit (Week 0/Day 1) for treatment response evaluation for this extension study.

The assessments and procedures performed during the baseline visit are specified in Table 1.

Ø

A screen failure is a subject who has given informed consent or assent, as applicable (and whose parents or legally authorized representatives have given informed consent, as applicable), failed to meet the inclusion criteria and/or met at least one of the exclusion criteria, and has not been administered investigational product.

For eligible subjects, all relevant study information (with the exception of the treatment response evaluation) recorded for Week 12 of the induction study or Week 52 or ET of the maintenance study will be used as the baseline visit data for this extension study.

After eligibility has been confirmed and all baseline procedures and assessments have been completed, each subject will be assigned to 1 of the 2 treatment groups as described in Section 6.2.2 and the first dose of investigational product will be administered.

7.2.1.2 Treatment Period

During the treatment period in this extension study, subjects will attend study visits every 4 weeks (Weeks 4, 8, 12, 16, etc.). Assessments and procedures to be performed at each visit are specified in Table 1.

Assessments and procedures to be performed at each visit beginning in Treatment Year 2 (Week 52) are specified in Table 2.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

For subjects who are tolerating investigational product and receiving clinical benefit in the judgment of the investigator, study participation may continue until the subject withdraws from the study, or the investigator or sponsor decide to withdraw the subject (eg, in the interest of

subject safety), or the sponsor decides to close the study, or the program is stopped completely.

Once study treatment has ended, ie, for any of the reasons described in Section 4.4, subjects will attend the EOT visit, at which assessments and procedures will be performed as shown in Table 2. The EOT visit is preferred to be an on-site visit; however, due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits, this visit may also be conducted at a subject's home, provided a qualified site staff member performs these evaluations following DTP guidance. After completion of the EOT visit, subjects will enter the safety follow-up period.

7.2.1.3 Follow-up Period

The safety follow-up period for this protocol is 12 weeks from the EOT visit for each subject. During the follow-up period, there will be a visit at the study site at 12 weeks (± 10 days) post-EOT. The 12-week safety follow-up visit is preferred to be an on-site visit; however, due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits, this visit may also be conducted at a subject's home, provided a qualified site staff member performs these evaluations following DTP guidance.

The assessments and procedures specified in Table 2 will be performed, including querying for SAEs, AEs, and concomitant treatments. All AEs and SAEs that are not resolved at the time of this visit will be followed to closure (see Section 8.1).

7.2.2 Subjects with Crohn's Disease

7.2.2.1 Baseline Visit (Week 0/Day 1)

For subjects entering into Study SHP647-304 from maintenance study SHP647-307 and who completed the 52-week treatment period, procedures performed (with the exception of the treatment response evaluation) at the Week 52 visit will be the baseline visit (Week 0/Day 1) assessments for this extension study. For subjects entering from maintenance study SHP647-307 and who completed participation prior to Week 52, procedures performed (with the exception of the treatment response evaluation) at the ET visit will be the baseline visit (Week 0/Day 1) assessments for this extension study.



Shire Ontamalimab SHP647-304 Protocol Amendment 4

For subjects entering into Study SHP647-304 from a maintenance study, baseline of the induction study will be used as the baseline visit (Week 0/Day 1) for treatment response evaluation for this extension study.

The assessments and procedures performed during the baseline visit are specified in Table 3.

A screen failure is a subject who has given informed consent or assent, as applicable (and whose parents or legally authorized representatives have given informed consent, as applicable), failed to meet the inclusion criteria and/or met at least one of the exclusion criteria, and has not been administered investigational product.

For eligible subjects, all relevant study information (with the exception of the treatment response evaluation) recorded for Week 16 of the induction study or Week 52 or ET of the maintenance study will be used as the baseline visit data for this extension study.

After eligibility has been confirmed and all baseline procedures and assessments have been completed, each subject will be assigned 1 of the 2 treatment groups as described in Section 6.2.2 and the first dose of investigational product will be administered.

7.2.2.2 Treatment Period

During the treatment period in this extension study, subjects will attend study visits every 4 weeks (Weeks 4, 8, 12, 16, etc.). Assessments and procedures to be performed at each visit are specified in Table 3.

Assessments and procedures to be performed at each visit beginning in Treatment Year 2 (Week 52) are specified in Table 4.

For subjects who are tolerating investigational product and receiving clinical benefit in the judgment of the investigator, study participation may continue until the subject withdraws from the study, or the investigator or sponsor decide to withdraw the subject (eg, in the interest of subject safety), or the sponsor decides to close the study, or the program is stopped completely.

Once study treatment has ended, ie, for any of the reasons described in Section 4.4, subjects will attend the EOT visit, at which assessments and procedures will be performed as shown in Table 4. The EOT visit is preferred to be an on-site visit; however, due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits, this visit may also

be conducted at a subject's home, provided a qualified site staff member performs these evaluations following DTP guidance. After completion of the EOT visit, subjects will enter the safety follow-up period.

7.2.2.3 **Follow-up Period**

The safety follow-up period for this protocol is 12 weeks from the EOT visit for each subject. During the follow-up period, there will be a visit at the study site at 12 weeks (± 10 days) post-EOT. The 12-week safety follow-up visit is preferred to be an on-site visit; however, due to a pandemic (eg, coronavirus disease [COVID-19]) or other future similar unexpected public health concerns requiring physical distancing that may result in subjects missing their visits, this visit may also be conducted at a subject's home, provided a qualified site staff member performs these evaluations following DTP guidance.

The assessments and procedures specified in Table 4 (for subjects with CD) will be performed, including querying for SAEs, AEs, and concomitant treatments. All AEs and SAEs that are not resolved at the time of this visit will be followed to closure (see Section 8.1).

Additional Care of Subjects After the Study 7.2.3

No aftercare is planned for this study.

7.3

Study Evaluations and Procedures Every effort should be made to ensure that the protocol-required tests and procedures are completed as described. However, it is anticipated that from time to time there may be circumstances, outside the control of the investigator, that may make it unfeasible to perform the tests and procedures. In these cases, the investigator will take all steps necessary to ensure the safety and well-being of the subject.

When timing of procedures and assessments coincide, the following order should be followed:

- Vital signs and ECG
- Laboratory sample collection •
- Endoscopy, if performed (see Sections 7.3.2.1 and 7.3.3.1) •

• Investigational product administration.

Notes:

- Blood and tissue samples may be stored for up to the duration allowed by local regulations but for no longer than 25 years.
- Endoscopy is optional after the implementation of Amendment 4; if performed, the results should be recorded.

7.3.1 Demographic and Other Baseline Characteristics

For subjects entering this extension study SHP647-304 from a maintenance study, all relevant demographic and baseline characteristics recorded for the induction study (SHP647-301, SHP647-302, SHP647-305, or SHP647-306) or maintenance study (SHP647-303 or SHP647-307) will be used as the baseline characteristics for this study.

7.3.2 Treatment Response Assessments – Subjects with Ulcerative Colitis

7.3.2.1 Endoscopy

Endoscopy is optional after the implementation of Amendment 4; if performed, the results should be recorded using the Mayo endoscopic subscore. Endoscopy may be performed at the time points specified in Table 1 and Table 2 and is to consist of either flexible sigmoidoscopy or colonoscopy (if preferred) for subjects with UC or colonoscopy (if preferred) for subjects with CD. If more than 2 endoscopies/colonoscopies are needed in a year, the subject should be discontinued.

If it is necessary, bowel preparation should be conducted as per local routine. The position of the endoscope will be based on the length of the instrument at various levels of insertion as well as the morphological features of the intestine as seen during the baseline endoscopy in the induction study (SHP647-301 or SHP647-302) or maintenance study (SHP647-303).

The endoscopy report and any photographs and/or video recordings taken during the procedure per local custom should be filed in the subject's medical record. Endoscopy results will be reviewed by a local reader.

7.3.2.2 Mayo Score

The Mayo score is a measure of UC disease activity. Mayo scores (total or partial) will be recorded at the time points specified in Table 1 and Table 2.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

21 Sep 2020

The total Mayo score ranges from 0 to 12 points and consists of the following 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease (see Appendix 2):

- Bowel movement frequency (0-3)
- Rectal bleeding (0-3)
- Findings of flexible sigmoidoscopy or endoscopy (0-3)
- Physician global assessment (PGA; 0-3).

The partial Mayo score consists of the Mayo score without the endoscopic subscores and ranges from 0 to 9 points.

The composite score is a recommended measure consisting of the Mayo score without the PGA subscore and ranges from 0 to 9 points. Note: After the implementation of Amendment 4, endoscopy is optional, and the composite score will be computed only if an endoscopy is performed.

The clinical composite score is a measure consisting of RB plus stool frequency without endoscopic and PGA subscore.

Subjects will be instructed to maintain a daily memory aid for the 7 days prior to each visit. In the memory aid, subjects will record the total number of bowel movements and the worst RB experienced each day (see Section 7.3.2.3). At the scheduled visit, the investigator will ask the subject to report the daily stool count and RB score and enter the data into the eCRF to calculate the clinical composite (and if appropriate, composite) score for that visit.

The Mayo stool frequency and RB subscores will be calculated based on each subject's data over the most recent 3 days (consecutive or nonconsecutive) prior to the visit, excluding the following days: day of any bowel preparation, day of endoscopy, any days between day of bowel preparation and day of endoscopy, and the 2 days after the day of endoscopy.

The mucosal appearance during the sigmoidoscopic portion of the endoscopic examination (if performed) will be assessed for the Mayo endoscopic subscore based on the scoring system provided in the protocol (see Appendix 2). The endoscopic appearance will be read by the operator or study site investigator using video recorded during the procedure. Locally read endoscopic subscores, if performed, will be used for treatment response analyses.

The PGA acknowledges the 3 other criteria: the patient's recollection of abdominal discomfort and general sense of well-being and other observations (such as physical findings and the patient's performance status). The endoscopic subscore and the PGA must be performed by a physician qualified to perform endoscopy; it is recommended that the same physician performs all such assessments for a particular subject throughout the study, and that the same physician who performed the assessments during the induction study does so during the current study.

7.3.2.3 Ulcerative Colitis Memory Aid

Subjects will be asked to report the following signs and symptom data, as experienced over the previous 24 hours, with the assistance of a memory aid, which they may use for the 7 days prior to each scheduled visit:

- Stool frequency
- Rectal bleeding severity

The memory aid guidelines for subjects with UC are presented in Appendix 2.

7.3.3 Treatment Response Assessments – Subjects with Crohn's Disease

7.3.3.1 Colonoscopy

Colonoscopy is optional after the implementation of Amendment 4; if performed, the results should be recorded using the SES-CD. Colonoscopy may be performed at the time points specified in Table 3 and Table 4. If more than 2 colonoscopies are needed in a year, the subject should be discontinued.

Bowel preparation regimens typically incorporate dietary modifications along with oral cathartics. Typically, the standard dose of a bowel preparation is split between the day before and the morning of the procedure. In this study, bowel preparation and colonoscopy are to be conducted as per local routine; however, sodium phosphate based preparations should be avoided, as such regimens can produce mucosal changes that mimic IBD.

A complete colonoscopy that includes the visualization of rectum, the sigmoid colon, the left colon, the transverse colon, the right colon, the ileocecal valve, and the terminal ileum should be performed. Incomplete endoscopy caused by but not limited to a complication during endoscopy, interruption of the endoscopy for any reasons cannot be accepted as complete colonoscopy with the exception of impassable stenosis or other CD-related complications as cause of failure to complete the colonoscopy procedure.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

The position of the endoscope will be based on the length of the instrument at various levels of insertion as well as the morphological features of the intestine as seen during the baseline endoscopy in the induction study (SHP647-305 or SHP647-306). The colonoscopy report and any photographs and/or video recordings taken during the procedure per local custom should be filed in the subject's medical record. Colonoscopy results will be reviewed by a local reader.

7.3.3.2 Simple Endoscopic Activity Score for Crohn's Disease

Colonoscopy, if performed, will be evaluated by the SES-CD scoring system at the time points specified in Table 3 and Table 4.

The SES-CD will be calculated using the subscores of each of the segments investigated and read by the local endoscopist at each of the visits when colonoscopy is performed. The baseline score will be based on the colonoscopy that was performed prior to the start time of the first dose of this study. If not taken in this study, the score for the baseline (Week 0/Day 1) visit will be based on the last colonoscopy performed in the study from which the subject is entering.

The SES-CD is a simple scoring system based on 4 endoscopic variables (presence and size of ulcers, proportion of surface covered by ulcers, proportion of affected surface, and presence and severity of stenosis [narrowing]) measured in the same 5 ileocolonic segments as the CD index of severity. Overall, values on the SES-CD range from 0 to 56, with higher values indicating more severe disease. The 4 endoscopic variables are scored from 0 to 3 in each bowel segment (ileum, right/transverse/left colon, and rectum):

- Presence and size of ulcers (none = score 0; diameter 0.1–0.5 cm = score 1;
 0.5–2 cm = score 2; diameter >2 cm = score 3)
- Extent of ulcerated surface (none = 0; <10% =1; 10%-30% = 2; >30% = 3); extent of affected surface (none = 0; <50% = 1; 50%-75% = 2; >75% = 3)
- Presence and type of narrowings (none = 0; single, can be passed = 1; multiple, can be passed = 2; cannot be passed = 3).

The maximum stenosis score in a segment distal to another evaluable segment cannot exceed 2, so that the stenosis scores cannot exceed a total of 11 (Reinisch et al., 2017).

The SES-CD is presented in Appendix 2.

7.3.3.3 **Crohn's Disease Activity Index**

The CDAI is a composite measure with 8 components; 3 components (abdominal pain severity, very soft stool/liquid stool frequency, and general well-being) will be self-reported by the subject, as described in Section 7.3.3.4, and 5 components will be recorded at the time points specified in Table 3 and Table 4.

The CDAI scores at visits specified in Table 3 and Table 4 will be calculated using the following:

- Components 1 to 3 from subject-reported data collected for 7 days before the visit (see Section 7.3.3.4) and
- Components 4 to 8 (weight, medical and physical examination, use of diarrhea treatment, and hematocrit value) collected at the visit

Change in CDAI has been used as a primary endpoint in multiple pivotal trials in the CD indication. The algorithm for calculating the CDAL score was first published by William mmerci Best and colleagues (Best et al., 1976).

The CDAI is presented in Appendix 2.

Crohn's Disease Memory Aid 7.3.3.4

Subjects will be asked to recall clinical data for the CDAI score. They may use a memory aid to record for the 7 days prior to each scheduled visit:

- Number of very soft or liquid bowel movements (as shown by Bristol Stool Form Scale type 6/7)
- Level of abdominal pain (using the parameters as described in CDAI)
- Sense of general well-being (using the parameters as described in CDAI)

The investigator will record this information in the eCRF and use it to calculate the CDAI score for that visit.

The memory aid guidelines for subjects with CD are presented in Appendix 2.

7.3.4 Safety

7.3.4.1 Medical and Medication History

For subjects entering from an induction or maintenance study, medical history, including UC or CD history, cardiac history, and smoking history, and prior medications will be collected at the screening visit of Study SHP647-301, SHP647-302, SHP647-305, or SHP647-306.

Concomitant medications and procedures will be documented throughout the SHP647-304 study at the time points specified in Table 1 and Table 2 (for subjects with UC) and in Table 3 and Table 4 (for subjects with CD).

7.3.4.2 Physical Examination (Including Weight)

Complete and targeted physical examinations and weight assessments will be performed at the times specified in Table 1 and Table 2 (for subjects with UC) and in Table 3 and Table 4 (for subjects with CD). Complete physical examination includes the review of the following body systems: general appearance; skin; head, eyes, ears, nose, and throat; heart; lungs; breast (optional); abdomen; external genitalia (optional); extremities; neurologic function; back; and lymph nodes. Targeted physical examination includes the review of the following body systems: skin, heart, lungs, eyes, abdomen, and examination of body systems where there are symptom complaints by the subject. For subjects with CD, targeted physical examination includes review of the skin and mucosa, specifically perianal for fistula and oral cavity for stomatitis as part of the CDAI assessment.

Weight will be measured at the time points specified in Table 1 and Table 2 (for subjects with UC), and Table 3 and Table 4 (for subjects with CD).

The complete physical examination performed at Week 12 of induction study SHP647-301 or SHP647-302, at Week 16 of induction study SHP647-305 or SHP647-306, or at the ET or Week 52 visit of maintenance study SHP647-303 or SHP647-307, will be the baseline (Week 0/Day 1) examination of Study SHP647-304. Abnormalities identified during this visit will be documented. Any changes from the baseline visit (Week 0/Day 1) in physical examination findings that are deemed clinically significant in the opinion of the investigator are to be recorded as an AE.

7.3.4.3 Targeted Neurological Assessment

Targeted neurological assessments to monitor for the development of signs and/or symptoms of PML will be performed at the time points specified in Table 1 and Table 2 (for subjects with UC), and Table 3 and Table 4 (for subjects with CD). Subjects will be evaluated to reveal any potential abnormalities in the following neurological domains: vision, motor, tactile sensation, coordination/cerebellar function, speech, verbal comprehension, and cognition/behavior.

If any abnormalities are indicated, subjects will be further evaluated to help clarify any potential abnormal responses. Focus will be placed on possible alternative etiology (eg, fracture or stroke). If additional evaluation reveals an unexplained new abnormality, neurologic examination(s), targeted to the abnormal domain, will be performed by an investigator or qualified personnel.

A step-wise approach for the proposed neurological assessment plan is provided in Table 7.

Domain	Step 1: Interim Neurologic History and Targeted Neurological Examination	O Step 2: If Abnormal Response
Vision	Diplopia or visual/visual field loss	Perform visual field assessment
Motor	Major motor weakness (eg, legs, arms)	Test leg strength (hopping, foot tapping), finger tapping, pronator drift, and bilateral muscle strength
Tactile sensation	Paresthesia, anesthesia in any domain (peripheral, central)	Pinprick test
Coordination/Cerebellar	Clumsiness, difficulty with walking, writing, or fine motor skills, etc.	Finger-nose, heel-shin, heel-toe walk, writing sample, draw a clock
Speech	Dysarthria, expressive aphasia	Naming objects, repeat multipart phrase, observe for dysarthria or aphasia
Verbal comprehension	Agnosia, receptive aphasia	Test to follow routine commands, eg, close eyes, touch finger to ear
Cognition/Behavior	New onset of difficulties with memory or thinking, important changes in behavior	Recall 3 objects over 1 minute, serial 7 s, proverbs; changes in activities of daily living over prior 6 months

Table 7	Quarterly Neurological Assessments
---------	------------------------------------


Shire Ontamalimab SHP647-304 Protocol Amendment 4

21 Sep 2020

Additionally, should there be any unexplained abnormal neurological findings, the subject is to be urgently referred to a neurologist. The sites will immediately inform the sponsor of any such occurrences. If the neurologist confirms the presence of PML, appropriate actions, including discontinuation of investigational product, will be taken. Suspected PML cases will be reviewed promptly by data monitoring committee (DMC) members with PML expertise and presented at the next scheduled DMC meeting(s). If PML is diagnosed, the treatment code will be unblinded and there will be an urgent meeting of the DMC. A flow diagram of the quarterly assessments and actions is presented in Figure 2. Any concerns from the DMC will be promptly communicated to the sponsor, investigator, and treating neurologist.

After the study is unblinded, assessment of potential PML will be conducted by independent physicians with PML expertise. If they conclude that a diagnosis of PML is likely, there will be an urgent meeting of the Safety Management Team (SMT) to review the data and make a recommendation regarding continuation of the study. Any concerns from the independent experts or the SMT will be promptly communicated to the investigator and treating neurologist.





DMC=data monitoring committee; IND=investigational new drug; neuro=neurological; PML=progressive multifocal leukoencephalopathy.

After the study has been unblinded, the flow diagram will be modified as shown in Figure 3.




Figure 3 Post-unblinding Flow Diagram for Quarterly Neurological Assessments

IND=investigational new drug; neuro=neurological; PML=progressive multifocal leukoencephalopathy; SMT=Safety Management Team.

It is important to note that assessments based on neurological evaluations are collected and evaluated in a different manner than observed or volunteered AEs. Given these differences, no attempt will be made to reconcile any apparent discrepancies between observed or volunteered AEs and data from neurological assessment collected from subjects. Investigators may determine if any finding on neurological testing constitutes an AE. Adverse event incidence rates will not be calculated from these neurological evaluation data but rather from the AE information recorded by the investigator.

7.3.4.4 Adverse Event Collection

At each study visit, subjects will be questioned in a general way to ascertain if AEs have occurred since the previous visit (eg, "Have you had any health problems since your last visit?"). Adverse events are collected from the time informed consent and/or assent is signed until the end of the defined follow-up period (See Section 8, Adverse and Serious Adverse Events Assessment).

21 Sep 2020

7.3.4.5 Vital Signs

Vital signs will be measured at the time points specified in Table 1 and Table 2 (for subjects with UC), and Table 3 and Table 4 (for subjects with CD). Additional collection times or changes to collection times will be permitted, as necessary to ensure appropriate collection of safety data. Vital signs include blood pressure, pulse, respiratory rate, and temperature. Vital signs should be recorded before collection of blood samples for laboratory assessments, where applicable.

Single measurements of sitting blood pressure will be recorded at each time point. Blood pressure should be determined by cuff with the subject's arm supported at the level of the heart and recorded to the nearest mmHg using the same method, the same arm (preferably the dominant arm), and the same position throughout the study.

Respiratory rate will be measured with the subject in a comfortable position. The observer should hold the extremity of the subject as a distraction for the patient (ie, pretending he/she is taking the subject's radial pulse) and count the respiration for 1 minute.

Body temperature should be taken using a thermometer and reported in degrees Celsius or Fahrenheit.

Any deviations from baseline (Week 0/Day 1) vital signs that are deemed clinically significant in the opinion of the investigator are to be recorded as an AE unless documented in the subject's medical history as a pre-existing medical condition.

7.3.4.6 Clinical Laboratory Evaluations

All clinical laboratory assays will be performed according to the central laboratory's normal procedures. Reference ranges are to be supplied by the central laboratory and will be used to assess the clinical laboratory data for clinical significance and out-of-range pathological changes. Clinical laboratory assays can also be performed by the local laboratory in case of issues related to COVID-19 (or other similar pandemic) and if deemed necessary by the investigator to confirm the subject's safety. In such a case, the investigative site must obtain the local laboratory's normal ranges as well as a CLIA (Clinical Laboratory Improvement Amendments) certificate, and the investigator must add the local laboratory as appropriate. The investigator should assess out-of-range clinical laboratory values for clinical significance, indicating if the value(s) is/are not clinically significant or clinically significant. Abnormal clinical laboratory values, which are unexpected or not explained by the subject's clinical condition, may, at the discretion of the investigator or sponsor, be repeated as soon as possible until confirmed, explained, or resolved.

Shire Ontamalimab SHP647-304 Protocol Amendment 4

The following clinical laboratory assessments will be performed at the time points specified in Table 1 and Table 2 (for subjects with UC) and in Table 3 and Table 4 (for subjects with CD):

Serum Chemistry				
• alkaline phosphatase	blood urea nitrogen			
• aspartate aminotransferase	• creatinine			
• alanine aminotransferase	• sodium			
• total bilirubin	• potassium			
• total protein	• chloride			
• albumin	• calcium			
• glucose	carbon dioxide			
Hematology				
• hemoglobin	• neutrophils			
• hematocrit	lymphocytes			
• mean corpuscular hemoglobin	• monocytes			
mean corpuscular hemoglobin concentration	 neutrophils lymphocytes monocytes eosinophils basophils platelet count 			
mean corpuscular volume	• basophils			
• erythrocyte (red blood cell) count	• platelet count			
leukocyte (white blood cell) count				
Urinalysis				
• glucose	• bilirubin			
• protein	• ketones			
• specific gravity	• hemoglobin			
• pH	• urobilinogen			
• nitrite	leukocyte esterase			

Shire Ontamalimab SHP647-304 Protocol Amendment 4

Diagnosis of *C. difficile* infection should be made using the central laboratory. If, for any reason, the central laboratory is not available, please see Appendix 4 for guidance regarding the diagnostic algorithms. When a subject experiences an increase in GI symptoms, which could be an exacerbation of disease, an infectious etiology must be evaluated including testing for *C. difficile* as described in Appendix 4.

Subjects performing home administrations consecutively for 3 months will need to perform liver function testing per FDA requirement. It may be done locally if it is not possible to collect samples at the central laboratory.

7.3.4.7 Pregnancy Test and Follicle-stimulating Hormone Test

A urine beta-human chorionic gonadotropin (β -hCG) pregnancy test will be performed on all females of childbearing potential at the time points specified in Table 1 and Table 2 (for subjects with UC) and Table 3 and Table 4 (for subjects with CD), if pregnancy is suspected, or on withdrawal of the subject from the study.

Pregnancy tests are not required for females of nonchildbearing potential who have undergone hysterectomy or bilateral oophorectomy, have medically confirmed ovarian failure, or are medically confirmed postmenopausal (cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; postmenopausal status should be confirmed by FSH testing in females who have had 12 consecutive months of spontaneous amenorrhea and are 51 years of age or older). This does not need to be performed if postmenopausal status was confirmed by FSH in induction study SHP647-301, SHP647-302, SHP647-305, SHP647-306, or maintenance study SHP647-303 or SHP647-307.

If a female subject's status has changed to postmenopausal since the induction study (SHP647-301, SHP647-302, SHP647-305, SHP647-306) or maintenance study (SHP647-303 or SHP647-307), the childbearing potential of the subject must be re-established and documented (FSH confirmation test) at baseline of SHP647-304. Once FSH results are received, and if postmenopausal status is uncertain, the routine pregnancy testing will continue as planned for the remainder of the study. If postmenopausal status is confirmed, routine pregnancy testing is no longer required.

7.3.4.8 Electrocardiogram

A 12-lead ECG will be recorded at the time points specified in Table 1 and Table 2 (for subjects with UC) and Table 3 and Table 4 (for subjects with CD). When timing of measurements coincide, ECGs should be performed before collection of blood samples for laboratory assessments.

A local ECG reader will be used in this study. The eligibility of the subject is based on the assessment of the ECG by the investigator. If abnormal results are observed following assessment by the local reader, the investigator, in consultation with the appointed sponsor or contract research organization (CRO) medical monitor, will reconfirm subject eligibility to continue.

If it is not possible to perform an ECG due to a COVID-19-related or other pandemic-related issue, the investigator is to ensure that an ECG is performed at the next possible visit (scheduled or unscheduled).

7.3.4.9 Monitoring for Type I and Type III Immune Reactions

Subjects will be educated on the signs and symptoms of hypersensitivity reactions and how to respond to them. In addition, subjects will be instructed to report hypersensitivity AEs to the investigator at the time of occurrence, and to seek immediate medical care if hypersensitivity develops. At each visit, the subject will be queried for AEs of special interest (AESIs) related to hypersensitivity.

Subjects will be also instructed to report AEs such as serum sickness, vasculitis, Arthus reaction, and severe injection related reactions to the investigator, and to seek immediate medical care if these events are severe in intensity.

Subjects who experience a hypersensitivity reaction or severe or serious injection-related reaction (eg, shortness of breath, wheezing, stridor, angioedema, life-threatening change in vital signs) should discontinue investigational product.

For subjects who experience an AE suggestive of the presence of circulating immune complexes formation (eg, fever, rash [including hives], arthralgia, myalgia, vasculitis, Arthus reaction, general ill feeling, itching, and swollen lymph nodes), the investigator will decide on treatment discontinuation.

Further details of hypersensitivity reactions as AESIs are provided in Section 8.1.3.1.

7.3.4.10 Evaluation of Increased Gastrointestinal Symptoms

When a subject experiences an increase in GI symptoms, which could be an exacerbation of disease, an infectious etiology must be evaluated including testing for *C. difficile* as described in Appendix 4. If the subject has undergone or is undergoing a glucocorticoid taper, the glucocorticoid dose should be increased to the pre-taper dose; when clinically stable, the taper may begin again per Table 5 (for subjects with UC), and Table 6 for subjects with CD).

Subjects should be assessed for possible treatment failure. If treatment failure is considered after infectious etiology has been ruled out or treated, and/or after increase in the glucocorticoid dose (if appropriate), then the procedures in Section 4.4.2 should be followed.

In each case, the appropriate AE (eg, infection, exacerbation) should be recorded in the subject's source document.

7.3.4.11 Colonoscopy in Subjects at Elevated Risk of Colorectal Cancer

Subjects at risk for colorectal cancer who undergo annual endoscopy may undergo a colonoscopy with all annual surveillance procedures followed (eg, excision of adenomatous polyps with pathology report included in source documents). This is not required by the protocol, but if performed, the results should be recorded. Subjects at high risk for colorectal cancer are those who meet either of the following criteria:

- Subjects with extensive colitis for ≥8 years or disease limited to left side of colon (ie, distal to splenic flexure) for ≥10 years before screening, regardless of age
- Subjects \geq 50 years of age at the time of signing of the informed consent form.

7.3.5 Others

7.3.5.1 Pharmacodynamic Assessments

Predose blood and stool samples will be collected at the time points specified in Table 1 and Table 2 (for subjects with UC), and Table 3 and Table 4 (for subjects with CD) for each of the following biomarkers:

- Serum CRP
- Stool fecal calprotectin

Stool samples will be analyzed for fecal calprotectin at the time points indicated in Table 1 and Table 2 (for subjects with UC), Table 3 and Table 4 (for subjects with CD).

Details of sample collection, handling, shipment, and analysis will be provided in the laboratory manual. In case of a DTP situation, samples can be collected at subject's home or nearby clinic; please refer to DTP guidance for further details.

7.3.6 Volume of Blood to Be Drawn from Each Subject – All Subjects

For subjects entering from an induction or maintenance study, the volume of blood to be drawn from each subject is summarized in Table 8 for Treatment Year 1 and Table 9 for Treatment Year 2 through Year 3.

Table 8 Volume of Blood to Be Drawn from Each Subject – Treatment Year 1 (All Subjects)

Assessment	Sample Volume (mL)	Number of Samples	Total Volume (mL)
Hematology	2	5	10
Serum chemistry	4	5	20
FSH	2	1	2
Blood samples for biomarkers			
Serum CRP	2	2	4
Total mL			36

CRP=C-reactive protein; FSH=follicle-stimulating hormone.

Table 9Volume of Blood to Be Drawn from Each Subject – Treatment Year 2 Through
Year 3 (All Subjects)

Assessment	Sample Volume (mL)	Number of Samples	Total Volume (mL)
Hematology	2	4	8
Serum chemistry	4	2	8
Blood samples for biomarkers			
Serum CRP	2	2	4
Total mL			20

CRP=C-reactive protein.

For subjects entering from a maintenance study, during this study (after the implementation of Amendment 4) it is expected that approximately 36 mL of blood will be drawn from each subject in the first year of study participation and approximately 20 mL of blood in each year thereafter. Additionally, it is expected that an approximate total of 30 mL of blood will be drawn from each subject at the EOT visit and the safety follow-up visit at 12 weeks following the last dose of investigational product.

Note: The amount of blood to be drawn for each assessment is an estimate. The amount of blood to be drawn may vary according to the instructions provided by the manufacturer or laboratory for an individual assessment. When more than 1 blood assessment is to be done at the time point/period, if they require the same type of tube, the assessments may be combined.

Fornor

8. ADVERSE AND SERIOUS ADVERSE EVENTS ASSESSMENT

8.1 Definition of Adverse Events, Period of Observation, Recording of Adverse Events

An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product (International Council for Harmonisation [ICH] Guidance E2A 1995).

All AEs are collected from the time the informed consent is signed until the defined follow-up period stated in Sections 7.2.1.3 and 7.2.2.3. Where possible, a diagnosis rather than a list of symptoms should be recorded. Resolved AEs considered to be significant by the investigator that occurred in Studies SHP647-301, SHP647-302, SHP647-303, SHP647-305, SHP647-306, or SHP647-307 will be captured as part of the SHP647-304 baseline medical history, while ongoing AEs from Studies SHP647-301, SHP647-302, SHP647-303, SHP647-305, SHP647-306, or SHP647-307 will be captured as AEs in Study SHP647-303, SHP647-305, SHP647-306, or SHP647-307 will be captured as AEs in Study SHP647-304. If a diagnosis has not been made, then each symptom should be listed individually. All AEs should be captured in the subject's source documents. In addition to untoward AEs, unexpected benefits outside the investigational product indication should also be captured in the subject's source document.

All AEs must be followed to closure (the subject's health has returned to his/her baseline status or all variables have returned to normal), regardless of whether the subject is still participating in the study. Closure indicates that an outcome is reached, stabilization achieved (the investigator does not expect any further improvement or worsening of the event), or the event is otherwise explained. When appropriate, medical tests and examinations are performed so that resolution of event(s) can be documented.

8.1.1 Severity Categorization

The severity of AEs must be recorded during the course of the event including the start and stop dates for each change in severity. An event that changes in severity should be captured as a new event. Worsening of pretreatment events, after initiation of investigational product, must be recorded as new AEs (for example, if a subject experiences mild intermittent dyspepsia before dosing of investigational product, but the dyspepsia becomes severe and more frequent after first dose of investigational product has been administered, a new AE of severe dyspepsia [with the appropriate date of onset] is recorded in the subject's source document).

The medical assessment of severity is determined by using the following definitions:

Mild: A type of AE that is usually transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.

Moderate: A type of AE that is usually alleviated with specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research subject.

Severe: A type of AE that interrupts usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention.

8.1.2 Relationship Categorization

A physician/investigator must make the assessment of relationship to investigational product for each AE. The investigator should decide whether, in his or her medical judgment, there is a reasonable possibility that the event may have been caused by the investigational product. If there is no valid reason for suggesting a relationship, then the AE should be classified as "not related." Otherwise, if there is any valid reason, even if undetermined or untested, for suspecting a possible cause-and-effect relationship between the investigational product and the occurrence of the AE, then the AE should be considered "related." The causality assessment must be documented in the source document.

Term	Relationship Definition
Related	The temporal relationship between the event and the administration of the investigational product is compelling and/or follows a known or suspected response pattern to that product, and the event cannot be explained by the subject's medical condition, other therapies, or accident.
Not Related	The event can be readily explained by other factors such as the subject's underlying medical condition, concomitant therapy, or accident and no plausible temporal or biologic relationship exists between the investigational product and the event.

The following additional guidance may be helpful:

8.1.3 Adverse Events of Special Interest


Adverse events of special interest will be captured and monitored during this study. Investigators will report all AESIs to the sponsor, regardless of causality, using the same timelines as described for SAE reporting (see Section 8.2.2). The following describe the AESIs and the criteria for reporting AESIs.


8.1.3.1 Hypersensitivity

Potential hypersensitivity, serum sickness, vasculitis, and Arthus reactions to ontamalimab will be regarded as AESIs. These events must be reported on Shire "Clinical Study SAE and Nonserious AE as Required by the Protocol Form" and within the time frame mandated for SAEs (see Section 8.2.2).

It is well known that the administration of foreign proteins can cause immune responses including hypersensitivity reactions such as anaphylaxis and serum sickness. Other immune responses to foreign proteins include the development of ADAs and neutralizing antibodies (NAbs).

Monoclonal antibodies have been used in human therapeutics since the 1980s. The first monoclonal antibody approved for human use (ORTHOCLONE OKT3[®]), was a murine protein which caused rapid production of NAbs. Since then, much effort has been expended to reduce the immunogenicity of these useful therapeutic proteins by reducing the extent of "foreignness" from chimeric antibodies such as infliximab, to humanized antibodies such as vedolizumab, and finally to fully human antibodies such as adalimumab and ontamalimab (Isabwe et al., 2018) (see Figure 4).





CONFIDENTIAL

Shire Ontamalimab SHP647-304 Protocol Amendment 4

21 Sep 2020

Ontamalimab is a fully human antibody of the immunoglobulin G2 subclass. In Phase 1 and Phase 2 clinical trials of ontamalimab, in which over 700 subjects were treated for up to 3 years, there has been no case of anaphylaxis. There have been 2 reported cases of drug hypersensitivity: serum sickness attributed to concomitant administration of penicillin; and a reaction characterized by dyspnea, facial erythema, and chest pain with onset 2 days after administration of the fifth dose of ontamalimab. The latter event mimicked a reaction that the subject had previously experienced after 4 doses of infliximab. In addition, low titer activity has been observed in ADA assays, including pretreatment samples and placebo-treated subjects, and no subject has had a 2-fold or greater increase in ADA titer. Analysis of PK and clinical parameters has shown no difference between subjects whose ADA assays results are positive as compared with those whose are negative.

Nonetheless the possibility of a hypersensitivity reaction occurring after drug exposure cannot be fully ruled out. The reactions of concern are Type I (anaphylaxis) and Type III (immune complex) reactions. The clinical presentation of anaphylactic reactions is described in Table 10.

Table 10 Clinical Criteria for Diagnosing Anaphylaxis (Type 1 Hypersensitivity)

Anaphylaxis is highly likely when below criterion and at least any one of the following criteria a and b are fulfilled:

Acute onset of an illness (minutes to several hours) with involvement of the skin, mucosal tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula)

AND AT LEAST ONE OF THE FOLLOWING

- a) Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, hypoxemia)
- b) Reduced BP^a or associated symptoms of end-organ dysfunction (eg, hypotonia [collapse], syncope, incontinence)

BP=blood pressure; PEF=peak expiratory flow.

^a Low systolic blood pressure for children is defined as less than 90 mmHg from 11 to 17 years. Source: Adapted from Sampson et al., 2006.

Type III hypersensitivity responses, including those mediated by immune complexes and T cells (delayed hypersensitivity responses in the older literature), are relatively rare with respect to therapeutic protein products and a high degree of clinical suspicion is necessary for the diagnosis (Center for Drug Evaluation and Research - Guidance for industry: Immunogenicity assessment for therapeutic protein products, 2014). Type III hypersensitivity reactions involve the formation of biologic/ADA immune complexes in the circulation which, when present in the correct stoichiometric ratio, become deposited in tissues. Once immune complexes are deposited, they can elicit complement activation and inflammation, leading to tissue damage. When immune complexes are deposited in tissues, they tend to localize in small postcapillary venules where there is loss of laminar blood flow, in sites of ultrafiltration where there is high pressure and fenestrated endothelium (eg, choroid plexus, ciliary body, synovium, and glomeruli), in sites of

turbulent blood flow (eg, coronary artery branches off aorta, aortic bifurcations, and cardiac valve leaflets), and in renal glomerular endothelium.

Signs and symptoms of immune complex deposition typically have onset 1 to 3 weeks after exposure (Warrington et al., 2018) usually improving in 7 to 10 days, with full recovery in 2 to 4 weeks and may include fever, rash (including hives), arthralgia, myalgia, vasculitis, Arthus reaction, general ill feeling, itching, and swollen lymph nodes.

8.1.4 **Outcome Categorization**

The outcome of AEs must be recorded during the course of the study in the eCRF. Outcomes are as follows:

- Fatal •
- Not Recovered/Not Resolved
- Recovered/Resolved
- Recovered/Resolved With Sequelae •
- Recovering/Resolving •
- Unknown. ٠

ommercial use only Symptoms of the Disease Under Study 8.1.5

Symptoms of the disease under study should not be classed as AEs as long as they are within the normal day-to-day fluctuation or expected progression of the disease and are part of the treatment response data to be collected in the study; however, significant worsening of the symptoms should be recorded as an AE.

8.1.6 **Clinical Laboratory and Other Safety Evaluations**

A change in the value of a clinical laboratory, vital sign, or ECG assessment can represent an AE if the change is clinically relevant or if, during treatment with the investigational product, a shift of a parameter is observed from a normal value to an abnormal value, or a further worsening of an already abnormal value. When evaluating such changes, the extent of deviation from the reference range, the duration until return to the reference range, either while continuing treatment or after EOT with the investigational product, and the range of variation of the respective parameter within its reference range, must be taken into consideration.

If, at the end of the treatment phase, there are abnormal clinical laboratory, vital sign, or ECG values which were not present at the pretreatment value observed closest to the start of study treatment, further investigations should be performed until the values return to within the reference range or until a plausible explanation (eg, concomitant disease) is found for the abnormal values.

The investigator should decide, based on the above criteria and the clinical condition of a subject, whether a change in a clinical laboratory, vital sign, or ECG parameter is clinically significant and therefore represents an AE.

8.1.7 Pregnancy

All pregnancies are to be reported from the time informed consent is signed until the defined follow-up period stated in Sections 7.2.1.3 and 7.2.2.3.

Any report of pregnancy for any female study participant or the partner of a male study participant must be reported within 24 hours to Shire Global Pharmacovigilance using the Shire Investigational and Marketed Products Pregnancy Report Form. A copy of the Shire Investigational and Marketed Products Pregnancy Report Form (and any applicable follow-up reports) must also be sent to the CRO/Shire medical monitor using the details specified in the emergency contact information section of the protocol. The pregnant female study participant must be withdrawn from the study.

Every effort should be made to gather information regarding the pregnancy outcome and condition of the infant. It is the responsibility of the investigator to obtain this information within 30 calendar days after the initial notification and approximately 30 calendar days postpartum. If the pregnancy outcome is a live birth, the vital status and clinical condition of the infant should be obtained and documented at 1 year postpartum.

Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality are considered SAEs and must be reported using the Shire "Clinical Study Serious Adverse Event and Nonserious AE as Required by the Protocol Form." Note: An elective abortion is not considered an SAE.

In addition to the above, if the investigator determines that the pregnancy meets serious criteria, it must be reported as an SAE using the Shire "Clinical Study Serious Adverse Event and Nonserious AE as Required by the Protocol Form" as well as the Shire Investigational and

Marketed Products Pregnancy Report Form. The test date of the first positive serum/urine β -hCG test or ultrasound result will determine the pregnancy onset date.

8.1.8 Abuse, Misuse, Overdose, and Medication Error

Abuse, misuse, overdose, or medication error (as defined below) must be reported to the sponsor according to the SAE reporting procedure whether or not they result in an AE/SAE as described in Section 8.2. Note: The 24-hour reporting requirement for SAEs does not apply to reports of abuse, misuse, overdose, or medication errors unless these result in an SAE.

The categories below are not mutually exclusive; the event can meet more than 1 category.

- Abuse Persistent or sporadic intentional intake of investigational product when used for a nonmedical purpose (eg, to alter one's state of consciousness or get high) in a manner that may be detrimental to the individual and/or society
- **Misuse** Intentional use of investigational product other than as directed or indicated at any dose (Note: this includes a situation where the investigational product is not used as directed at the dose prescribed by the protocol)
- **Overdose** Intentional or unintentional administration of investigational product at a dosing interval that is less than 2 weeks between doses
- Medication Error An error made in prescribing, dispensing, administration, and/or use of an investigational product. For studies, medication errors are reportable to the sponsor only as defined below.

Cases of subjects missing doses of the investigational product are not considered reportable as medication errors.

Medication errors should be collected/reported for all products under investigation.

The administration and/or use of the unassigned treatment is/are always reportable as a medication error.

The administration and/or use of an expired investigational product should be considered as a reportable medication error.

There is no specific antidote for overdose with ontamalimab. Treatment should be symptomatic and supportive.

21 Sep 2020

8.1.9 **Unexpected Adverse Event**

An unexpected AE is an AE whose nature, severity, specificity, or outcome is not consistent with the term, representation, or description used in the reference safety information (RSI). "Unexpected" also refers to the AEs that are mentioned in the IB as occurring with a class of drugs or as anticipated from the pharmacological properties of the product, but are not specifically mentioned as occurring with the particular product under investigation.

The expectedness of AEs will be determined by the sponsor using the IB as the RSI. This determination will include considerations such as the number of AEs previously observed, but not on the basis of what might be anticipated from the pharmacological properties of a product.

8.1.10 **Suspected Unexpected Serious Adverse Reaction**

A suspected unexpected serious adverse reaction (SUSAR) is defined as any suspected adverse reaction to study treatment (ie, including active comparators) that is both serious and unexpected.

The event(s) must meet all of the following:

- Suspected adverse reaction •
- Serious
- •
- •

8.2 **Serious Adverse Event Procedures**

8.2.1

.eaction Unexpected Assessed as related to study treatment. ous Adverse Event Procedures ference Safety Inform for safety inform The reference for safety information for this study is Section 6.8 of the ontamalimab IB, which the sponsor has provided under separate cover to all investigators.

8.2.2 **Reporting Procedures**

All initial and follow-up SAE reports must be reported by the investigator to the Shire Global Drug Safety Department and the CRO/Shire medical monitor within 24 hours of the first awareness of the event. Note: The 24-hour reporting requirement for SAEs does not apply to reports of abuse, misuse, overdose, or medication errors (see Section 8.1.8) unless they result in an SAE.

CONFIDENTIAL

Shire Ontamalimab SHP647-304 Protocol Amendment 4

The investigator must complete, sign, and date the Shire "Clinical Study Serious Adverse Event and Nonserious AE as Required by the Protocol Form" and verify the accuracy of the information recorded on the form with the corresponding source documents (Note: Source documents are not to be sent unless requested) and fax or e-mail the form to the Shire Global Drug Safety Department. A copy of the Shire "Clinical Study Serious Adverse Event and Nonserious AE as Required by the Protocol Form" (and any applicable follow-up reports) must also be sent to the CRO/Shire medical monitor using the details specified in the emergency contact information section of the protocol.

8.2.3 Serious Adverse Event Definition

An SAE is any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose:

- Results in death.
- Is life-threatening.

Note: The term "life-threatening" in the definition of "serious" refers to an event in which the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe.

- Requires inpatient hospitalization or prolongation of existing hospitalization. Note: Hospitalizations, which are the result of elective or previously scheduled surgery for pre-existing conditions, which have not worsened after initiation of treatment, should not be classified as SAEs. For example, an admission for a previously scheduled ventral hernia repair would not be classified as an SAE; however, complication(s) resulting from a hospitalization for an elective or previously scheduled surgery that meet(s) serious criteria must be reported as SAE(s).
- Results in persistent or significant disability/incapacity.
- Is a congenital abnormality/birth defect.
- Is an important medical event.

Note: Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency department or at home; blood dyscrasias or convulsions that do not result in inpatient hospitalization; or the development of drug dependency or drug abuse.

8.2.4 Serious Adverse Event Collection Time Frame

All SAEs (regardless of relationship to study) are collected from the time the subject signs the informed consent until the defined follow-up period stated in Sections 7.2.1.3 and 7.2.2.3 must be reported to the Shire Global Drug Safety Department <u>and</u> the CRO/Shire medical monitor within 24 hours of the first awareness of the event.

In addition, any SAE(s) considered "related" to the investigational product and discovered by the investigator at any interval after the study has completed must be reported to the Shire Global Drug Safety Department within 24 hours of the first awareness of the event.

8.2.5 Serious Adverse Event Onset and Resolution Dates

The onset date of the SAE is defined as the date the event meets serious criteria. The resolution date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the date the event is considered chronic. In the case of hospitalizations, the hospital admission and discharge dates are considered the onset and resolution dates, respectively.

In addition, any signs or symptoms experienced by the subject after signing the informed consent form, or leading up to the onset date of the SAE, or following the resolution date of the SAE, must be recorded as an AE, if appropriate.

8.2.6 Fatal Outcome

Any SAE that results in the subject's death (ie, the SAE was noted as the primary cause of death) must have fatal checked as an outcome with the date of death recorded as the resolution date. For all other events ongoing at the time of death that did not contribute to the subject's death, the outcome should be considered not resolved, without a resolution date recorded.

For any SAE that results in the subject's death or any ongoing events at the time of death, unless another investigational product action was previously taken (eg, drug interrupted, reduced, withdrawn), the action taken with the investigational product should be recorded as "dose not changed" or "not applicable" (if the subject never received investigational product). The investigational product action of "withdrawn" should not be selected solely as a result of the subject's death.

8.2.7 Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting

The sponsor or the CRO is responsible for notifying the relevant regulatory authorities, US central Institutional Review Boards (IRBs), and European Union (EU) central ethics committees (ECs) of related, unexpected SAEs (ie, SUSARs).

In addition, the CRO is responsible for notifying active sites of all related, unexpected SAEs (ie, SUSARs) occurring during all interventional studies across the ontamalimab program.

The investigator is responsible for notifying the local IRB, local EC, or the relevant local regulatory authority of all SAEs that occur at his or her site as required.

8.2.8 Safety Monitoring for Potential Cases of Drug-induced Liver Injury

The following safety monitoring and stopping criteria are provided for elevated hepatic blood tests based on normal and elevated baseline alanine aminotransferase (ALT) and total bilirubin levels.

Abnormal values in ALT concurrent with abnormal elevations in total bilirubin that meet the criteria outlined below in the absence of other causes of liver injury are considered potential cases of drug-induced liver injury (potential Hy's Law cases) and should always be considered important medical events.

The threshold of laboratory abnormalities for a potential case of drug-induced liver injury depends on the subject's individual baseline values and underlying conditions. Subjects who present with the following laboratory abnormalities per Table 11 should be evaluated further to definitively determine the etiology of the abnormal laboratory values. The measurement(s) should be reconfirmed with another blood draw preferably within 48 to 72 hours of the initial finding of potential concern. Please refer to laboratory manual for further instructions.

<u>Guidance for Dosing Interruption:</u> Investigator-directed delays in dosing due to abnormal laboratory findings or AEs should be discussed with the medical monitor to determine whether the subject should continue with the treatment.

Treatment-emergent ALT	Treatment- emergent total bilirubin	Treatment- emergent symptoms	Action
Normal baseline:	Normal	None	Repeat ALT, AST, ALP, TBL, in 2-5 days.
$ALT \ge 5 \times ULN$			Follow-up for symptoms.
Elevated baseline ^a : ALT >3× baseline	Patients with Gilbert's syndrome or		Initiate evaluation for other etiologies of abnormal liver tests.
<i>or</i> ≥300 U/L (whichever occurs first)	<u>hemolysis</u> : No change in baseline TBL		Testing for hepatitis A, B, and/or C infection may be warranted. Subjects who entered an induction study (SHP647-301, SHP647-302, SHP647-305 or SHP647-306) or maintenance study (SHP647-303 or SHP647-307) with HBcAb with or without HBsAb, would need evaluation with HBV DNA to rule out HBV reactivation. ^c
Normal baseline:	Normal	None	Interrupt investigational product ^b
ALT ≥8× ULN Elevated baseline ^a :		USC .	Initiate close monitoring and workup for competing etiologies.
$ALT \ge 5 \times baseline$ or	Patients with Gilbert's syndrome or hemolysis: No change	None	Investigational product can be restarted only if another etiology is identified and liver enzymes return to baseline.
≥500 U/L (whichever occurs first)	hemolysis: No change in baseline TBL		Testing for hepatitis A, B, and/or C infection may be warranted. Subjects who entered an induction study (SHP647-301, SHP647-302, SHP647-305 or SHP647-306) or maintenance study (SHP647-303 or SHP647-307) with HBcAb with or without HBsAb, would need evaluation with HBV DNA to rule out HBV reactivation. ^c

Table 11 Safety Monitoring Rules for Treatment-emergent Elevated ALT and/or Bilirubin

Treatment-emergent ALT	Treatment- emergent total bilirubin	Treatment- emergent symptoms	Action
Normal baseline: ALT ≥3× ULN Elevated baseline ^a : ALT ≥2× baseline or ≥300 U/L (whichever occurs first)	TBL≥2mg/dL increased over baseline or <u>Patients with Gilbert's</u> <u>syndrome of</u> <u>hemolysis</u> : Doubling of baseline direct bilirubin	None	Interrupt investigational product ^b Initiate close monitoring and workup for competing etiologies. Investigational product can be restarted only if another etiology is identified and liver enzymes return to baseline. Testing for hepatitis A, B, and/or C infection may be warranted. Subjects who entered an induction study (SHP647-301, SHP647-302, SHP647-305 or SHP647-306) or maintenance study (SHP647-303 or SHP647-307) with HBcAb with or without HBsAb, would need evaluation with HBV DNA to rule out HBV reactivation. ^c
Normal baseline: $ALT \ge 5 \times ULN$ Elevated baseline ^a : $ALT \ge 2 \times$ baseline or $\ge 300 U/L$ (whichever occurs first)	Normal or elevated	Severe fatigue, nausea, vomiting, right upper quadrant pain or Immunologic symptoms Rash Eosinophilia >5%	Interrupt investigational product ^b Initiate close monitoring and workup for competing etiologies. Investigational product can be restarted only if another etiology is identified and liver enzymes return to baseline. Testing for hepatitis A, B, and/or C infection may be warranted. Subjects who entered an induction study (SHP647-301, SHP647-302, SHP647-305 or SHP647-306) or maintenance study (SHP647-303 or SHP647-307) with HBcAb with or without HBsAb, would need evaluation with HBV DNA to rule out HBV reactivation. ^c

Table 11 Safety Monitoring Rules for Treatment-emergent Elevated ALT and/or Bilirubin

ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; HBcAb=hepatitis B core antibody; HBsAb=hepatitis B surface antibody; HBV=hepatitis B virus; TBL=total bilirubin; ULN=upper limit of normal.

^a Elevated baseline ALT defined as $ALT \ge 1.5 \times ULN$.

^b Confirmatory repeat liver-related blood tests should be performed within 2-3 days before the investigational product is interrupted.

^c If HBV DNA positive, antivirals would need to be started as soon as possible.

Source: Adapted from Chalasani and Regev, 2016.

9. DATA MANAGEMENT AND STATISTICAL METHODS

9.1 Data Collection

The investigators' authorized site personnel must enter the information required by the protocol in the eCRF. A study monitor will visit each site in accordance with the monitoring plan and review the eCRF data against the source data for completeness and accuracy. Discrepancies between source data and data entered in the eCRF will be addressed by qualified site personnel. When a data discrepancy warrants correction, the correction will be made by authorized site personnel. Data collection procedures will be discussed with the site at the site initiation visit and/or at the investigator's meeting. It is expected that site personnel will complete the eCRF entry within approximately 3 business days of the subject's visit.

9.2 Clinical Data Management

Data are to be entered into a clinical database as specified in the CRO's data management plan. Quality control and data validation procedures are applied to ensure the validity and accuracy of the clinical database.

Data are to be reviewed and checked for omissions, errors, and values requiring further clarification using computerized and manual procedures. Data queries requiring clarification are to be communicated to the site for resolution. Only authorized personnel will make corrections to the clinical database, and all corrections are documented in an auditable manner.

9.3 Data Handling Considerations

These data will be handled in such a way that, before unblinding, any data that may unblind study team personnel will be presented as blinded information or otherwise will not be made available. If applicable, unblinded data may be made available to quality assurance representatives for the purposes of conducting independent drug audits.

9.4 Statistical Analysis Process

The study will be analyzed by the sponsor or its agent.

The statistical analysis plan (SAP) will provide the statistical methods and definitions for the analysis of the treatment response and safety data, as well as describe the approaches to be taken for summarizing other study information such as subject disposition, demographics and baseline characteristics, investigational product exposure, and prior and concomitant medications. The SAP will also include a description of how missing, unused and spurious data will be addressed. The SAP will be finalized before unblinding to preserve the integrity of the statistical analysis and study conclusions.

All statistical analyses will be performed using SAS[®] Version 9.3 or higher (SAS Institute, Cary, NC 27513, US).

Unless otherwise specified, summary tabulations will be presented by indication and treatment group. All data listings will be sorted by indication, treatment group, site, and subject number, and will include the subject's age, sex, and race. Summaries will be presented by indication separately and also overall. Summaries may be presented by the status at entry into this study (eg, induction nonresponder, maintenance ontamalimab completer, maintenance discontinuation rollovers, etc.).

For categorical variables, the number and percentage of subjects within each category (with a category for missing data as needed) of the parameter will be presented. For continuous variables, the number of subjects, mean, median, standard deviation, minimum, and maximum values will be presented.

Note: The overall impact of COVID-19 (or other similar pandemic) on data analyses is unknown at the time of the writing of this amendment; details on changes to any analyses or any additional analyses to evaluate the impact of COVID-19 (or other similar pandemic) on the study objectives will be described in the SAP.

9.5 Planned Interim Analysis, Adaptive Design, and Data Monitoring Committee

An external DMC will be established to review the overall safety of the study subjects on an ongoing basis.

Until the time of unblinding, the DMC will be responsible for the ongoing monitoring of safety of subjects enrolled in the study according to the DMC charter. Recommendations made by the DMC to alter the conduct of the study or to amend the protocol will be forwarded to Shire for review and for a final decision. Shire or its designee will notify investigative sites and regulatory authorities as appropriate, of DMC recommendations (which may include summaries of aggregate analyses of endpoint events and of safety data that are not endpoints).

Further details regarding the DMC can be found in the DMC charter, which will be available before the administration of investigational product to any subject. Analyses of the data for DMC review will be conducted according to the DMC charter and the DMC SAP. Because no formal hypothesis testing for safety assessments is planned, multiplicity concerns regarding repeated analyses are not applicable.

See Section 7.3.4.3 for details on the handling of suspected PML cases in this study.

9.6 Sample Size Calculation and Power Considerations

A maximum of 451 subjects are projected to enroll into this study. No formal sample size estimation was performed on this study.

On 29 May 2020, Takeda announced the closure of the ontamalimab Phase 3 clinical development program, which included induction and maintenance studies for subjects with moderate to severe IBD who had failed at least 1 prior treatment. With this closure, the induction and maintenance studies were discontinued before full enrollment, and the planned direct-entry of 800 subjects with UC that was added with Amendment 3 was not initiated. The previously projected sample size of 3384 subjects will not be attained.

As of 04 Sep 2020, there were 334 subjects that were enrolled in this SHP647-304 study. With 117 subjects active in the ongoing SHP647 induction and maintenance studies, up to a maximum of 451 subjects may be enrolled into this study.

9.7 **Study Population**

The full analysis set (FAS) will consist of all subjects in the randomized set who receive at least 1 dose of investigational product in the SHP647-304 study.

The safety set will consist of all subjects who receive at least 1 dose of investigational product in the SHP647-304 study.

9.8 **Efficacy Analyses**

Efficacy will not be formally evaluated in this study. Treatment response analyses are described below.

9.8.1 **Treatment Response Analyses – Subjects with Ulcerative Colitis**

Treatment response analyses will be performed using the FAS. lercial use

9.8.1.1 **Secondary Endpoints**

The secondary endpoint is as follows:

Treatment response over time, with response defined as clinical composite score that • has decreased by ≥ 2 points and $\geq 30\%$, with an accompanying decrease in the subscore for RB \geq 1 point of a subscore for RB \geq 1, and/or composite score that has decreased by $\geq 30\%$ and ≥ 3 points compared to the baseline value for induction *60,* studies.

Secondary endpoints will be summarized by treatment group using descriptive statistics at each assessment visit. Summaries may be presented by the status at entry into the study (eg, induction nonresponder, maintenance ontamalimab completer, maintenance discontinuation rollovers, etc.). Statistical summaries will include number of subjects and percentages, and 95% confidence intervals.

The detailed analyses will be described in the SAP.

9.8.2 **Treatment Response Analyses – Subjects with Crohn's Disease**

Treatment response analyses will be performed using the FAS.

Secondary Endpoints 9.8.2.1

The secondary endpoint is as follows:

Treatment response over time, with response defined as CDAI score that has • decreased by ≥ 100 points compared to the baseline value for induction studies and/or SES-CD that has decreased by $\geq 25\%$ compared to the baseline value for induction studies.

Secondary endpoints will be summarized by treatment group using descriptive statistics at each assessment visit. Summaries may be presented by the status at entry into the study (eg, induction nonresponder, maintenance ontamalimab completer, maintenance discontinuation rollovers, etc.). Statistical summaries will include number of subjects and percentages, and 95% confidence intervals.

The detailed analyses will be described in the SAP. 9.9 Safety Analyses The primary endpoint is the assessment of safety as measured by: incidence and severity of AEs; incidence and nature of serious infections; and actual values and change from baseline, as well as incidence of abnormalities, in laboratory tests, ECGs, and vital signs.

All safety analyses will be performed using the safety set. Subjects will be analyzed according to the treatment they actually received. Summaries will be presented by indication separately and also overall. Summaries may be presented by the status at entry into this study (eg, induction nonresponder, maintenance ontamalimab completer, maintenance early discontinuation rollovers, etc.).

Adverse events will be coded using the Medical Dictionary for Regulatory Activities.

CONFIDENTIAL

Shire Ontamalimab SHP647-304 Protocol Amendment 4

21 Sep 2020

Page 128

Treatment-emergent AEs are defined as AEs with start dates or worsening dates at the time of or following the first exposure to investigational product in the SHP647-304 study. The number of events, incidence, and percentage of TEAEs will be calculated overall, by system organ class, by preferred term, by indication, and by treatment group. Treatment-emergent AEs will be further summarized by severity and relationship to investigational product. Adverse events leading to withdrawal, SAEs, and deaths will be similarly summarized/listed. Adverse events of special interest will be summarized by treatment group.

Clinical laboratory tests, vital signs, and ECG findings will be summarized by indication, treatment group, and visit. Potentially clinically important findings will also be summarized or listed.

Further details of safety analyses will be described in the SAP.

Fornoncommercialuse only

10. SPONSOR'S AND INVESTIGATOR'S RESPONSIBILITIES

This study is conducted in accordance with current applicable regulations, ICH, EU Directive 2001/20/EC and its updates, and local ethical and legal requirements.

Compliance with these regulations and guidelines also constitutes compliance with the ethical principles described in the Declaration of Helsinki.

The name and address of each third-party vendor (eg, CRO) used in this study will be maintained in the investigator's and sponsor's files, as appropriate.

10.1 Sponsor's Responsibilities

10.1.1 Good Clinical Practice Compliance

The study sponsor and any third party to whom aspects of the study management or monitoring have been delegated will undertake their assigned roles for this study in compliance with all applicable industry regulations, ICH Good Clinical Practice (GCP) Guideline E6 (1996) and E6 R2 (2017), EU Directive 2001/20/EC, as well as all applicable national and local laws and regulations.

Visits to sites are conducted by representatives of the study sponsor and/or the company organizing/managing the research on behalf of the sponsor to inspect study data, subjects' medical records, and eCRFs in accordance with current GCP and the respective local and (inter)national government regulations and guidelines. Records and data may additionally be reviewed by auditors or by regulatory authorities.

The sponsor ensures that local regulatory authority requirements are met before and during the study (including annual safety reporting, ie, Development Safety Update Reports). The sponsor (or a nominated designee) is responsible for the preparation, submission, and confirmation of receipt of any regulatory authority approvals required before release of investigational product for shipment to the site.

10.1.2 Indemnity/Liability and Insurance

The sponsor of this research adheres to the recommendations of the Association of British Pharmaceutical Industry Guidelines. If appropriate, a copy of the indemnity document is supplied to the investigator before study initiation, per local country guidelines.

The sponsor ensures that suitable clinical study insurance coverage is in place before the start of the study. An insurance certificate is supplied to the CRO and investigator as necessary.

10.1.3 Public Posting of Study Information

The sponsor is responsible for posting appropriate study information on applicable websites. Information included in clinical study registries may include participating investigators' names and contact information.

10.1.4 Submission of Summary of Clinical Study Report to Competent Authorities of Member States Concerned and Ethics Committees

The sponsor will upload the clinical study report to the EudraCT database and will also provide a summary of the clinical study report for submission to the competent authority of the countries concerned as required by local regulatory requirement(s). This requirement will be fulfilled within 1 year for nonpediatric studies as per guidance. The ECs will be provided with a copy of the same summary as locally required.

10.1.5 Study Suspension, Termination, and Completion

The sponsor may suspend or terminate the study, or part of the study, at any time for any reason. If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory agencies, and IRBs/ECs are notified as appropriate. Additionally, the discontinuation of a registered clinical study which has been posted to a designated public website will be updated accordingly.

The sponsor and/or its representative will make an end-of-study declaration to the relevant competent authority as required by Article 10 (c) of Directive 2001/20/EC.

10.2 Investigator's Responsibilities

10.2.1 Good Clinical Practice Compliance

The investigator must undertake to perform the study in accordance with ICH GCP Guideline E6 (1996) and E6 R2 (2017), EU Directive 2001/20/EC, and applicable regulatory requirements and guidelines.

It is the investigator's responsibility to ensure that adequate time and appropriately trained resources are available at the site before commitment to participate in this study. The investigator should also be able to estimate or demonstrate a potential for recruiting the required number of suitable subjects within the agreed recruitment period.

The investigator will maintain a list of appropriately qualified persons to whom the investigator has delegated significant study-related tasks, and shall, upon request of the sponsor, provide documented evidence of any licenses and certifications necessary to demonstrate such qualification. Curriculum vitae for investigators and sub-investigators are provided to the study sponsor (or designee) before starting the study.

If a potential research subject has a primary care physician, the investigator should, with the subject's consent, inform them of the subject's participation in the study.

A coordinating principal investigator is appointed to review the final clinical study report for multicenter studies. Agreement with the final clinical study report is documented by the signed and dated signature of the principal investigator (single-site study) or coordinating principal investigator (multicenter study), in compliance with Directive 2001/83/EC as amended by Directive 2003/63/EC and ICH Guidance E3 (1995).

10.2.2 Protocol Adherence and Investigator Agreement

The investigator and any co-investigators must adhere to the protocol as detailed in this document. The investigator is responsible for enrolling only those subjects who have met protocol eligibility criteria. Investigators are required to sign an investigator agreement to confirm acceptance and willingness to comply with the study protocol.

If the investigator suspends or terminates the study at their site, the investigator will promptly inform the sponsor and the IRB/EC and provide them with a detailed written explanation. The investigator will also return all investigational product, containers, and other study materials to

the sponsor. Upon study completion, the investigator will provide the sponsor, IRB/EC, and regulatory agency with final reports and summaries as required by (inter)national regulations.

Communication with local IRBs/ECs, to ensure accurate and timely information is provided at all phases during the study, may be done by the sponsor, applicable CRO, investigator, or for multicenter studies, the coordinating principal investigator according to national provisions and will be documented in the investigator agreement.

10.2.3 Documentation and Retention of Records

10.2.3.1 Case Report Forms

Case report forms are supplied by the CRO and should be handled in accordance with instructions from the sponsor.

The investigator is responsible for maintaining adequate and accurate medical records from which accurate information is recorded in eCRFs, which have been designed to record all observations and other data pertinent to the clinical investigation. The eCRFs must be completed by the investigator or designee as stated in the site delegation log.

All data in the eCRF will have a separate source (eg, paper or electronic patient-reported outcome); no data will be recorded directly in the eCRF.

All data sent to the sponsor must be endorsed by the investigator.

The clinical research associate (CRA)/study monitor will verify the contents against the source data per the monitoring plan. If the data are unclear or contradictory, queries are sent for corrections or verification of data.

10.2.3.2 Recording, Access, and Retention of Source Data and Study Documents

Original source data to be reviewed during this study will include, but are not limited to: subject's medical file, subject diary, original clinical laboratory reports, and histology and pathology reports.

All key data must be recorded in the subject's medical records.

The investigator must permit authorized representatives of the sponsor; the respective national, local, or foreign regulatory authorities; the IRB/EC; and auditors to inspect facilities and to have direct access to original source records relevant to this study, regardless of media.

CONFIDENTIAL

Shire Ontamalimab SHP647-304 Protocol Amendment 4

Page 133

The CRA/study monitor (and auditors, IRB/EC or regulatory inspectors) may check the eCRF entries against the source documents. The consent form includes a statement by which the subject agrees to the monitor/auditor from the sponsor or its representatives, national or local regulatory authorities, or the IRB/EC, having access to source data (eg, subject's medical file, appointment books, original laboratory reports, x-rays, etc.). Nonstudy site personnel will not disclose any personal information or personal medical information.

These records must be made available within reasonable times for inspection and duplication, if required, by a properly authorized representative of any regulatory agency (eg, the FDA, EMA, UK Medicines and Healthcare products Regulatory Agency) or an auditor.

Essential documents must be maintained according to ICH GCP requirements and may not be destroyed without written permission from the sponsor.

Sites are to ensure that all study documents related to DTP are complete, accurate, and retained at the site according to the document retention requirements.

10.2.3.3 Audit/Inspection

To ensure compliance with relevant regulations, data generated by this study must be available for inspection upon request by representatives of, for example, the US FDA (as well as other US national and local regulatory authorities), the EMA, the Medicines and Healthcare products Regulatory Agency, other regulatory authorities, the sponsor or its representatives, and the IRB/EC for each site.

10.2.3.4 Financial Disclosure

The investigator is required to disclose any financial arrangement during the study and for 1 year after, whereby the outcome of the study could be influenced by the value of the compensation for conducting the study, or other payments the investigator received from the sponsor. The following information is collected: any significant payments from the sponsor or subsidiaries such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation or honoraria; any proprietary interest in investigational product; any significant equity interest in the sponsor or subsidiaries as defined in 21 Code of Federal Regulations 54 2(b) (1998).

10.3 Ethical Considerations

10.3.1 Informed Consent

It is the responsibility of the investigator to obtain written informed consent from all study subjects prior to any study-related procedures. All consent documentation must be in accordance with applicable regulations and GCP. Each subject or the subject's legally authorized representative, as applicable, is requested to sign and date the subject informed consent form or a certified translation if applicable, after the subject has received and read (or been read) the written subject information and received an explanation of what the study involves, including but not limited to: the objectives, potential benefits and risk, inconveniences, and the subject's rights and responsibilities. A copy of the informed consent documentation (ie, a complete set of subject information sheets and fully executed signature pages) must be given to the subject or the subject's legally authorized representative, as applicable. This document may require translation into the local language. Signed consent forms must remain in each subject's study file and must be available for verification at any time.

The principal investigator provides the sponsor with a copy of the consent form that was reviewed by the IRB/EC and received their favorable opinion/approval. A copy of the IRB/EC's written favorable opinion/approval of these documents must be provided to the sponsor prior to the start of the study unless it is agreed to and documented (abiding by regulatory guidelines and national provisions) prior to study start that another party (ie, sponsor or coordinating principal investigator) is responsible for this action. Additionally, if the IRB/EC requires modification of the sample subject information and consent document provided by the sponsor, the documentation supporting this requirement must be provided to the sponsor.

10.3.2 Institutional Review Board or Ethics Committee

For sites outside the EU, it is the responsibility of the investigator to submit this protocol, the informed consent document (approved by the sponsor or their designee), relevant supporting information and all types of subject recruitment information to the IRB/EC for review, and all must be approved before site initiation.

The applicant for an EC opinion can be the sponsor or investigator for sites within the EU; for multicenter studies, the applicant can be the coordinating principal investigator or sponsor, according to national provisions.

Responsibility for coordinating with IRBs/ECs is defined in the investigator agreement.

21 Sep 2020

Page 135

Before implementing changes in the study, the sponsor and the IRB/EC must approve any revisions of all informed consent documents and amendments to the protocol unless there is a subject safety issue.

Investigational product supplies will not be released until the sponsor has received written IRB/EC approval of and copies of revised documents.

For sites outside the EU, the investigator is responsible for keeping the IRB/EC apprised of the progress of the study and of any changes made to the protocol, but in any case at least once a year; this can be done by the sponsor or investigator for sites within the EU, or for multicenter studies, it can be done by the coordinating principal investigator, according to national provisions. The investigator must also keep the local IRB/EC informed of any serious and significant AEs.

10.4 Privacy and Confidentiality

All US-based sites and laboratories or entities providing support for this study, must, where applicable, comply with the Health Insurance Portability and Accountability Act (HIPAA) of 1996. A site that is not a covered entity as defined by HIPAA must provide documentation of this fact to the sponsor or designee.

The confidentiality of records that may be able to identify subjects will be protected in accordance with applicable laws, regulations, and guidelines.

After subjects have consented to take part in the study, the sponsor and/or its representatives reviews their medical records and data collected during the study. These records and data may, in addition, be reviewed by others including the following: independent auditors who validate the data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or market ontamalimab; national or local regulatory authorities; and the IRB(s)/EC(s) which gave approval for the study to proceed. The sponsor and/or its representatives accessing the records and data will take all reasonable precautions in accordance with applicable laws, regulations, and guidelines to maintain the confidentiality of subjects' identities.

Subjects are assigned a unique identifying number; however, their initials and date of birth may also be collected and used to assist the sponsor to verify the accuracy of the data (eg, to confirm that laboratory results have been assigned to the correct subject).

CONFIDENTIAL

Shire Ontamalimab SHP647-304 Protocol Amendment 4

The results of studies – containing subjects' unique identifying number, relevant medical records, and possibly initials and dates of birth – will be recorded. They may be transferred to, and used in, other countries which may not afford the same level of protection that applies within the countries where this study is conducted. The purpose of any such transfer would include: to support regulatory submissions, to conduct new data analyses to publish or present the study results, or to answer questions asked by regulatory or health authorities.

10.5 Study Results/Publication Policy

Shire will endeavor to publish the results of all qualifying, applicable, and covered studies according to external guidelines in a timely manner regardless of whether the outcomes are perceived as positive, neutral, or negative. Additionally, Shire adheres to external guidelines (eg, Good Publication Practices 2) when forming a publication steering committee, which is done for large, multicenter Phase 2-4 and certain other studies as determined by Shire. The purpose of the publication steering committee is to act as a noncommercial body that advises or decides on dissemination of scientific study data in accordance with the scope of this policy.

All publications relating to Shire products or projects must undergo appropriate technical and intellectual property review, with Shire agreement to publish before release of information. The review is aimed at protecting the sponsor's proprietary information existing either at the commencement of the study or generated during the study. To the extent permitted by the publisher and copyright law, the principal investigator will own (or share with other authors) the copyright on his/her publications. To the extent that the principal investigator has such sole, joint or shared rights, the principal investigator grants the sponsor a perpetual, irrevocable, royalty-free license to make and distribute copies of such publications.

The term "publication" refers to any public disclosure including original research articles, review articles, oral presentations, abstracts and posters at medical congresses, journal supplements, letters to the editor, invited lectures, opinion pieces, book chapters, electronic postings on medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral or other form.

Subject to the terms of the paragraph below, the investigator shall have the right to publish the study results, and any background information provided by the sponsor that is necessary to include in any publication of study results, or necessary for other scholars to verify such study results. Notwithstanding the foregoing, no publication that incorporates the sponsor's confidential information shall be submitted for publication without the sponsor's prior written agreement to publish and shall be given to the sponsor for review at least 60 days before

21 Sep 2020

submission for publication. If requested in writing by Shire, the institution and principal investigator shall withhold submission of such publication for up to an additional 60 days to allow for filing of a patent application.

If the study is part of a multicenter study, the first publication of the study results shall be made by the sponsor in conjunction with the sponsor's presentation of a joint, multicenter publication of the compiled and analyzed study results. If such a multicenter publication is not submitted to a journal for publication by the sponsor within an 18-month period after conclusion, abandonment, or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter study publication of the study results, an investigator may individually publish the study results from the specific site in accordance with this section. The investigator must, however, acknowledge in the publication the limitations of the single-site data being presented.

Unless otherwise required by the journal in which the publication appears, or the forum in which it is made, authorship will comply with the International Committee of Medical Journal Editors current standards. Participation as an investigator does not confer any rights to authorship of publications.

LUES NO For non-commercial

11. REFERENCES

- Best, W. R., Becktel, J. M. and Singleton, J. W. 1979. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). *Gastroenterology*, 77, 843-6.
- Best, W. R., Becktel, J. M., Singleton, J. W. and Kern, F. 1976. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology*, 70, 439-44.
- Briskin, M., Winsor-Hines, D., Shyjan, A., Cochran, N., Bloom, S., Wilson, J., McEvoy, L. M., Butcher, E. C., Kassam, N., Mackay, C. R., Newman, W. and Ringler, D. J. 1997. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. *Am J Pathol*, 151, 97-110.
- Chalasani, N. and Regev, A. 2016. Drug-Induced Liver Injury in Patients With Preexisting Chronic Liver Disease in Drug Development: How to Identify and Manage? *Gastroenterology*, 151, 1046-1051.
- Dignass, A., Eliakim, R., Magro, F., Maaser, C., Chowers, Y., Geboes, K., Mantzaris, G., Reinisch, W., Colombel, J.-F., Vermeire, S., Travis, S. and Lindsay, J. 2012. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis. *Journal of Crohn's and Colitis*, 6, 965-990.
- Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J. F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H. J., Danese, S., Fox, L., Milch, C., Sankoh, S., Wyant, T., Xu, J. and Parikh, A. 2013. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*, 369, 699-710.
- Isabwe, G. A. C., Garcia Neuer, M., de Las Vecillas Sanchez, L., Lynch, D. M., Marquis, K., and Castells, M. 2018. Hypersensitivity reactions to therapeutic monoclonal antibodies: Phenotypes and endotypes. *J Allergy Clin Immunol*, 142, 159-170 e2.
- Khanna, S., Shin, A. and Kelly, C. 2017. Management of Clostridium difficile Infection in Inflammatory Bowel Disease: Expert Review from the Clinical Practice Updates Committee of the AGA Institute. *Clin Gastroenterol Hepatol*, 15, 166-74.
- Lacy, C., Armstrong, L., Goldman, M. and Lance, L. 2001-2002. *Drug Information Handbook,* Cleveland, OH, LexiComp, Inc.
- Liaskou, E., Karikoski, M., Reynolds, G. M., Lalor, P. F., Weston, C. J., Pullen, N., Salmi, M., Jalkanen, S. and Adams, D. H. 2011. Regulation of mucosal addressin cell adhesion molecule 1 expression in human and mice by vascular adhesion protein 1 amine oxidase activity. *Hepatology*, 53, 661-72.
- Loftus, E. V., Jr., Colombel, J. F., Feagan, B. G., Vermeire, S., Sandborn, W. J., Sands, B. E., Danese, S., D'Haens, G. R., Kaser, A., Panaccione, R., Rubin, D. T., Shafran, I., McAuliffe, M., Kaviya, A., Sankoh, S., Mody, R., Abhyankar, B. and Smyth, M. 2017. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. *J Crohns Colitis*, 11, 400-411.
- McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., Loo, V., Shaklee Sammons, J., Sandora, T. J. and Wilcox, M. H. 2018. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). *Clinical Infectious Diseases*, 66, e1-e48.

- Molodecky, N. A., Soon, I. S., Rabi, D. M., Ghali, W. A., Ferris, M., Chernoff, G., Benchimol, E. I., Panaccione, R., Ghosh, S., Barkema, H. W. and Kaplan, G. G. 2012. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. *Gastroenterology*, 142, 46-54.e42; quiz e30.
- Pullen, N., Molloy, E., Carter, D., Syntin, P., Clemo, F., Finco-Kent, D., Reagan, W., Zhao, S., Kawabata, T. and Sreckovic, S. 2009. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. *Br J Pharmacol*, 157, 281-93.
- Reinisch, W., Colombel, J.-F., D'Haens, G., Sandborn, W. J., Rutgeerts, P., Geboes, K.,
 Petersson, J., Eichner, S., Zhou, Q., Robinson, A. M., Read, H. A. and Thakkar, R. 2017.
 Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with
 Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. *Journal of Crohn's and Colitis*, 11, 425-434.
- Sampson, H. A., Munoz-Furlong, A., Campbell, R. L., Adkinson, N. F., Jr., Bock, S. A., Branum, A., Brown, S. G., Camargo, C. A., Jr., Cydulka, R., Galli, S. J., Gidudu, J., Gruchalla, R. S., Harlor, A. D., Jr., Hepner, D. L., Lewis, L. M., Lieberman, P. L., Metcalfe, D. D., O'Connor, R., Muraro, A., Rudman, A., Schmitt, C., Scherrer, D., Simons, F. E., Thomas, S., Wood, J. P. and Decker, W. W. 2006. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. *The Journal of allergy and clinical immunology*, 117, 391-7.
- Schroeder, K. W., Tremaine, W. J. and Ilstrup, D. M. 1987. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med, 317, 1625-9.
- Shane, A. L., Mody, R. K., Crump, J. A., Tarr, P. I., Steiner, T. S., Kotloff, K., Langley, J. M., Wanke, C., Warren, C. A., Cheng, A. C., Cantey, J. and Pickering, L. K. 2017. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. *Clinical Infectious Diseases*, 65, 1963-1973.
- Shyjan, A. M., Bertagnolli, M., Kenney, C. J. and Briskin, M. J. 1996. Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the alpha 4 beta 7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences. *J Immunol*, 156, 2851-7.
- Steffen, B. J., Breier, G., Butcher, E. C., Schulz, M. and Engelhardt, B. 1996. ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro. *Am J Pathol*, 148, 1819-38.
- Vermeire, S., Loftus, E. V., Colombel, J.-F., Feagan, B. G., Sandborn, W. J., Sands, B. E., Danese, S., D'Haens, G. R., Kaser, A., Panaccione, R., Rubin, D. T., Shafran, I., McAuliffe, M., Kaviya, A., Sankoh, S., Mody, R., Abhyankar, B. and Smyth, M. 2017. Long-term Efficacy of Vedolizumab for Crohn's Disease. *Journal of Crohn's and Colitis*, 11, 412-424.
- Warrington, R., Silviu-Dan, F. and Wong, T. 2018. Drug allergy. *Allergy, Asthma & Clinical Immunology*, 14, 1-11.

APPENDIX 1 PROTOCOL HISTORY

Document	Date	Global/Country/Site Specific
Protocol Amendment 4	21 Sep 2020	Global
Protocol Amendment 3	07 Nov 2019	Global
Protocol Amendment 2	17 Sep 2018	Global
Protocol Amendment 1	18 Dec 2017	Global
Original Protocol	13 Jul 2017	Global

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number Amendment Date Global/Region/Country/Site Spe		
3	07 Nov 2019	Global

Protocol Amendment Summary and Rationale:

The main purpose of SHP647-304 Amendment 3 is to allow for direct entry of subjects with moderate to severe ulcerative colitis (UC) who had not participated previously in any of the Phase 3 induction studies (SHP647-301, SHP647-302) or maintenance study (SHP647-303). This includes UC subjects who were ineligible for an induction study due to previous treatment with ontamalimab during a Phase 1 or Phase 2 study or previous treatment with vedolizumab, or subjects who had met the eligibility criteria for induction study SHP647-301 or SHP647-302 but were unable to enroll because of an enrollment cap in their particular country.

The significant changes in SHP647-304 Protocol Amendment 3 relative to the previous edition, SHP647-304 Protocol Amendment 2, are captured below.

FORT

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number Amendment Date		Global/Region/Country/Site Specifi	
3	07 Nov 2019	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Product Quality Complaints	Updated language regarding reporting of product quality complaints.	To align product quality complaints language with current Shire template.	
Study Synopsis, Number of Subjects (total and for each treatment arm)	Updated total sample size projected for the enrollment in the study.	To reflect changes in sample size in the SHP647-301, SHP647-302, and SHP647-303 studies and revised projections for the number of subjects who may rollover from those studies, and to reflect targeted sample size for direct-entry UC subjects who may enter directly based on the completed A7281010 study and assessment of the literature.	
Study Synopsis, Rationale	Added language to describe	To specify inclusion of UC subjects	
Section 2.1, Rationale for the Study	UC subjects who would be entering directly.	who had not previously participated in an induction (SHP647-301 or SHP647-302) or maintenance (SHP647-303) study.	
Study Synopsis, Methodology	Revised language to reflect	To reflect inclusion of UC subjects	
Section 3.1, Study Design and Flowchart	inclusion of direct-entry UC subjects.	entering directly.	
Section 6.2.2, Allocation of Subjects to Treatment	Updated Figure 1, Study Design Flow Chart to include direct-entry UC subjects.		
<	or l		

Protocol Amendment				
Summary of Change(s) Since the Last Version of the Approved Protocol				
Amendment Number	Amendment Date	Global/Region/Country/Site Specific		
3	07 Nov 2019	Global		
Section(s) Affected by Change	Description of Change	Rationale		
Study Synopsis, Methodology Section 3.1, Study Design and Flowchart	Updated language to clarify that the e-diary will be available daily throughout the study.	To provide additional clarity around the collection of e-diary data.		
Table 1, Schedule of Assessments – Treatment Year 1 (UC Subjects, Entering from Study SHP647-301, SHP647-302, or SHP647-303), footnote "m"				
Table 2, Schedule of Assessments – Treatment Year 2 Through End of Study (UC Subjects, Entering from Study SHP647-301, SHP647-302, or SHP647-303), footnote "k"				
Table 3, Schedule of Assessments – Treatment Year 1 (CD Subjects, Entering from Study SHP647-305, Study SHP647-306, or Study SHP647-307), footnote "1"	roialuse			
Table 4, Schedule of Assessments – Treatment Year 2 Through End of Study (CD Subjects, Entering from Study SHP647-305, Study SHP647 306, or Study SHP647 307), footnote "j"	non-commercialuse			
Study Synopsis, Methodology	Added treatment failure language	To reflect inclusion of UC subjects		
Section 3.1, Study Design and Flowchart	for direct-entry UC subjects.	entering directly.		
Section 4.4.2.1, Treatment Failure Assessment and Stopping Criteria				
Study Synopsis, Inclusion and exclusion criteria	Added the term 'highly effective methods for female and medically	To clarify what is meant by appropriate contraception methods.		
Section 4.1.2, Exclusion Criteria	appropriate methods for male study			
Section 4.2.2, Exclusion Criteria	subjects' in the parentheses after the term 'appropriate contraception methods'.			
	For UC and CD subjects entering from an induction or maintenance study, added to exclusion criterion number 4 that females who are lactating also are excluded.	To clarify that females who are lactating are excluded.		

Protocol Amendment				
Summary of Change(s) Since the Last Version of the Approved Protocol				
Amendment Number 3	Amendment Date 07 Nov 2019	Global/Region/Country/Site Specific Global		
Section(s) Affected by Change	Description of Change	Rationale		
Study Synopsis, Inclusion and exclusion criteria Section 4.2, Eligibility Criteria – Direct-entry Subjects with Ulcerative Colitis	Added inclusion and exclusion criteria for UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.		
Study Synopsis, Endpoints and statistical analysis Section 9.4, Statistical Analysis Process	Updated efficacy endpoints to reflect inclusion of direct-entry UC subjects.	To reflect inclusion of direct-entry UC subjects.		
Section 9.8.1, Efficacy Analyses – Subjects with Ulcerative Colitis				
Study Synopsis, Analysis Sets	Updated PD analysis set definition	To clarify that PD values must be		
Section 9.7, Study Population	to include the word 'evaluable' in the definition: 'The pharmacodynamics (PD) analysis set will consist of all subjects who receive at least 1 dose of investigational product in study SHP647-304 and have at least 1 evaluable postdose PD value.'	evaluable, and for consistency with the PK analysis set.		
Study Synopsis, Safety Endpoints	Updated safety endpoints to reflect	To reflect inclusion of direct-entry UC subjects.		
Section 9.9, Safety Analyses	inclusion of direct-entry UC subjects. Added that adverse events of special interest will be summarized by treatment group.	To include analysis of adverse events of special interest.		
Table 1, Schedule of Assessments – Treatment Year 1 (UC Subjects, Entering from Study SHP647-301, SHP647-302, or SHP647-303)	Added visit numbers to the Schedules of Assessments.	For clarity regarding visit numbers.		
Table 2, Schedule of Assessments – Treatment Year 2 Through End of Study (UC Subjects, Entering from Study SHP647-301, SHP647-302, or SHP647-303)				
Table 3, Schedule of Assessments – Treatment Year 1 (CD Subjects, Entering from Study SHP647-305, SHP647-306, or SHP647-307)				
Table 4, Schedule of Assessments – Treatment Year 2 Through End of Study (CD Subjects, Entering from Study SHP647-305, SHP647-306, or SHP647-307)				

Protocol Amendment Summary of Change(s) Since the Last Version of the Approved Protocol		
3	07 Nov 2019	Global
Section(s) Affected by Change	Description of Change	Rationale
Table 1, Schedule of Assessments – Treatment Year 1 (UC Subjects, Entering from Study SHP647-301, SHP647-302, or SHP647-303), footnote "j"	Added language to specify subjects at risk for colorectal cancer must undergo annual colonoscopy with appropriate surveillance procedures followed.	To specify surveillance of subjects at elevated risk of colorectal cancer.
Table 2, Schedule of Assessments – Treatment Year 2 Through End of Study (UC Subjects, Entering from Study SHP647-301, SHP647-302, or SHP647-303), footnote "g"		
Section 7.2.2.1, Endoscopy		
Section 7.2.4.12, Colonoscopy in Subjects at Elevated Risk of Colorectal Cancer		
Table 1, Schedule of Assessments – Treatment Year 1 (UC Subjects, Entering from Study SHP647-301, SHP647-302, or SHP647-303), footnote "q"	Added new row in Tables 1, 2, 5, and 6, new subsection to Section 7.2.5, and language to describe monitoring for hypersensitivity.	To address Food and Drug Administration (FDA) recommendation to evaluate the risk of hypersensitivity reactions in the Phase 3 studies and aid in the
Table 2, Schedule of Assessments – Treatment Year 2 Through End of Study (UC Subjects, Entering from Study SHP647-301, SHP647-302, or SHP647-303), footnote "n"	hypersensitivity.	collection of relevant safety data.
Table 3, Schedule of Assessments – Treatment Year 1 (CD Subjects, Entering from Study SHP647-305, SHP647-306, or SHP647-307), footnote "p"	5	
Table 4, Schedule of Assessments – Treatment Year 2 Through End of Study (CD Subjects, Entering from Study SHP647-305, SHP647-306, or SHP647-307), footnote "m"		
Section 7.2.4.10, Monitoring for Hypersensitivity		
Table 3, Schedule of Assessments – Treatment Year 1 (UC Subjects, Direct Entry)	Added new Schedules of Assessments tables for UC subjects entering directly.	To provide detailed procedures for UC subjects entering the study directly.
Table 4, Schedule of Assessments – Treatment Year 2 Through End of Study (UC Subjects, Direct Entry)		

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number	Amendment Date	Global/Region/Country/Site Specific
3	07 Nov 2019	Global
Section(s) Affected by Change	Description of Change	Rationale
Section 4.3, Reproductive Potential	Updated text to reflect results of an enhanced pre- and postnatal development (ePPND) toxicity study in nonhuman primates. Added language to describe UC subjects who would be entering directly.	Updated information to reflect preliminary results from an ePPND toxicity study of ontamalimab in nonhuman primates, which indicated that, at the dose levels tested (30 and 60 mg/kg), infant losses were increased in ontamalimab-exposed animals when compared both to control animals in the study and to the historical control animal data from the testing facility.
	S	The relevance of this finding to humans is unknown but cannot be excluded. Results of the ePPND study were
		reported in the ontamalimab Investigator's Brochure Edition 8.0.
	Added the term 'highly effective methods for female and medically appropriate methods for male study subjects' in parentheses after the terms 'appropriate form of contraception' and 'appropriate method of contraception'.	Added to reflect inclusion of UC subjects who had not previously participated in an induction (SHP647-301 or SHP647-302) or maintenance (SHP647-303) study. To clarify what is meant by appropriate contraception methods.
Section 4.3.1, Contraceptive Methods for Female Study Subjects	Added text to specify that contraception methods with low user dependency should preferably be used, in particular when contraception is introduced as a result of participation in the clinical study.	To align with guidance document "Recommendations related to contraception and pregnancy testing in clinical trials" of Clinical Trial Facilitation Group.
Section 4.4.2, Subject Withdrawal Criteria	The term 'major protocol deviations' has been changed to 'protocol deviations'.	For consistency with Section 4.4.3 (Reasons for Withdrawal).
Section 5.1.2.1, Permitted Treatment	Added the statement "any permitted treatment may be initiated or discontinued as clinically appropriate."	To clarify that during the study any permitted treatment may be initiated or discontinued as clinically appropriate.
Table 5, Glucocorticoid Tapering – Subjects with Ulcerative Colitis Table 6, Glucocorticoid Tapering – Subjects with Crohn's Disease	Changed to column heading from 'Second Taper' to 'Subsequent Taper'.	To clarify that, as this is long-term study, there may be more than two tapers of glucocorticoid dosing.

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number	Amendment Date	Global/Region/Country/Site Specific
3	07 Nov 2019	Global
Section(s) Affected by Change	Description of Change	Rationale
Section 5.2, Prior and Concomitant Treatment – Direct-entry Subjects with Ulcerative Colitis	Added new subsection to describe prior and concomitant treatment for UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.
Section 7.1.2, Direct-entry Subjects with Ulcerative Colitis	Added new subsection to describe study schedule for UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.
Section 7.2.1, Demographic and Other Baseline Characteristics Appendix 2, Scales and Assessments	Added text to describe assessment of demographics/baseline characteristics for UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.
	Added stool frequency screening questions to Appendix 2.	El al
Section 7.2.3, Efficacy Assessments – Direct-entry Subjects with Ulcerative Colitis	Added new subsection to describe efficacy assessments for UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.
Section 7.2.4, Safety Section 7.2.5, Others	Updated the text in the subsections to describe inclusion of UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.
Table 7, Quarterly Neurological Assessments	Column heading changed from 'targeted neurological history' to 'interim neurologic history and targeted neurologic examination'.	To align with language of newly proposed electronic case report form.
Section 7.2.4.6, Clinical Laboratory Evaluations Section 7.2.4.11, Evaluation of Increased Gastrointestinal Symptoms	Added text to describe evaluation of increased gastrointestinal symptoms.	To clarify that infectious etiology must be evaluated when a subject experiences an increase in gastrointestinal symptoms.
Section 7.2.5.7, Additional Clinical Laboratory Assessments – Direct-entry Subjects with Ulcerative Colitis	Added new subsection to describe additional clinical laboratory assessments as part of screening, for UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.
Section 7.2.5.10, Chest X-ray (Direct-entry Subjects with Ulcerative Colitis Only)	Added new subsection to describe screening chest x-ray to be performed for UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.
Section 7.2.5.12, Anti-vedolizumab Antibodies (Only for Direct-entry UC Subjects with Ulcerative Colitis Previously Treated with Vedolizumab)	Added new subsection to describe collection of a blood sample for measurement of anti-vedolizumab antibodies, for UC subjects entering directly who had received prior vedolizumab treatment.	To reflect inclusion of a baseline anti-vedolizumab antibody measurement for UC subjects entering directly who had received prior vedolizumab treatment.

Protocol Amendment Summary of Change(s) Since the Last Version of the Approved Protocol		
3	07 Nov 2019	Global
Section(s) Affected by Change	Description of Change	Rationale
Section 7.2.6, Volume of Blood to Be Drawn from Each Subject – UC and CD Subjects	Decreased serum chemistry sample volume from 6 mL to 4 mL.	To correct the sample volume needed for the serum chemistry test.
Section 7.2.6, Volume of Blood to Be Drawn from Each Subject – UC and CD Subjects	Increased pharmacokinetic sample volume from 3 mL to 5 mL.	To correct the sample volume needed for the pharmacokinetic assessment.
Section 7.2.8, Volume of Blood to Be Drawn from Each Subject – UC Subjects Entering Directly	Added new subsection to provide blood volumes for UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.
Section 8.1, Definition of Adverse Events, Period of Observation, Recording of Adverse Events	Updated the text to describe inclusion of UC subjects entering directly.	To reflect inclusion of UC subjects entering directly.
Table 11, Safety Monitoring Rules for Treatment-emergent Elevated ALT and/or Bilirubin	150	
Section 8.1.3, Adverse Events of Special Interest	Added new subsection to describe classification of hypersensitivity as an adverse event of special interest.	To address FDA recommendation to evaluate the risk of hypersensitivity reactions in the Phase 3 studies and aid in the collection of relevant safety data.
Section 8.1.7, Pregnancy	Added text to specify that in cases of pregnancy, where the outcome is a live birth, the vital status and clinical condition of the infant should be obtained and documented at 1 year postpartum.	To extend the timeframe for follow-up of pregnancy outcomes for female study participants or partners of male study participants, in response to preliminary findings of the ePPND study.
Section 9.5, Planned Interim Analysis, Adaptive Design, Data Monitoring Committee, and Hypersensitivity Adjudication Committee	Added text to specify that an external hypersensitivity adjudication committee will be established to review data from subjects who experience a suspected Type I or Type III hypersensitivity reaction.	To address FDA recommendation to evaluate the risk of hypersensitivity reactions in the Phase 3 studies and aid in the collection of relevant safety data.
Section 9.6, Sample Size Calculation and Power Considerations	Updated sample size projections for UC subjects entering from an induction or maintenance study. Added targeted sample size for UC subjects entering directly.	To reflect changes in sample size in the SHP647-301, SHP647-302, and SHP647-303 studies and revised projections for the number of subjects who may rollover from those studies, and to provide targeted sample size for direct-entry UC subjects who may enter directly based on the completed A7281010 study and assessment of the literature.

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number 3	Amendment Date 07 Nov 2019	Global/Region/Country/Site Specific Global
Section(s) Affected by Change	Description of Change	Rationale
Section 9.8.1.2, Exploratory Efficacy Endpoints	For the endpoint "Change from induction study (SHP647-301 or SHP647-302) baseline, or Study SHP647-304 baseline for direct-entry subjects, in abdominal pain, diarrhea and urgency item scores, absolute stool frequency, absolute rectal bleeding, and total sign/symptom score based on subject daily e-diary entries (sum of rectal bleeding, stool frequency, abdominal pain, diarrhea, and urgency) over time", revised the final part of the text in parentheses to read "(average of rectal bleeding, stool frequency, abdominal pain, diarrhea, and urgency)".	To correctly describe the scoring of patient-reported UC sign and symptom data.
Section 9.8.2.2, Exploratory Efficacy Endpoints	For the endpoint "Change from induction study (SHP647-305 or SHP647-306) baseline in abdominal pain, very soft stool/liquid stool frequency (as shown by type 6/7 on BSFS), total stool frequency, rectal urgency, rectal bleeding, nausea, vomiting, and incontinence, and total sign/symptom score based on subject daily e-diary entries (average of rectal bleeding, stool frequency, abdominal pain, very soft stool/liquid stool, and rectal urgency) over time", revised the final part of the text in parentheses to read "(average of rectal bleeding, stool frequency, abdominal pain, very soft stool/liquid stool, and rectal urgency)". For the endpoint, "Subject TSQM total scores and 4 domain scores over time", deleted reference to "total scores".	To correctly describe the scoring of patient-reported CD sign and symptom data. To correctly describe scoring for the Treatment Satisfaction Questionnaire for Medication (TSQM).
Section 9.10.1, Pharmacodynamic Analyses	Added that biomarker endpoints will be summarized by indication along with treatment group and visit.	Added for clarity.

Protocol Amendment Summary of Change(s) Since the Last Version of the Approved Protocol		
3	07 Nov 2019	Global
Section(s) Affected by Change	Description of Change	Rationale
Section 10.1.5, Study Suspension, Termination, and Completion	To clarify that the end-of-study declaration may be made by the sponsor or alternatively its representatives.	Added for clarity.
Appendix 1, Protocol History	Added Summary of Changes for Amendment 2 relative to Amendment 1, and for Amendment 1 relative to original protocol.	For completeness, such that the Protocol History section includes the summary of changes made with all prior global amendments to this protocol.
Appendix 5, Determination of Failure or Intolerance to Prior Treatment for Ulcerative Colitis	Added new appendix section, "Determination of failure or intolerance to prior treatment for ulcerative colitis" to provide guidance as related to inclusion criterion #5 in which subjects meeting these criteria on prior conventional treatments (eg, sulfasalazine, mesalamine, glucocorticoids, immunosuppressants, or anti-TNF) may be eligible for this study.	To provide granularity regarding the eligibility of direct-entry UC subjects who demonstrated inadequate response, loss of response, or intolerance on conventional treatment.
Throughout protocol	'SHP647' was updated to 'ontamalimab'' throughout the protocol.	To reflect that ontamalimab is the international nonproprietary name for SHP647.
Throughout protocol	Minor changes to wording and editorial changes.	To improve clarity, consistency, and remove redundancy of text.

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number Amendment Date Global/Region/Country/Site Spec		
2	14 Sep 2018	Global

Protocol Amendment Summary and Rationale:

The main purpose of SHP647-304 Amendment 2 is to further clarify the rationale for the study design with regard to subjects who would enter following participation in one of the maintenance studies (SHP647-303 or SHP647-307) and have been classified as nonresponsive to treatment and met the protocol-specified definition of treatment failure. This amendment clarifies how subjects will be monitored for safety and clinical benefit, and for assessment of potential treatment failure and criteria for withdrawal of treatment in this long-term extension study. The amendment also describes the potential benefit for subjects, including for those who previously had been classified as nonresponsive to active treatment. Additionally, this amendment elevates efficacy endpoints based on clinical remission and endoscopic outcomes from "exploratory" to "secondary" to emphasize that assessment of efficacy and monitoring of clinical benefit is an important aspect of the study. The significant changes in SHP647-304 Protocol Amendment 2 relative to the previous edition, SHP647-304 Protocol Amendment 1, are captured below.

	Protocol Amendment	
Summary of Cha	nge(s) Since the Last Version of the	Approved Protocol
Amendment Number	Amendment Date	Global/Region/Country/Site Specific
2	14 Sep 2018	Global
Section(s) Affected by Change	Description of Change	Rationale
Emergency Contact Information Section 8.2.2, Reporting Procedures Section 8.2.4, Serious Adverse Event Collection Time Frame	Replaced "Shire Global Pharmacovigilance" with "the Shire Global Drug Safety Department." Updated the fax number for serious adverse event reporting.	To provide updated and correct information.
Study Synopsis, Methodology Section 3.1, Study design and flowchart	Added language to clarify that efficacy data will be collected to monitor clinical benefit, and to provide information on treatment failure assessment as also outlined in Section 4.1.1, Treatment Failure Assessment and Stopping Criteria.	To emphasize and further describe that subjects will be monitored for clinical benefit and for assessment of potential treatment failure.
Study Synopsis, Methodology Study Synopsis, Maximum duration of subject involvement in the study Section 3.1, Study Design and Flowchart Section 3.2, Duration and Study Completion Definition	Added text to clarify that a subject's maximum duration of treatment is expected to be 7 years, subject to local or country requirements, and removed the phrase "or until SHP647 becomes available commercially, whichever occurs earlier."	To provide clarity regarding the maximum duration of study participation.

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number	Amendment Date	Global/Region/Country/Site Specific
2	14 Sep 2018	Global
Section(s) Affected by Change	Description of Change	Rationale
Study Synopsis, Exclusion Criteria – Subjects with CD Section 4.2.2, Exclusion Criteria (Subjects with Crohn's Disease)	Revised exclusion criterion #3 (for subjects with CD) to add that subjects who developed acute severe complications of CD that required immediate intervention and/or CDAI score >450 are excluded.	To further define the criterion related to disease severity for subjects with CD.
Study Synopsis, Inclusion and exclusion criteria Section 4.1.2, Exclusion Criteria (Subjects with Ulcerative Colitis) Section 4.2.2, Exclusion Criteria (Subjects with Crohn's Disease)	Updated exclusion criterion #5 (for subjects with UC and subjects with CD) to indicate the exclusion of subjects who do not agree to postpone donation of any organ or tissue, including male subjects are planning to bank or donate sperm and female subjects who are planning to harvest or donate eggs, for the duration of the study and for 16 weeks after last dose of investigational product.	To specify the exclusion of subjects who do not agree to postpone donation of any organ or tissue, including sperm banking or donation for male subjects and egg donation or harvest for female subjects, are excluded.
Study Synopsis, Objectives Section 2.2.2, Secondary Objectives – Subjects with Ulcerative Colitis Section 2.2.3, Secondary Objectives – Subjects with Crohn's Disease	Moved efficacy objectives related to clinical remission and endoscopic outcomes, from "exploratory" to "secondary."	To emphasize that this study will evaluate efficacy as well as safety.
Study Synopsis, Endpoints and statistical analyses Section 9.8.1, Efficacy Analyses – Subjects with Ulcerative Colitis Section 9.8.2, Efficacy Analyses – Subjects with Crohn's Disease	Moved efficacy endpoints based on clinical remission and endoscopic outcomes, from "exploratory" to "secondary."	To emphasize that this study will evaluate efficacy as well as safety.
Schedule of Assessments Table 8 Volume of Blood to Be Drawn from Each Subject – Treatment Year 1	Added PK and ADA sample collection at 2 additional time points, Week 4 and Week 12.	To obtain additional PK and ADA measurements earlier in the study to identify immunogenicity status, particularly for those subjects entering the study who are naïve to active treatment or who would be restarting active treatment after receiving placebo in the maintenance study.

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number	Amendment Date	Global/Region/Country/Site Specific
2	14 Sep 2018	Global
Section(s) Affected by Change	Description of Change	Rationale
Section 1.3, Benefit/Risk Assessment	Added new section describing benefit and risk of SHP647 treatment.	To provide a summary of benefit and risk information for SHP647.
Section 2.1, Rationale for the Study	Added language to clarify the rationale for the study design, ie to offer access to active treatment to subjects who may have benefited from treatment at the end of a maintenance study, to subjects who had received placebo or an insufficient duration of active treatment in an induction study, or who may have met treatment failure criteria in a maintenance study. Added text to emphasize that efficacy data will be collected regularly for all subjects, to allow for monitoring of clinical benefit and evaluation of potential treatment failure. Added a statement (from Section 6.1.1, Blinding the Treatment Assignment) to explain the reason for the double-blind study design. Added text (from Section 6.2.2, Allocation of Subjects to Treatment) to describe the treatment allocation for entering subjects. Added reference citation (Pullen et al, 2009) to the first paragraph where the SHP647 molecule is described.	To improve clarity of the study rationale.
Section 4.4.1, Subject Withdrawal Criteria	Added pregnancy as a reason that a subject may be withdrawn from study treatment. Removed initiation of a new therapy for UC or CD as a reason that a subject should be withdrawn from study treatment.	For clarity and consistency with language in Section 8.1.6. To reflect that a new therapy may be permitted as described in Section 5.2.1 and Section 5.3.1.

Protocol Amendment		
Summary of Change(s) Since the Last Version of the Approved Protocol		
Amendment Number 2	Amendment Date 14 Sep 2018	Global/Region/Country/Site Specific Global
Section(s) Affected by Change	Description of Change	Rationale
Section 4.4.1.1, Treatment Failure Assessment and Stopping Criteria	Added language that subjects will be assessed regularly for efficacy to monitor clinical benefit and for evaluation of potential treatment failure.	To improve clarity regarding assessment of potential treatment failure and criteria for withdrawal from study treatment.
Section 5.2, Concomitant Treatment – Subjects with Ulcerative Colitis Section 5.3, Concomitant Treatment – Subjects with Crohn's Disease	Added a statement that additional safety assessments may be necessary for concomitant treatments, in accordance with the safety recommendations for the treatments. This change was made with SHP647-304 Protocol Administrative Change Memo #3, dated 22 Mar 2018.	To provide correct information/guidance.
Section 5.2.1, Permitted Treatment (Subjects with Ulcerative Colitis)	Revised language to clarify tapering of glucocorticoids. Removed requirement for a stable dose of medicinal marijuana to be maintained during the study. Added that dietary and herbal supplements and probiotics should be recorded as concomitant medications.	To provide correct information and for consistency of language provided for UC and CD.
Section 5.2.2, Prohibited Treatment (Subjects with Ulcerative Colitis) Section 5.3.2, Prohibited Treatment (Subjects with Crohn's Disease)	Revised language to clarify tapering of glucocorticoids. Added text to clarify the prohibition of anti-TNF treatment or other biologics including biosimilars or nonbiologic agents with immunomodulatory properties, except for azathioprine [AZA], 6-mercaptopurine [6-MP], and methotrexate, which are permitted. Added text to clarify the prohibition of leukocyte apheresis or selective lymphocyte, monocyte, or granulocyte apheresis or plasma exchange. Added text to specify that subjects who enter the 16-week safety follow-up period will no longer need to abstain from the medications that were prohibited during the treatment period and	To provide correct information, and for consistency of language for the UC and CD indications and alignment with the induction and maintenance study protocols. To clarify that once subjects enter the 16-week safety follow-up period, medications that were prohibited during the treatment period, including other treatments for UC or CD, will be allowed.

Protocol Amendment Summary of Change(s) Since the Last Version of the Approved Protocol		
2	14 Sep 2018	Global
Section(s) Affected by Change	Description of Change	Rationale
	that other treatments for UC or CD will be allowed. Biologics or nonbiologic immunosuppressants should not be initiated without prior discussion with the sponsor study physician or designee due to the long half-life of SHP647.	
Section 5.3.1, Permitted Treatment (Subjects with Crohn's Disease)	Revised language to clarify tapering of glucocorticoids. Removed requirement for antidiarrheal opiate drugs, medicinal marijuana, and dietary and herbal supplements to be at a stable dose at study entry and maintained at a stable dose during the study. Removed parenteral or rectal glucocorticoids from the list of prohibited medications.	To provide correct information and for alignment of permitted medications across UC and CD, where applicable.
Section 7.2, Study Procedures	Added language to specify that the duration of blood and tissue sample storage is dependent on local regulations.	To clarify that local regulations should be considered for duration of blood and tissue sample storage.
Section 7.2.4.6, Clinical Laboratory Evaluations	Added information on laboratory testing for <i>C. difficile</i> infection, including diagnostic algorithms.	To provide appropriate guidance regarding laboratory testing for <i>C. difficile</i> infection.
Section 7.2.5.2, Pharmacodynamic Assessments	Revised text to clarify the stool sample collection and assessment.	To improve clarity in the description of stool sample collection and assessment.
Section 8.2.8, Safety Monitoring Rules	Added new section describing safety monitoring and stopping algorithms for elevated hepatic blood tests.	To provide appropriate guidance on patients who have been enrolled with elevated liver function test values or who experience and increase in liver function test(s) during the study.
Section 9.9, Safety Analyses	Added text to clarify that the primary endpoint is assessment of safety.	To improve clarity and for alignment with language in the study synopsis.
Section 10, Sponsor's and Investigator's Responsibilities	Added a statement that compliance with the noted regulations and guidelines also constitutes compliance with the ethical principles described in the Declaration of Helsinki.	To clarify that the study is conducted in accordance with the ethical principles in the Declaration of Helsinki.

Protocol Amendment			
Summary of Change(s) Since the Last Version of the Approved Protocol			
Amendment Number	Amendment Date	Global/Region/Country/Site Specific	
2	14 Sep 2018	Global	
Section(s) Affected by Change	Description of Change	Rationale	
Appendix 4, Guidance for Diagnosis and Treatment of Increased Gastrointestinal Symptoms	Added new Appendix 4, "Guidance for Diagnosis and Treatment of Increased Gastrointestinal Symptoms related to diagnosis and treatment of <i>C. difficile</i> infection."	To provide updated guidance for diagnosis and treatment of <i>C. difficile</i> infection.	
Throughout protocol	Minor changes to wording.	To improve clarity, consistency, and remove redundancy of text.	

Fornon-commercialuse only

	Protocol Amendment	
	ge(s) Since Last Version of App	
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Change a	nd Rationale	Section(s) Affected by Change
Revised study title to reflect inclusion of sub <i>Now reads:</i> "A Phase 3 Long-term Safety Extension Stu Moderate to Severe Ulcerative Colitis or Cr	dy of SHP647 in Subjects with	Title page Protocol signature page Study Synopsis, Title of the study
Updated the email address for Shire Drug Sa information page: <i>Now reads:</i> Email globalpharmacovigilancedrugsafety @shire.		Emergency contact information
Updated the email address for reporting of p originate in the European Union and Rest of is the same for all regions.		Product quality complaints
Now reads:	0	
Origin of Product Quality Complaint	E-mail Address	
North and South America, the European Union, and Rest of World		
European Union and Rest of World	PQCROW@shire.com	
Updated the projected number of subjects to with CD entering from Studies SHP647-305 SHP647-307. <i>Now reads:</i> Number of subjects (total and for each tre Approximately 1114-2453 subjects are proje study.	, SHP647-306, and eatment arm):	Study Synopsis, Number of subjects (total and for each treatment arm)
Updated approximate number of sites and countries in which this study will be conducted.		Study Synopsis, Sites and region(s)
Now reads:		Section 3.3, Sites and regions
This study will be conducted in approximate approximately 33 37 countries.	ely 350 439 sites in	
Revised planned study period to reflect inclu entering from Studies SHP647-305, SHP647		Study Synopsis, Study period (planned)
Now reads:		
Study period (planned):		
2018 - 2024 2025		

	Protocol Amendment	
Summary of	Change(s) Since Last Version of Ap	proved Protocol
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Ch	ange and Rationale	Section(s) Affected by Change
Revised language in the primary obje with CD entering from Studies SHP6 SHP647-307.	ctive to reflect inclusion of subjects	Study Synopsis, Objectives Section 2.2.1, Primary Objective
Now reads:		
Objectives:		
Primary: To evaluate the safety and with SHP647 in subjects with modera		
Revised language in the rationale to c double-blinded, and to reflect inclusio Studies SHP647-305, SHP647-306, a	on of subjects with CD entering from	Study Synopsis, Rationale Section 2.1, Rationale for the Study
Now reads:		E
as an induction therapy (SHP647-301 SHP647-306) and did not meet the	response criteria (clinical and/or ppropriate) required for entry into or SHP647-307), or 2) were n one of the 2 multicenter, double- d, parallel-group study evaluating	
Revised language to reflect inclusion Studies SHP647-305, SHP647-306, a Now reads:		Study Synopsis, Methodology Section 3.1, Study design and
This is a Phase 3 double-blind, multi- evaluate the long-term safety and effi- moderate to severe UC or CD. The st 6 separate Phase 3 studies: 2 multicer placebo-controlled, parallel group stu- induction therapy in subjects with mo- and SHP647-302); 2 multicenter, ra- controlled, parallel group studies er therapy in subjects with moderate (SHP647-306); 1 multicenter, double- controlled, parallel-group study evalu- in subjects with moderate to severe U double-blind, randomized, placebo- evaluating SHP647 as maintenance to severe CD (SHP647-307).	cacy of SHP647 in subjects with hudy will enroll subjects from hter, randomized, double-blind, dies evaluating SHP647 as an oderate to severe UC (SHP647-301 ndomized, double-blind, placebo- valuating SHP647 as an induction to severe CD (SHP647-305 and blind, randomized, placebo- tating SHP647 as maintenance therapy IC (SHP647-303); and 1 multicenter, -controlled, parallel-group study	
	in this study. Eligible subjects	

	Protocol Amendment		
Summary of Change(s) Since Last Version of Approved Protocol			
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global	
Description of Ch	ange and Rationale	Section(s) Affected by Change	
SHP647-307 without treat 25 mg or 75 mg of SHP647 the same dose of SHP647 in If results for confirmation the time of the end of stud will have 1 additional week	intenance study SHP647-303 or ment failure and received either every 4 weeks will continue to receive a this long-term safety extension study. of treatment failure are pending at y visit in study SHP647-307, sites k to confirm final status of the or not) before enrolling the subject		
 Randomization will be strat by the status from the study follows: (1) did not meet the endoscopic response/remiss study; (2) treatment failure if (3) maintenance study composition subjects receiving placebo, to assignment within each strat. For UC subject for this strate collected at: For UC subjects, the Week (SHP647-301 or SHP647-301 remination visit of the main will be considered and recorrectors study. For CD subjects, the Weel (SHP647-305 or SHP647-305 remination visit of the main which will be considered at this extension study. 	bletion without treatment failure for to facilitate balance of treatment tum. udy will be assessed from study data a 12 visit of the induction study 802), OR the Week 52 or Early intenance study (SHP647-303), which rded as the baseline visit for this a 16 visit of the induction study 806), OR the Week 52 or Early aintenance study (SHP647-307), and recorded as the baseline visit for an additional window of 1 week for failure status is still under the Week 52 visit of the maintenance		
undergo safety, efficacy, biomarker, assessments at these visits as outlined	using pre-filled syringes. Subjects will pharmacokinetic, and health outcome d in the Schedules of Assessments is in Year 1, for subjects with UC and e 4 for assessments beginning in bjects with UC and CD,		
tolerability of long-term treatment w	ith SHP647. Safety will be measured events (AEs); incidence and nature of		

Summary of	Protocol Amendment	newed Bustanal
	Change(s) Since Last Version of App	
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Cha	ange and Rationale	Section(s) Affected by Change
incidence of abnormalities, in laborate antidrug antibodies.	ory tests, ECGs, and vital signs; and	
For subjects with UC, patient-report stool frequency, rectal bleeding severi urgency frequency, and abdominal pai using a daily e-diary for 10 days befor score is a measure of UC disease activ 4 subscores: stool frequency, rectal bl- physician global assessment (PGA). T Mayo score without the endoscopic su- recommended measure consisting of t subscore, and will be used for the exp Mayo scores and composite score will entries. For subjects with CD, patient-repor (abdominal pain severity, very soft BSFS type 6/7] frequency, rectal ble frequency, total stool frequency) will for 14 days before each specified vis measure with 8 components. Five co- visits, and 3 components (abdominal stool/liquid stool frequency, and ger reported by the subject and will be for 14 days before each specified vis assessments.	ity and frequency, diarrhea frequency, in worst severity) will be collected re each specified visit. The Mayo rity consisting of the following eeding, findings of endoscopy, and he partial Mayo score consists of the abscores. The composite score is a he Mayo score without the PGA loratory efficacy endpoints. The l be based on subject daily e-diary red CD signs and symptom data stool/liquid stool [as shown by eeding frequency, rectal urgency sea severity, incontinence II be collected using a daily e-diary sit. The CDAI is a composite omponents will be captured at the l pain severity, very soft neral well-being) will be self- collected as part of the daily e-diary	
Combined language regarding eligibil potential, from inclusion criterion no.	5 and exclusion criterion no. 4 and	Study Synopsis, Inclusion and exclusion criteria
deleted inclusion criterion no.5 as it w	as redundant.	Section 4.1, Eligibility Criteria -
Now reads:		Subjects with UC
Inclusion Criteria – Subjects with U		
the protocol, or females of nonch	with the contraceptive requirements of ildbearing potential. Males and who are sexually active must agree to	
Exclusion Criteria – Subjects with U	UC:	
4. Female subjects Subjects are fema study SHP647-301, SHP647-302, or S planning to become pregnant during th	SHP647-303, or females who are	

		Protocol Amendment	
		Change(s) Since Last Version of A	
А	mendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
	Description of Ch	ange and Rationale	Section(s) Affected by Change
TB since Now rea 10. Subj since tes have be	ext to clarify the exclusion cr e initial testing at screening ir ads: jects with known exposure to sting at screening in study SH	iterion regarding known exposure to a one of the induction studies. <i>Mycobacterium tuberculosis</i> (TB) P647-301 or SHP647-302 and who nent for latent or active disease, but	Study Synopsis, Inclusion and exclusion criteria Section 4.1, Eligibility Criteria - Subjects with UC
studies subsecti Criteria. <i>Now rea</i> Inclusio	SHP647-305, SHP647-306, an ons: Section 4.2.1, Inclusion ads: on Criteria – Subjects with C	Criteria and Section 4.2.2, Exclusion	Study Synopsis, Inclusion and exclusion criteria Section 4.2, Eligibility Criteria – Subjects with Crohn's Disease
for enro 13. 14. 15.	 billment into the study: Subjects and/or their parer representative must have a willingness to fully comply restrictions. Subjects must be able to vo and dated (personally or virepresentative) informed c to participate in the study. Subjects must have been pi 305, SHP647-306, or SHP6 following clinical trial mile Completed the Weel SHP647-305 or SHP efficacy criteria (clin response/remission a maintenance study S Completed the Weel SHP647-307. Withdrew early from due to treatment fail failed treatment, at the SHP647-307), as defined to subjects receiving any treatment for the subjects receiving any treatment fail 	nt or legally authorized in understanding, ability, and with study procedures and oluntarily provide written, signed, ia a legally authorized onsent and/or assent, as applicable, reviously enrolled in study SHP647 47-307, and reached 1 of the stones: a 16 visit in induction study 647-306, and did NOT meet the nical and/or endoscopic as appropriate) for entry into 5HP647-307. a 52 visit in maintenance study in maintenance study SHP647-307 fure (or were considered to have the time of the last visit in study ined in the SHP647-307 protocol. atment(s) for CD described in	
10.	Section 5.3.1, are eligible p	rovided they have been, and are le dose for the designated period of	

	Summary of	Protocol Amendment Change(s) Since Last Version of Ap	neroved Protocol
	mendment Number	Amendment Date	Global/Country/Site Specific
A	1	18 Dec 2017	Global
	Description of Cha		Section(s) Affected by Change
Exclusi	on Criteria – Subjects with (
Subject net:	s are excluded from the stud	ly if any of the following criteria are otocol deviation(s) (as determined	
18.	product because of an AE,	discontinued investigational regardless of relatedness to study SHP647-305, SHP647-306, or	
19.	Subjects who are likely to r	equire major surgery for CD.	
20.	SHP647-305, SHP647-306, planning to become pregna males or females of childbe	ecame pregnant during study or SHP647-307, females who are nt during the study period, or aring potential not agreeing to contraception methods through ticipation (see Section 4.3)	
21.		ning to donate sperm and do not uration of the study and through 16 estigational product.	
22.	Subjects who, in the opinion will be uncooperative or un procedures.	n of the investigator or the sponsor, able to comply with study	
23.	cell carcinoma, squamous c	diagnosed malignancy or other than resected cutaneous basa cell carcinoma, or carcinoma in situ as been treated with no evidence of	
24.	evidence of an unstable clin hematologic, GI [except dis cardiovascular, pulmonary syndrome], or local active i	nfection/infectious illness) that, in t, will substantially increase the risk	
25.	psychiatric condition or lab (ECG) abnormality that ma study participation or inves or may interfere with the in	rere acute or chronic medical or boratory or electrocardiogram ay increase the risk associated with stigational product administration interpretation of study results and, stigator, would make the subject o this study.	
26.		ure to <i>Mycobacterium tuberculosis</i> ing in Study SHP647-305 or	

	Protocol Amendment	1.0
	Change(s) Since Last Version of App	
Amendment Number	Amendment Date	Global/Country/Site Specific
1	18 Dec 2017	Global
	ange and Rationale	Section(s) Affected by Change
relatives of those site staff 1	nembers or subjects who are involved in the conduct of the	
(other than SHP647-305, SI	ting in other investigational studies HP647-306, or SHP647-307) or plan stigational studies during long-term 4.	
Revised definition of safety analysis s CD entering from Studies SHP647-30	et to reflect inclusion of subjects with 5, SHP647-306, and SHP647-307.	Study Synopsis, Endpoints and statistical analysis
Added definition for FAS.	0,	Section 9.7, Study Population
Revised definition of PK and PD anal	ysis sets for clarity.	
Now reads:	ysis sets for clarity.	
Endpoints and statistical analysis:	C/C	
Analysis Sets:	NOT	
The screened set will consist of all sul consent document for the SHP647-30	bjects who have signed an informed	
The randomized set will consist of all a randomization number has been assi	subjects in the screened set for whom igned in the SHP647-304 study.	
The full-analysis set (FAS) will cons set who have received at least 1 dos	ist of all subjects in the randomized of investigational product.	
The safety set will consist of all subje investigational product in the SHP647 received during the induction and mai SHP647-302, SHP647-303, SHP647- SHP647- 303 307).	7-304 study, regardless of treatment ntenance studies (SHP647-301,	
The pharmacokinetic (PK) analysis s safety set for whom who receive at le Study SHP647-304 and have at leas sample was collected.concentration v	ast 1 dose of SHP647 in t 1 evaluable postdose PK blood	
The pharmacodynamic (PD) analysis safety set for whom who receive at le Study SHP647-304 and have at least collected v alue.	ast 1 dose of SHP647 in	
Deleted redundant text in synopsis un	der "Primary Endpoint."	
Now reads:		
Primary Endpoint: The primary end assessment of safety as measured by: incidence and nature of serious infect	incidence and severity of AEs;	

	Protocol Amendment	
Summary of	f Change(s) Since Last Version of App	proved Protocol
Amendment Number 1	Global/Country/Site Specific Global	
Description of Ch	ange and Rationale	Section(s) Affected by Change
baseline, as well as the incidence of a ECGs, and vital signs; and antidrug a		
Added further details on planned sun analyses. Clarified definition of TEA		Study Synopsis, Endpoints and statistical analysis
Now reads:		Section 9.9, Safety Analyses
analyzed according to the treatment t will be coded using the Medical Dict	dication separately and also overall. ne status at entry into this study	
preferred term, and by treatment grou	llowing the first exposure to 7-304 study. The number of events, will be calculated overall, by SOC, by up. Treatment-emergent AEs will be elationship to investigational product. onal product, AEs leading to	
Revised titles of Table 1 and Table 2 subjects.	to clarify that they apply to UC	Study Synopsis, Study Schedules: Table 1, Table 2, Table 3, Table 4
Titles now read: Table 1: Schedule of Assessments – Entering from Study SHP647-301,		
Table 2: Schedule of Assessments – Study (UC Subjects, Entering from SHP647-303)	Treatment Year 2 through End of a Study SHP647-301, SHP647-302, or	
Added 2 new schedules of assessmer Studies SHP647-305, SHP647-306, a	nts for subjects with CD entering from and SHP647-307, entitled:	
Table 3: Schedule of Assessments – Entering from Study SHP647-305, Study SHP647-307)		
	Treatment Year 2 through End of 1 Study SHP647-305, SHP647-306,	

	Protocol Amendment		
Summary of Change(s) Since Last Version of Approved Protocol			
Amendment Number	Amendment Date	Global/Country/Site Specific	
1	18 Dec 2017	Global	
Description of Cha	ange and Rationale	Section(s) Affected by Change	
Updated the header rows for the follow the safety follow-up visits are 8 and 1 dose. This change was communicated administrative change memo #1, dated <i>Now reads:</i> 8 wks post-last dose EOT	6 weeks post-EOT, not post-last in protocol SHP647-304	Table 2	
16 wks post- last dose EOT			
Deleted footnote connected to vital sig as the order of assessments is listed in Deleted the following (footnote "f" to Vital signs (including blood pressure, temperature) and 12 lead ECG should blood samples for laboratory assessme	Section 7.2 Study Procedures. Table 1 and footnote "c" to Table 2): pulse, respiratory rate, and the performed prior to collection of ents.	Study Schedules: Table 1 and Table 2	
Added the following statement after the consistency with Table 1:	he numbered footnotes to Table 2, for		
"Note: Refer to Section 7.2 for the o be performed. Timing of visits is rel			
Added new subsection to Section 1 (In on the CD indication. <i>New text:</i>	ntroduction) to provide background	Section 1.1.2, Crohn's Disease	
1.1.2 Crohn's Disease	allie		
Crohn's disease (CD) is a chronic, r granulomatous inflammation of the Although the terminal ileum and ris involved sites, CD can affect any pa to the perianal region. Inflammation (full-thickness), segmental, and disc predominantly determined by the p Patients typically present with symp diarrhea, rectal bleeding, which ma and weight loss due to pain on eatin disease progresses, extraintestinal n conditions can develop, including be stenosis, as well as painful skin ulce	gastrointestinal (GI) tract. ght colon are the most commonly rt of the GI tract, from the mouth n is typically transmural ontinuous, and symptoms are art of bowel or organ involved. otoms including abdominal pain, y be persistent and lead to anemia, g and malabsorption. As the nanifestations and associated owel obstruction, fistulas, and		
The incidence of CD is estimated to 100,000 persons per year in Europe 100,000 persons per year in North A incidence has been observed betwee can occur at any age, peak incidence to fourth decades of life, with a seco latter decades of life (Molodecky et	be up to 12.7 cases per and up to 20.2 cases per America. No clear difference in on men and women. Although CD e has been observed in the second and modest rise in incidence in the		
Crohn's disease is a lifelong condition of life. The traditional approach to the second secon			

_		Protocol Amendment	
		Change(s) Since Last Version of Ap	proved Protocol
	Amendment Number	Amendment Date	Global/Country/Site Specific Global
	1	18 Dec 2017	
	Description of Cha	nge and Rationale yramid where, progressing from	Section(s) Affected by Change
mild to less po more to sympto acid (5 immun metho anti-in need fo	o severe disease, therapeutic c otent drugs at the base of the p toxic drugs at the top. Current omatic management with diet 5-ASA), opiates (loperamide), nosuppressive agents (azathio) trexate [MTX]), and biologic ttegrin agents. Despite recent	hoices proceed step by step from oyramid to more potent but also t treatment primarily consists of ary modifications, 5 aminosalicylic systemic glucocorticoids,	
these a	apply only to subjects with UC.	ploratory Objectives to clarify that	Section 2.2.2, Exploratory Objective
	d language of exploratory effica re specific about the efficacy me	acy objectives for subjects with UC to easures.	
Now re Section		- Subjects with Ulcerative Colitis	
•	outcomes (including remissi score of patient-reported sy locally read endoscopy, Ma clinical remission over time	term SHP647 treatment on clinical on over time based on composite mptoms using daily diary and yo-based remission over time, , partial Mayo score over time, based on composite score, and se over time)	
•	To evaluate the effect of lon endpoints related to endosc	g term SHP647 treatment on opic healing	
•	To evaluate the effect of long abdominal pain, urgency, dia and bleeding scores.	term SHP647 treatment on trhea, and absolute stool frequency	
•		HRQL) (as measured by se Questionnaire [IBDQ], Short F-36]) and European Quality of Life	
•	To evaluate the impact of lon incidence of hospitalizations		
•	using EQ 5D and work produ	term SHP647 treatment on HRQL activity as measured by the Work mpairment Questionnaire - UC	
•	patientsubject satisfaction wi	g-term SHP647 treatment on ith medication treatment as t Satisfaction Questionnaire for	

	ummary of Ch	Protocol Amendment ange(s) Since Last Version of App	proved Protocol
Amendment Nun		Amendment Date	Global/Country/Site Specific
Amenument Ivun	IDEI	18 Dec 2017	Global
Descri	ption of Chang	e and Rationale	Section(s) Affected by Change
To evaluate the		erm SHP647 treatment on	
	impact of long-t -related and oth	erm SHP647 treatment on er surgeries.	
• To evaluate SH treatment.	P647 pharmacok	inetics during long-term	
• To evaluate the biomarkers.	impact of long-t	erm SHP647 treatment on selected	
Added new section to de CD.	scribe the explor	atory objectives for subjects with	Section 2.2.3, Exploratory Objectives – Subjects with Crohn's Disease
New text:			E
Section 2.2.3 Explorato	ry Objectives –	Subjects with Crohn's Disease	
clinical outcom	es (including 2- ime, 2-item PR	erm SHP647 treatment on item PRO-based clinical O-based and CDAI-based	
	e effect of long-t ed to endoscopi	erm SHP647 treatment on c healing.	
abdominal pair (as shown by ty total stool freq	n severity, very 7pe 6/7 on Brist	erm SHP647 treatment on soft stool/liquid stool frequency ol Stool Form Scale [BSFS]), gency, rectal bleeding, nausea, nce.	
		erm SHP647 treatment on DQ, SF-36, and EQ-5D-5L).	
	-	-term SHP647 treatment on ad total inpatient days.	
	e impact of long D-related and of	-term SHP647 treatment on her surgeries.	
	e effect of long-t measured by t	erm SHP647 treatment on work ne WPAI-CD.	
	-	-term SHP647 treatment on nent as measured by the TSQM.	
• To evaluate the incidence of EI	· · · · · · · · · · · · · · · · · · ·	-term SHP647 treatment on	
• To evaluate SE treatment.	IP647 pharmac	okinetics during long-term	
 To evaluate the selected biomatic 		-term SHP647 treatment on	

		Protocol Amendment	
	Summary of	Change(s) Since Last Version of App	proved Protocol
Amen	dment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
	Description of Cha	ange and Rationale	Section(s) Affected by Change
		of subjects with CD entering from	Section 3.1, Study Design and Flow Chart
	re 1 Overview of SHP64 undant with Figure 2 Stud	7 Phase 3 Ulcerative Colitis Studies dy Design Flow Chart.	Figure 1 Study Design Flow Chart
Updated Figure inclusion of the second seco		Study Design Flow Chart to reflect	
Now reads:			
Section 3.1,	Study Design and Flow C	Chart	
induction the and SHP647- controlled, p therapy in s SHP647-306 controlled, p therapy in su 1 multicente group studie with moders All subjects Study SHP64	erapy in subjects with mo -302); 2 multicenter, ran parallel group studies ev ubjects with moderate to (c); 1 multicenter, double- arallel-group studies eval bjects with moderate to se er, double-blind, random es evaluating SHP647 as ate to severe CD (SHP64 will receive active drug in 47-304 will be assigned to	n this study. Eligible subjects entering receive either 25 mg or 75 mg of	
SHP647 even into this stud	-	dependent on how the subject entered	
	SHP647-307 without th 25 mg or 75 mg of SHP receive the same dose of extension study. If resul failure are pending at the Study SHP647-307, site confirm final status of	maintenance study SHP647-303 or reatment failure and received either 647 every 4 weeks will continue to 5 SHP647 in this long-term safety lts for confirmation of treatment the time of the end of study visit in es will have 1additional week to the subject (treatment failure or he subject to Study SHP647-304.	
·	Randomization will be s and by the status from entering, as follows: (1) (clinical and/or endosc appropriate) in an indu maintenance study, or (3) without treatment failu	e randomized using a 1:1 allocation. tratified by indication (UC or CD) the study from which they are) did not meet the response criteria opic response/remission as ction study; (2) treatment failure in a 3) maintenance study completion are for subjects receiving placebo, to tment assignment within each	

	Protocol Amendment	
Summary of	Change(s) Since Last Version of App	proved Protocol
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
	ange and Rationale	Section(s) Affected by Change
stratum.	ange and Rationale	Section(s) Affected by Change
The eligibility of a subject for this stu collected at:	dy will be assessed from study data	
(SHP647-301 or SHP647-3) Termination visit of the main	12 visit of the induction study 02), OR the Week 52 or Early ntenance study (SHP647-303), which ded as the baseline visit for this	
(SHP647-305 or SHP647-30 Termination visit of the ma which will be considered an this extension study, with a subjects whose treatment fa	16 visit of the induction study 06), OR the Week 52 or Early intenance study (SHP647-307), nd recorded as the baseline visit for n additional window of 1 week for ailure status is still under e Week 52 visit of the maintenance	
undergo safety, efficacy, biomarker, p assessments at these visits as outlined (Table 1 and Table 3 for assessments CD , respectively; Table 2 and Table Year 2 through End of Study, for sub respectively).	using pre-filled syringes. Subjects will bharmacokinetic, and health outcome in the Schedules of Assessments in Year 1, for subjects with UC and 4 for assessments beginning in jects with UC and CD,	
The primary objective of this study is tolerability of long-term treatment wit by: incidence and severity of adverse serious infections; actual values and c incidence of abnormalities, in laborate antidrug antibodies.	AND SHP647. Safety will be measured events (AEs); incidence and nature of hange from baseline, as well as the	
	re each specified visit. The Mayo vity consisting of the following eeding, findings of endoscopy, and The partial Mayo score consists of the ibscores. The composite score is a the Mayo score without the PGA loratory efficacy endpoints. The	
For subjects with CD, patient-repor (abdominal pain severity, very soft BSFS type 6/7] frequency, rectal blo	stool/liquid stool [as shown by	

Summary of	Change(s) Since Last Version of Ap	proved Protocol
Amendment Number	Amendment Date	Global/Country/Site Specific
1	18 Dec 2017	Global
Description of Ch	ange and Rationale	Section(s) Affected by Change
frequency, vomiting frequency, nau		
frequency, total stool frequency) wi for 14 days before each specified vis measure with 8 components. Five co visits, and 3 components (abdomina stool/liquid stool frequency, and gen reported by the subject and will be for 14 days before each specified vis assessments.	sit. The CDAI is a composite omponents will be captured at the al pain severity, very soft neral well-being) will be self- collected as part of the daily e-diary	
Figure 1: Study Design Flow Chart		
Footnote to Figure 1 now reads:		
EOT = End of Treatment; LTS = long	-term safety; Q4W = every 4 weeks	14
For Induction Studies SHP647-301 ar 12 weeks. For Induction Studies SH Treatment Period = 16 weeks. For M SHP647-307, Treatment Period = 52	P647-305 and SHP647-306, Maintenance Studies SHP647-303 and	
status from the study from which the not meet the response criteria (clini response/remission as appropriate) failure in a maintenance study, or (3) without treatment failure for subject balance of treatment assignment with	cal and/or endoscopic in an induction study; (2) treatment maintenance study completion ts receiving placebo, to facilitate	
** For subjects who are tolerating stu in the judgment of the investigator, st SHP647 becomes available commerci study, or the investigator or sponsor d the interest of subject safety), or the sp the program is stopped in the indica continue in a safety follow-up period investigational product. A subject's m is expected to be approximately 7 ye commercially available, whichever	ally, the subject withdraws from the lecide to withdraw the subject (eg, in ponsor decides to close the study, or ation or completely. Subjects will for 16 weeks from the last dose of naximum duration of participation ears or until SHP647 becomes	
Revised expected duration of study to Added statement to clarify a subject's treatment.	reflect inclusion of subjects with CD. anticipated maximum duration of	Study Synopsis, Methodology Study Synopsis, Maximum duration of subject involvement in the study
Now reads:		Section 3.1, Study Design and Flow
For subjects who are tolerating study the judgment of the investigator, study	y participation may continue until	Chart Figure 1, Study Design Flow Chart
SHP647 becomes available commerci study, or the investigator or sponsor d		Section 3.2, Duration and Study
the interest of subject safety), or the s		Completion Definition
the program is stopped in the indica maximum duration of treatment is	ation or completely. A subject's	Section 7.1.2, Treatment Period

	Protocol Amendment	
	Change(s) Since Last Version of App	
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Ch	ange and Rationale	Section(s) Affected by Change
Subjects will enter a 16-week safety f dose of investigational product. The f A subject's maximum duration of par approximately 6 7 years. It is expected approximately 6 7 years.	inal visit will be in person at the site. ticipation is expected to be	
Revised for clarity.		Section 4.3, Reproductive Potential
Now reads:		
future studies. To minimize the risk o embryo or fetus in the clinical study, subjects who, in the opinion of the im- having children and with their partner	or humans; these will be assessed in f unintentional exposure of the all sexually active male and female vestigator, are biologically capable of rs are at risk of pregnancy, must agree m of contraception, in accordance with the duration of the active treatment.	
(ie, a method that results in a failure r with the preferred and usual lifestyle (eg, calendar, ovulation, symptothern declaration of abstinence for the dura product, and withdrawal are not accep contraception.	nal, postovulation methods), tion of exposure to investigational stable appropriate methods of	
During the induction studies (SHP64' and SHP647 302 -306) or maintenance SHP647-307), the investigator or des will confirm subject's childbearing po- childbearing potential, it must be com- subject has selected the most appropri- permitted list of contraception method		
Subjects must affirm the consistent and selected methods. Regular contracept at the time points specified in Table 1 and Table 3 and Table 4 (for subject will be documented. In addition, the sistic immediately if the selected contra pregnancy is known or suspected.		
4.3.1 Contraceptive Methods for Fe	emale Study Subjects	
induction studies (SHP647-301, SHP	subject's status has changed since the	
	ng potential must already be using an	

	Protocol Amendment	
Summary of	Change(s) Since Last Version of App	roved Protocol
Amendment Number	Amendment Date	Global/Country/Site Specific
1	18 Dec 2017	Global
	ange and Rationale	Section(s) Affected by Change
advised to use acceptable appropriat period and for 16 weeks following th	ive form of contraception, and must be te contraceptives throughout the study e last dose of investigational product. hey should be administered according	
Female subjects should be in one of t	he following categories:	
the second se	ntive months of spontaneous f age); postmenopausal status should mulating hormone (FSH) testing.	
acts: hysterectomy, bilateral	dergone one of the following surgical tubal ligation, bilateral oophorectomy and at least 6 weeks poststerilization or arian failure.	12
test result at baseline. Femal agree to practice true absti	ening and a negative urine pregnancy es of childbearing potential must nence (abstain refrain from sexual pregnancy) or agree to use acceptable	
contraceptives associated wi	r when used consistently and ogestogen-containing) hormonal th inhibition of ovulation (oral, abilized for at least 30 days before the	
 Progestogen-only hormonal inhibition of ovulation plus a 	contraception associated with a barrier method	
• Intrauterine device (IUD)		
Intrauterine hormone-release	ing system (IUS)	
Bilateral tubal occlusion		
 Male sterilization/vasectomi of sperm in the postvasector 	zed partner with documented absence ny ejaculate	
True abstinence (see-Section	14.3).	
4.3.2 Contraceptive Methods for M	ale Study Subjects	
Contraception is required for all sexu their female sexual partners, must ag acceptable appropriate methods of c period and for 16 weeks following th	ree to use 1 of the following	
Appropriate methods of contracept	tion for male subjects are:	
	de; however, if spermicide is not itional contraception (ie, one of those	

		Protocol Amendment	
	Summary of (Change(s) Since Last Version of App	roved Protocol
14	Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
	Description of Cha	nge and Rationale	Section(s) Affected by Change
	listed below) must be used in	addition to a male condom	
•	Male sterilization with docu postvasectomy ejaculate.	mented absence of sperm in the	
(unless		ual partners of male subjects are sterile [surgically or documented	
Se	se of a highly effective method ection 4.4.1 OR an acceptable p te of >1% per year):	of contraception listed in nethod of contraception (failure	
0	however, if spermicide is not	ide (use by female sexual partner); available in the country, additional e listed below) must be used in	
0	Sterile sexual partner		
0	Intrauterine device with spern	nicide (use by female sexual partner)	
0	Contraceptive sponge with sp partner)	ermicide (use by female sexual	
0	Intravaginal system (eg, vagin diaphragm with spermicide, o (use by female sexual partner	r a cervical cap with spermicide)	
	al, implantable, transdermal, or se by female partner) plus a bar	injectable hormonal contraceptive ier method.	
	ale sterilization with absence of aculate.	sperm in the postvasectomy	
	d incorrect statement that total a would be recorded on withdrawa	mount of investigational product l from the study.	Section 4.4, Withdrawal of Subjects
Now re	eads:		
evaluat All sub the pro are una made t Comm must b	tions listed for the End of Treatu ojects who discontinue investigation tocol-specified 16-week follow- able to attend in person for the for o collect information on AEs and ents (spontaneous or elicited) on e recorded. The reason for termine	complaints made by the subject	

	Protocol Amendment	
Summary of	Change(s) Since Last Version of App	roved Protocol
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Cha	ange and Rationale	Section(s) Affected by Change
Updated to reflect inclusion of subject Now reads: Additional reasons a subject may be v include but are not limited to: AEs, SA failure to return for visits.	withdrawn from active treatment	Section 4.4.1, Subject Withdrawal Criteria
A subject should be withdrawn from s	tudy treatment:	
• If a new therapy is initia	ted for UC or CD, or	
• If a subject undergoes su	rgery for UC or CD.	
Updated to include treatment failure d Now reads: Subjects with UC who Enter from Sta SHP647-303 Subjects with UC may enter the study (SHP647-301 or SHP647-302) or mai may have received either active drug of study with clinical response, some with induction study (SHP647-301 or SHP treatment failure in maintenance study To assure ensure that placebo-treated SHP647-302 or SHP647-303 have sup permit assessment of response, assess begin prior to Week 12. Treatment failure is determined by ind and rectal bleeding in subjects who has or failure to improve to a clinically sig responded, who enrolled as treatment enrolment into this trial but then exper-	ady SHP647-301, SHP647-302, or y from either an induction intenance study (SHP647-303), and or placebo. Some subjects entered the thout achieving clinical response in 647-302), or entered following y SHP647-303. subjects from Study SHP647-301, afficient exposure to active drug to ment of treatment failure should not if there is an unexplained clinical er of clinical response. reased (worsened) stool frequency we previously responded to SHP647, guificant degree in those who never failures, or who improved after	Section 4.4.1.1, Treatment Failure
viral or bacterial gastroenter infection should be ruled out other laboratory tests. If a po treatment failure should not treatment has been complete be expected to have resolved	nent failure should be withdrawn from tiologies have been ruled out. All nal product should undergo the	
The ultimate decision of withdrawal f investigator based on the assessment of	rom the active treatment is left to the	

	Protocol Amendment	
	Change(s) Since Last Version of App	
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
benefit and tolerance of the study drug	ange and Rationale	Section(s) Affected by Change
Subjects with CD who Enter from Sta SHP647-307	Sector state and sector states and sector	
Subjects with CD may enter the stu (SHP647-305 or SHP647-306) or ma and may have received either active entered the study with clinical respo clinical response in induction study entered following treatment failure	aintenance study (SHP647-307), drug or placebo. Some subjects onse, some without achieving (SHP647-305 or SHP647-306), or	
To ensure that placebo-treated subj SHP647-306 or SHP647-307 have su permit assessment of response, asse not begin prior to Week 16.	afficient exposure to active drug to	
Treatment failure should be assesse exacerbation or unacceptably low le	-	
Treatment failure is determined by pain and/or very soft stool/liquid sto previously responded to their assign to a clinically significant degree in t enrolled as treatment failures, or wi this trial but then experienced wors	ool frequency in subjects who have ned treatment, or failure to improve hose who never responded, who ho improved after enrolment into	
difficile infection should be cultures and other laborator identified, treatment failure course of treatment has been	ses of disease exacerbation, gastroenteritis and Clostridium ruled out by appropriate stool y tests. If a potential other cause is should not be assessed until a full in completed or if untreated, the to have resolved based on its natural	
	vestigational product should veek follow-up period. The ultimate ive treatment is left to the at of disease activity and other luding need for rescue medication, n for further treatment of CD, l/or the occurrence of a treatment-	
Added treatment failure as a reason fo Now reads:	or withdrawal from the study.	Section 4.4.2, Reasons for Withdrawal
The reason for withdrawal must be de recorded in the subject's medical reco		

CONFIDENTIAL

	Protocol Amendment	
	Change(s) Since Last Version of A	
Amendment Number	Amendment Date	Global/Country/Site Specific
1	18 Dec 2017	Global
		Section(s) Affected by Change
reason) Death Physician decision Pregnancy Screen failure Site terminated by sponsor Study terminated by sponsor Made the following edits to the permitt Section 5.2.1 Permitted Treatment The following treatments for UC are p 5-aminosalicylate (5-ASA; m Immunosuppressants (azathio [6-MP], methotrexate [MTX] The use of Oral glucocorticoid once subject achieves adequat guided by investigator clinica tapering scheme, based on Eu Organisation (ECCO) guidelin	t are not limited to: t are investigator must specify the t are treatments for clarity: t are investigator must specify the t are treatments for clarity: t are investigator must specify the t are permitted; t apering should star t are treatment response and should be t are permitted; t apering should star t are treatment response and should be t are investigator in the study of the t are permitted in the study. biotices are allowed in the study. biotices are allowed in the study. biotices are allowed in the study. coid Tapering – Subjects with coid-dependent subjects per the	Section 5.2, Concomitant Treatmen Subjects with Ulcerative Colitis Section 5.2.1, Permitted Treatment Section 5.2.2, Prohibited Treatment Table 5

	Protocol Amendment	
Summary of (Change(s) Since Last Version of App	proved Protocol
Amendment Number	Amendment Date	Global/Country/Site Specific
1	18 Dec 2017	Global
Description of Cha	nge and Rationale	Section(s) Affected by Change
^a Glucocorticoid dependent subjects Subjects who are unable to reduce equivalent of prednisone 10 mg/day within 3 months of starting glucocor disease 	glucocorticoids below the (or budesonide below 3 mg/day)	
OR		
• Subjects who have a relapse within (Dignass et al., 2012)	of stopping glucocorticoids	
Made the following edits to prohibited	treatments:	
Section 5.2.2, Prohibited Treatment		
The following common treatments are As the subjects are transferred from St SHP647-303, during which these treats washout period is applicable.	udy SHP647-301, SHP647-302, or ments were also prohibited, no	
 Anti-integrin or antiadhesion vedolizumab, efalizumab, etra 	molecule treatment (eg, natalizumab, olizumab).	
 Anti-TNF treatment and other properties. 	r biologics with immunomodulatory	
Live (attenuated) vaccines are	e not permitted during the study.	
Any investigational product	other than the study drug.	
Treatments not listed in this section ma Section 5.2.1 for further details.	ay be considered allowable; see	
No new nonpharmacological therap GI function should be started during		
Added new section to describe permitt treatments for subjects with CD.	ed and prohibited concomitant	Section 5.3, Concomitant Treatment Subjects with Crohn's Disease
New section reads:		Section 5.3.1, Permitted Treatment
5.3 Concomitant Treatment – Subje	cts with Crohn's Disease	Section 5.3.2, Prohibited Treatment
Concomitant treatment refers to all of the first dose of investigational pr the safety follow-up period, inclusive	oduct in this study and the end of	
5.3.1 Permitted Treatment		
Following treatments for CD are per	mitted as concomitant medication:	
• Oral 5-aminosalicylate (5-ASA;	mesalamine) and sulfasalazine.	
• Immunosuppressants (azathiopi [6-MP], methotrexate [MTX]).	rine [AZA], 6-mercaptopurine	
 Oral glucocorticoids; however, t achieves adequate treatment res investigator clinical judgment. 	tapering should start once subject ponse and should be guided by	

Summary of	Protocol Amendment Change(s) Since Last Version of Appr	roved Protocol
Amendment Number	Amendment Date	
Amenoment Number	18 Dec 2017	Global/Country/Site Specific Global
Description of Ch	ange and Rationale	Section(s) Affected by Change
or SHP647-306, or maintenanc glucocorticoid dose is 20 mg/da	and the second	
glucocorticoids are pro	ohibited (see Section 5.3.2).	
• [Table 6 added to describe g with CD.]	glucocorticoid tapering for subjects	
During the glucocorticoid taper, su CD signs or symptoms that, in the attributable to reduction in glucoco occur, the investigator can instruct preceding week's daily dosage. The change (eg, increased stool frequen be recorded.	orticoid dose. If signs or symptoms the subject to revert to the signs or symptoms leading to this	
(diphenoxylate hydrochloride and	IMODIUM [®] (loperamide), LOMOTIL [®] atropine sulfate), tincture of opium, ects should be on stable doses at the nd for the duration of the study.	
Medicinal marijuana (cannabis) un obtained from a licensed pharmacy dose during the study.	nder a physician's prescription, or provider may be used in a stable	
Routine nonlive vaccinations are al	lowed during the study.	
Dietary and herbal supplements an study, provided they are being take baseline visit (Visit 1) and for the d recorded as concomitant medicatio	en at stable doses at the time of the uration of the study. They should be	
Use of nicotine-containing prepara concomitant medication.	tions should be recorded as	
5.3.2 Prohibited Treatment		
The following common treatments study. As the subjects are transfer 305 or SHP647-306, during which t prohibited, no washout period is ap	red from induction studies SHP647- these treatments were also	
• Parenteral and rectally admini	stered glucocorticoids.	
 Prednisone dose >20 mg per da corticosteroid dose and 9 mg/d 		
other nonestablished therapies	pressants used in transplantation or for CD (eg, mycophenolate mofetil, domide, tofacitinib, or tacrolimus).	

_		1000 C	Protocol Amendment	
		1	Change(s) Since Last Version of App	
	Ame	ndment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
		Description of Cha	nge and Rationale	Section(s) Affected by Change
•	Rectall	y administered 5-ASA.		
•	Bismut	h subsalicylate products		
		NF treatment and other ties including biosimilars	biologics with immunomodulatory s.	
		tegrin or antiadhesion m umab, efalizumab, etroli	oolecule treatment (eg, natalizumab, zumab).	
	Lymph aphere		tive monocyte granulocytes	
•	Live (a	ttenuated) vaccines.		
•	Fecal n	nacrobiota transplantatio	DII.	23
•	Any in	vestigational product oth	er than the study drug.	
		s not listed in this section 1 for further details.	may be considered allowable, see	
GI f	unction	should be started durin		
_			d at any time during the study.	
SHP	647-30	6, or SHP647-307.	ntering from Study SHP647-305,	Section 6.2.2, Allocation of Subject to Treatment
SHP	647 is c		the doses (25 mg or 75 mg) of cious dose, subjects may all be	
Now	reads:	<	0	
Sect	ion 6.2.	2 Allocation of Subjects to	o Treatment	
subj	ects wil y 4 wee	l be allocated to receive ei	g the confirmation of eligibility, ther 25 mg or 75 mg of SHP647 SC at on how the subject entered into this	
	·	SHP647-307 without tre 25 mg or 75 mg of SHP6	maintenance study SHP647-303 or atment failure and received either 647 every 4 weeks will continue to SHP647 in this long-term safety	
	•	Randomization will be st or CD) and by the subje	e randomized using a 1:1 allocation. tratified by whether i ndication (UC sets status from the study from this study following, as follows:	
		(1) nonresponse in an in SHP647 302; (2) treatmostudy SHP647 303, or (3)	duction study SHP647 301 or ent failure in a maintenance) maintenance study SHP647 303 atment failure for subjects receiving	

	Protocol Amendment	
Summary of Change(s) Since Last Version of Approved Protocol		
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Change and Rationale		Section(s) Affected by Change
-	nce of treatment assignment within bjects as they consent to take part in different than the numbers assigned 7-303, SHP647-305, SHP647-306, on number represents a unique al product allocated to the subject, ndividual subject treatment is em. tification numbers, separate from ers, may also be assigned to subjects ctated by the study. In these cases, ng identification number may not be or 75 mg dose of SHP647 is , ie based on emergent data from	NY STELOU(S) AIRCLES BY CHARGE
treatment assignment switched to the continue as an open-label study at th Added the following paragraph here (for edits for clarity.	at dose level.	Section 6.1.1, Blinding the Treatment Assignment
Now reads:	the set	Now reads:
The fill volume for all syringes will be the same. Added text to clarify blinding and unblinding of treatment assignment for subjects with CD.		Now reads: Section 9.3, Data Handling Considerations
Now reads:	and the second second second	
The purpose of the blinding in this exter blind in maintenance study SHP647-30 307 for CD subjects while it remains to study SHP647-303 for UC has comple treatment assignment in this study for 1 blinded. Similarly, when Study SHP6 data are unblinded, the treatment as subjects does not need to remain blin	3 for UC subjects and SHP647- hese studies are ongoing. When ted and data are unblinded, the UC subjects does not need to remain 47-307 for CD has completed and signment in this study for CD	

Protocol Amendment Summary of Change(s) Since Last Version of Approved Protocol		
Description of Change and Rationale		Section(s) Affected by Change
Updated to reflect inclusion of subject the study one or the other dose of SHI subjects may be switched over to that <i>Now reads:</i>	P647 is determined to be efficacious,	Section 6.2.2, Allocation of Subjects to Treatment
This is a double-blind study. Followin subjects will be allocated to receive e every 4 weeks. Allocation is dependen study:		
SHP647-307 without tre 25 mg or 75 mg of SHP	I maintenance study SHP647-303 or eatment failure and received either 647 every 4 weeks will continue to f SHP647 in this long-term safety	
Randomization will be s or CD) and by the subj which they are entering (1) nonresponse in an ir SHP647-302; (2) treatm SHP647-303, or (3) mai completion without treat	e randomized using a 1:1 allocation stratified by whether indication (UC ectsstatus from the study from thisstudy following, as follows: aduction study SHP647-301 or ent failure in a maintenance study intenance study SHP647-303 atment failure for subjects receiving ance of treatment assignment within	
Subject numbers are assigned to all su the study. The subject numbers will b in SHP647-301, SHP647-302, SHP64 and SHP647 303-307 . The randomizat number corresponding to investigatio once eligibility has been determined. will receive a randomization number completed a maintenance study (SH to receive the same SHP647 dose in treatment is automatically assigned by	e different than the numbers assigned 47-303, SHP647-305, SHP647-306, tion number represents a unique nal product allocated to the subject, To preserve blinding, all subjects er, including those subjects who IP647-303 or SHP647-307) and are this study. Individual subject	
Investigational product packaging ide randomization numbers/unique identi for specific treatment assignment as d the same investigational product pack assigned to more than 1 subject.	fiers, may also be assigned to subjects lictated by the study. In these cases,	
If during the study either the 25 mg determined to be the efficacious dos the induction and/or maintenance s treatment assignment switched to the continue as an open-label study at t	se, ie based on emergent data from tudies, subjects may have their hat dose, and the study would	
Edited to add studies from which subj extension study.	jects with CD would be entering this	Section 6.2.3, Dosing

	Protocol Amendment	
Summary of Change(s) Since Last Version of Approved Protocol		
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Cha	nge and Rationale	Section(s) Affected by Change
Now reads: As some subjects may enter this study active treatment in the induction (SHP 305 , or SHP647- 302 306) or maintenan study, after the first administration of i must be observed by a member of the total duration should be determined at For subsequent administrations, obser- discretion of the investigator. Injection should be completed by a member of t	647-301, SHP647-302 , SHP647 - nce (SHP647-303 or SHP647-307) investigational product, the subject study staff for at least 30 minutes (the the discretion of the investigator). vation of the subject is at the a site and allergic reaction monitoring	
Updated to include study procedures f	or subjects with CD.	Section 7, Study Procedures
Now reads:		Section 7.1.1, Baseline Visit (Week
Study 7 Study Procedures	C	(0/Day 1)
The investigator may schedule visits (i those listed on the schedules of assess subjects with UC; Table 3 and Table to conduct evaluations or assessments the subject. 7.1.1 Baseline Visit (Week 0/Day 1) Subjects with UC, Entering from Stud	ments (Table 1 and Table 2 for e 4 for subjects with CD), in order required to protect the wellbeing of	Section 7.1.2, Treatment Period Section 7.1.3, Follow-up Period
SHP647-303 For subjects entering into Study SHP SHP647-301 or SHP647-302, procedu will be the baseline (Week 0/Day 1) as	res performed at the Week 12 visit	
For subjects previously enrolled in en maintenance study SHP647-303 and w procedures performed at the Week 52 (Week 0/Day 1) assessments for this e previously enrolled in entering from w who withdrew prior to completion of t performed at the Early Termination (E (Week 0/Day 1) assessments for this e procedures performed during the basel	who completed the treatment period, visit will be the baseline extension study. For subjects maintenance study SHP647-303 and the treatment period, procedures ET) visit will be the baseline extension study. The assessments and	
A screen failure is a subject who has g applicable (and whose parents or legal given informed consent, as applicable) and/or met at least 1 of the exclusion c or administered investigational produc	ly authorized representatives have), failed to meet the inclusion criteria criteria, and has not been randomized	
The composite score and total Mayo s the SHP647-304 study (Week 12/Visit Week 52/Visit 14 or ET visit of the ma Week 0/Day 1 of this extension study)	t 6 of the induction studies, or aintenance study; used for	
For eligible subjects, all relevant study of the induction studies or Week 52 or		

	Protocol Amendment	
Summary of Change(s) Since Last Version of Approved Protocol		
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
	ange and Rationale	Section(s) Affected by Change
assessments completed at Week 12 in ET in the maintenance study should be baseline visit assessments performed After eligibility has been confirmed a assessments have been completed, ea 2 treatment groups as described in Se	ave been completed before any other for this extension study. nd all baseline procedures and ch subject will be assigned 1 of the ction 6.2.2 and the first dose of	
investigational product will be admin Subjects with CD Entering from Stu SHP647-307	the sector of the sector of the sector of the	
For subjects entering into Study SE SHP647-305 or SHP647-306, proce visit will be the baseline (Week 0/D study.		113
SHP647-307 and who completed th performed at the Week 52 visit will assessments for this extension study maintenance study SHP647-307 and of the treatment period, procedures Termination (ET) visit will be the b for this extension study. The assess during the baseline visit are specifie A screen failure is a subject who ha as applicable (and whose parents of have given informed consent, as ap	be the baseline (Week 0/Day 1) 7. For subjects entering from d who withdrew prior to completion s performed at the Early aseline (Week 0/Day 1) assessments ments and procedures performed ed in Table 3. s given informed consent or assent, r legally authorized representatives plicable), failed to meet the st 1 of the exclusion criteria, and has	
For eligible subjects, all relevant st Week 16 of the induction studies or study will be used as the baseline vi	ndy information recorded for Week 52 or ET of the maintenance sit data for this extension study. mpleted at Week 16 in the induction atenance study should have been	
After eligibility has been confirmed assessments have been completed, e 2 treatment groups as described in investigational product will be adm	each subject will be assigned 1 of the Section 6.2.2 and the first dose of	
7.1.2 Treatment Period		
During the first year (48 weeks) of tre subjects will attend study visits every Assessments and procedures to be per Table 1 (for subjects with UC) and	4 weeks (Weeks 4, 8, 12, 16, etc). formed at each visit are specified in	
Assessments and procedures to be per	formed at each visit beginning in	

	Summary of Change(s) Since Last Version of Approved Protocol		
Amendment Number Amendment Date Global/Country/Site Specific			
Amenun	1	18 Dec 2017	Global Global
		ange and Rationale	Section(s) Affected by Change
Treatment Year		cified in Table 2 (for subjects with	Section(s) Anteend by Change
UC) and in Tal For subjects wh the judgment of SHP647 becom study, or the inv the interest of st the program is Once study trea Section 4.4, sub assessments and subjects with U completion of th 7.1.3 Follow-up The safety follo of investigation During the follo	ble 4 for subjects with the are tolerating study of the investigator, study the investigator, study the investigator, study the investigator or sponsor of ubject safety), or the s stopped in the indic turnent has ended, ie, for bjects will attend the E d procedures will be p UC) and in Table 4 for the EOT visit, subjects p Period pow-up period for this p and product administer to w-up period, there with	h CD). drug and receiving clinical benefit in y participation may continue until ially, the subject withdraws from the lecide to withdraw the subject (eg, in sponsor decides to close the study, or	
The assessment UC) and Table querying for SA that are not reso	• 4 (for subjects with AEs, AEs, and concom	ified in Table 2 (for subjects with CD) will be performed, including itant treatments. All AEs and SAEs is visit with be followed to closure (see	
The assessment UC) and Table querying for SA that are not reso Section 8.1). • Ad fo	e 4 (for subjects with AEs, AEs, and concom- olved at the time of this dded statement that bl r up to but not longer	CD) will be performed, including itant treatments. All AEs and SAEs	Section 7.2, Study Evaluations and Procedures
The assessment UC) and Table querying for SA that are not reso Section 8.1). • Ad fo co da • Re co	4 (for subjects with AEs, AEs, and concom- olved at the time of this dded statement that bl r up to but not longer ommunicated in protoc ated 14 Sep 2017). evised from "blood sa	CD) will be performed, including intant treatments. All AEs and SAEs is visit will be followed to closure (see ood and tissue samples may be stored than 25 years (this change was	Procedures
The assessment UC) and Table querying for SA that are not reso Section 8.1). • Ad fo co da • Re co co	e 4 (for subjects with AEs, AEs, and concom- olved at the time of this dded statement that bl r up to but not longer ommunicated in proto- tied 14 Sep 2017). evised from "blood sa ollection" to clarify that ollection, eg urine.	CD) will be performed, including itant treatments. All AEs and SAEs is visit will be followed to closure (see ood and tissue samples may be stored than 25 years (this change was col administrative change memo #2, mple collection" to "laboratory sample at this includes other sample	Procedures
The assessment UC) and Table querying for SA that are not reso Section 8.1). • Ad fo co da • Re co co	e 4 (for subjects with AEs, AEs, and concom- olved at the time of this dded statement that bl r up to but not longer ommunicated in proto- ted 14 Sep 2017). evised from "blood sa ollection" to clarify that ollection, eg urine.	CD) will be performed, including itant treatments. All AEs and SAEs is visit will be followed to closure (see ood and tissue samples may be stored than 25 years (this change was col administrative change memo #2, mple collection" to "laboratory sample at this includes other sample	Procedures
The assessment UC) and Table querying for SA that are not reso Section 8.1). • Ad fo co da • Re co co • M po <i>Now reads:</i> Every effort sho procedures are o time to time the investigator, tha procedures. In t	e 4 (for subjects with AEs, AEs, and concom- olved at the time of this dded statement that blar up to but not longer ommunicated in protoc ated 14 Sep 2017). evised from "blood sa ollection" to clarify that ollection, eg urine. foved investigational point in the ordering of pould be made to ensur- completed as describe are may be circumstan at may make it unfeasi	CD) will be performed, including itant treatments. All AEs and SAEs is visit with be followed to closure (see ood and tissue samples may be stored than 25 years (this change was col administrative change memo #2, mple collection" to "laboratory sample at this includes other sample product administration to the last bullet procedures. e that the protocol-required tests and d. However, it is anticipated that from ces, outside the control of the ible to perform the tests and igator will take all steps necessary to	Procedures
The assessment UC) and Table querying for SA that are not reso Section 8.1). • Ad fo co da • Re co co • M po <i>Now reads:</i> Every effort sho procedures are o time to time the investigator, tha procedures. In t ensure the safet	A (for subjects with AEs, AEs, and concom- olved at the time of this dded statement that blar out to but not longer ommunicated in proto- outed 14 Sep 2017). evised from "blood sa ollection" to clarify that ollection, eg urine. for every dinvestigational point in the ordering of build be made to ensur- completed as describe are may be circumstan at may make it unfeasi- these cases, the investi- y and well-being of the f procedures and assess	CD) will be performed, including itant treatments. All AEs and SAEs is visit with be followed to closure (see ood and tissue samples may be stored than 25 years (this change was col administrative change memo #2, mple collection" to "laboratory sample at this includes other sample product administration to the last bullet procedures. e that the protocol-required tests and d. However, it is anticipated that from ces, outside the control of the ible to perform the tests and igator will take all steps necessary to	Procedures

	Protocol Amendment	
	hange(s) Since Last Version of App	
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Chan	ge and Rationale	Section(s) Affected by Change
 Vital signs and ECG Blood Laboratory sample col Endoscopy (see Section 7.2.2.) Investigational product admitional product admitinter admitinter admitional product admitionadmitional product	1) inistration amples may be stored for up to	
Added reference to the induction and m subjects with CD would enter this exten <i>Now reads:</i> All relevant demographic and baseline o induction studies (SHP647-301, SHP64 302 306) or maintenance study (SHP647	aintenance studies from which asion study. characteristics recorded for the 47- 302, SHP64 7- 305, or SHP647- 7-303 or SHP647-307) will be used	Section 7.2.1, Demographic and Other Baseline Characteristics
as the baseline characteristics for this ex Added new section to describe efficacy		Section 7.2.3, Efficacy Assessments -
New section reads:	assessments for subjects since .	Subjects with Crohn's Disease
7.2.3 Efficacy Assessments – Subjects	with Crohn's Disease	
7.2.3.1 Patient reported Outcome - Co Patient-reported CD signs and sympt PRO-CD daily e-diary (electronic har visits as outlined in Table 3 and Table CD signs and symptoms items using t subjects at the start of the study. Con staff at each visit. The site staff will in appropriate use of the e-diary, partic	om data will be collected using a adheld device) for 14 days before e 4. Subjects will enter data on the e diary that will be provided to apliance will be assessed by site	Section 7.2.3.1, Patient reported Outcome - Crohn's Disease Diary Section 7.2.3.2, Colonoscopy Section 7.2.3.3, Simple Endoscopic
80% (eg, <12 out of 14 diary entries),		Activity Score for Crohn's Disease
80% (eg, <12 out of 14 diary entries), Subjects will be asked to record the for as experienced over the previous 24 h	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data,	
Subjects will be asked to record the fe	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data, iours, in the e-diary:	Activity Score for Crohn's Disease Section 7.2.3.4, Crohn's Disease
Subjects will be asked to record the for as experienced over the previous 24 h	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data, ours, in the e-diary: meric rating scale [NRS])	Activity Score for Crohn's Disease Section 7.2.3.4, Crohn's Disease
Subjects will be asked to record the fo as experienced over the previous 24 h • Abdominal pain severity (nu • Very soft stool/liquid stool fr	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data, ours, in the e-diary: meric rating scale [NRS])	Activity Score for Crohn's Disease Section 7.2.3.4, Crohn's Disease
Subjects will be asked to record the for as experienced over the previous 24 h • Abdominal pain severity (nu • Very soft stool/liquid stool fr type 6/7)	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data, ours, in the e-diary: meric rating scale [NRS])	Activity Score for Crohn's Disease Section 7.2.3.4, Crohn's Disease
 Subjects will be asked to record the for as experienced over the previous 24 h Abdominal pain severity (nu Very soft stool/liquid stool fri type 6/7) Total stool frequency 	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data, ours, in the e-diary: meric rating scale [NRS])	Activity Score for Crohn's Disease Section 7.2.3.4, Crohn's Disease
 Subjects will be asked to record the feas experienced over the previous 24 h Abdominal pain severity (nu Very soft stool/liquid stool fr type 6/7) Total stool frequency Rectal bleeding frequency 	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data, ours, in the e-diary: meric rating scale [NRS])	Activity Score for Crohn's Disease Section 7.2.3.4, Crohn's Disease
 Subjects will be asked to record the feas experienced over the previous 24 h Abdominal pain severity (nu Very soft stool/liquid stool frequency Total stool frequency Rectal bleeding frequency Rectal urgency frequency 	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data, ours, in the e-diary: meric rating scale [NRS])	Activity Score for Crohn's Disease Section 7.2.3.4, Crohn's Disease
 Subjects will be asked to record the feas experienced over the previous 24 h Abdominal pain severity (nu Very soft stool/liquid stool frequency Total stool frequency Rectal bleeding frequency Rectal urgency frequency Nausea severity 	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data, ours, in the e-diary: meric rating scale [NRS])	Activity Score for Crohn's Disease Section 7.2.3.4, Crohn's Disease
 Subjects will be asked to record the feas experienced over the previous 24 h Abdominal pain severity (nu Very soft stool/liquid stool fr type 6/7) Total stool frequency Rectal bleeding frequency Rectal urgency frequency Nausea severity Vomiting frequency 	ularly when compliance is below or lower than the previous visit. ollowing signs and symptom data, ours, in the e-diary: meric rating scale [NRS]) equency (as shown by BSFS	Activity Score for Crohn's Disease Section 7.2.3.4, Crohn's Disease

	Protocol Amendment	
Summary of Change(s) Since Last Version of Approved Protocol		
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
	ange and Rationale	Section(s) Affected by Change
		Section(s) Anected by Change
The first 2 items (abdominal pain so stool frequency) will be used to calc PRO will be calculated using the fo	ulate the 2-item PRO. The 2-item	
calculated based on the 7 n of data collection before th available, the 2-item PRO	nost recent days during the 10 days e visit. If fewer than 7 days are will be calculated on all available fewer than 5 days are available, the	
based on the 7 most recent collection before the colone 7 days are available, the 2-	y, the 2-item PRO will be calculated days during the 10 days of data oscopy preparation. If fewer than item PRO will be calculated on all 5 days. If fewer than 5 days are will be treated as missing.	
The PRO-CD daily e-diary is prese	nted in Appendix 2.	
7.2.3.2 Colonoscopy	I.S.	
Colonoscopy will be performed at t and Table 4.	he time points specified in Table 3	
of the procedure. In this study, bow to be conducted as per local routine		
A complete colonoscopy should be p visualization of rectum, the sigmoid colon, the right colon, the ileocecal Incomplete endoscopy caused by bu during endoscopy, interruption of t cannot be accepted as complete colo impassable stenosis or other CD rel failure to complete the colonoscopy	colon, the left colon, the transverse valve and the terminal ileum. It not limited to complication he endoscopy for any reasons phoscopy with the exception of ated complications as cause of	
The position of the endoscope will be instrument at various levels of inser- features of the intestine as seen dur- induction study (SHP647-305 or SH and any photographs and/or video procedure per local custom should record. Colonoscopy results will be 7.2.3.3 Simple Endoscopic Activity	tion as well as the morphological ing the baseline endoscopy in the IP647-306). The colonoscopy report recordings taken during the be filed in the subject's medical reviewed by a local reader.	
7.2.3.3 Simple Endoscopic Activity Colonoscopy will be evaluated by th time points specified in Table 3 and	e SES-CD scoring system at the	

6	Protocol Amendment	1 Parts 1
	Change(s) Since Last Version of Appr	
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Ch	ange and Rationale	Section(s) Affected by Change
segments investigated and read by visits when colonoscopy is perform on the colonoscopy that was perform dose given at the end of this study.	ed. The baseline score will be based med closest to the start time of the The score for the Baseline on the last colonoscopy performed in	
ulcers, proportion of affected surfa- stenosis [narrowing]) measured in t the Crohn's disease index of severit range from 0–56, with higher value The 4 endoscopic variables are scor (ileum, right/transverse/left colon, a	rs, proportion of surface covered by ce, and presence and severity of the same 5 ileocolonic segments as ty. Overall, values on the SES-CD s indicating more severe disease. red from 0–3 in each bowel segment and rectum):	14
 Presence and size of ulcers 0.5 cm = score 1; 0.5-2 cm = score 2; diameter 	(none = score 0; diameter 0.15) er >2 cm = score 3)	
	e (none = 0; <10% =1; 10%- t of affected surface (none = 0; >75% = 3)	
	wings (none = 0; single, can be e passed = 2; cannot be passed = 3).	
The maximum stenosis score in a se segment cannot exceed 2, so that th total of 11 (Reinsich et al., 2017).	e stenosis scores cannot exceed a	
The SES-CD is presented in Appen	dix 2.	
7.2.3.4 Crohn's Disease Activity Inc	lex	
The CDAI is a composite measure of (abdominal pain severity, very soft general wellbeing) will be self repor recorded as part of the daily e-diary and 5 components will be recorded Table 3 and Table 4.	stool/liquid stool frequency, and rted by the subject and will be y, as described in Section 7.2.3.1	
The CDAI scores at visits specified calculated using the following:	in Table 3 and Table 4 will be	
e-diary data collected ≥10 o	bject-reported PRO-CD daily days before the visit using the same described for the 2-item PRO	
the second se	, medical and physical examination, and hematocrit value) collected at	

	Protocol Amendment		
Summary of Change(s) Since Last Version of Approved Protocol			
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global	
Description of Ch	ange and Rationale	Section(s) Affected by Change	
Change in CDAI has been used as a pivotal trials in the CD indication. 7 CDAI score was first published by 7 al, 1976). The CDAI is presented in Appendix	The algorithm for calculating the William Best and colleagues (Best et		
Updated to add reference to subjects v 306, and SHP647-307.	with CD from SHP647-305, SHP647-	Section 7.2.4, Safety Section 7.2.4.1, Medical and	
7.2.4.1 Medical and Medication His	tory	Medication History	
Medical history, including UC or CD history, cardiac history, and smoking history, and prior medications will be collected at the screening visit (Visit 1) of Study SHP647-301, SHP647-302, SHP647-305, or SHP647-302-306. Concomitant medications and procedures will be documented throughout the SHP647-304 study at the time points specified in Table 1 and Table 2 (for subjects with UC) and Table 3 and		Section 7.2.4.2, Physical Examination (Including Weight) Section 7.2.4.3, Targeted Neurological Assessment	
Table 4 (for subjects with CD). 7.2.4.2 Physical Examination (Inclu)	JS		
of the following body systems: skin (s fistula and mouth for stomatitis), he fields (eyes), abdomen, and examinat symptom complaints by the subject. If physical examination includes revie specifically perianal for fistula and the CDAI assessment.	Table 1 and Table 2 (for subjects for subjects with CD). Complete iew of the following body systems: ad, eyes, ears, nose, and throat; elds (eyes); breast (optional);); extremities; neurologic function; sical examination includes the review specifically including perianal for eart, lungs, confrontational visual ion of body systems where there are for subjects with CD, targeted w of the skin and mucosa, oral cavity for stomatitis as part of		
	points specified in Table 1 and Table 2 and Table 4 (for subjects with CD).		
The complete physical examination p study SHP647-301 or SHP647-302, e SHP647-305 or SHP647-306, or at V maintenance study SHP647-303 or SI (Week 0/Day 1) examination of study identified during this visit will be doc baseline visit (Week 0/Day 1) in phys deemed clinically significant in the op recorded as an AE.	t-at Week 16 of induction study Week 52 or the ET visit of HP647-307 , will be the baseline SHP647-304. Abnormalities umented. Any changes from the ical examination findings that are		
7.2.4.3 Targeted Neurological Asses	sment		
Targeted neurological assessments to	monitor for the development of signs		

Protocol Amendment Summary of Change(s) Since Last Version of Approved Protocol		
Description of Ch	ange and Rationale	Section(s) Affected by Change
and/or symptoms of progressive mult will be performed at the time points s subjects with UC) and Table 3 and Subjects will be evaluated to reveal a following neurological domains: visio coordination/cerebellar function, spec cognition/behavior.	pecified in Table 1 and Table 2 (for Table 4 (for subjects with CD). ny potential abnormalities in the on, motor, tactile sensation,	
Added reference to CD studies SHP6 307.	47-305, SHP647-306, and SHP647-	Section 7.2.4.5, Vital Signs
Clarified that temperature is reported	in degrees Celsius or Fahrenheit.	
<i>Now reads:</i> Vital signs will be measured at the tir		
Table 2 (for subjects with UC) and with CD). Additional collection time be permitted, as necessary to ensure a Vital signs include blood pressure, pu Vital signs should be recorded before samples are collected for laboratory	s or changes to collection times will appropriate collection of safety data. Ilse, respiratory rate, and temperature. Induction of blood	
point. Blood pressure should be deter	l recorded to the nearest mmHg using	
Respiratory rate will be measured wit position. The observer should hold th distraction for the patient (ie, pretend radial pulse) and count the respiration	e extremity of the subject as a ing he/she is taking the subject's	
Oral temperature should be taken by p the tongue for at least 30 seconds and Celsius or Fahrenheit. Tympanic ter	the temperature reported in degrees	
	0/Day 1) vital signs that are deemed f the investigator are to be recorded as ect's medical history as a pre-existing	
Added reference to CD studies SHP6 307.	47-305, SHP647-306, and SHP647-	Section 7.2.5.2, Pharmacodynamic Assessments
Deleted statement regarding a separat each biomarker; this is outlined in the		
7.2.5.2 Pharmacodynamic Assessm	ents	
Predose blood samples will be collect Table 1 and Table 2 (for subjects win subjects with CD) for each of the fol	th UC) and Table 3 and Table 4 (for	
• Serum C-reactive protein (C	RP)	

	Protocol Amendment	
Summary of	proved Protocol	
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Cha	nge and Rationale	Section(s) Affected by Change
 Serum soluble MAdCAM Blood β₇⁺ T cells A separate blood sample will be collect Stool samples will be analyzed for fec indicated in Table 1 and Table 2 (for s Table 4 (for subjects with CD). 	al calprotectin at the time points	
Details of sample collection, handling, provided in the laboratory manual.	, shipment, and analysis will be	
Added reference to CD studies SHP64 307.	17-305, SHP647-306, and SHP647-	Section 7.2.5.3, Health-related Quality of Life Assessments
Deleted reference to Patient Global Im Global Impression of Change as these this study.	assessments are not being done in	
7.2.5.3 Health-related Quality of Lif	e Assessments	
(for subjects with UC) and Table 3 a using an electronic device. All health of questionnaires should be completed be study site staff should check for comp (PRO) questionnaires.	outcome and patient-reported efore any other assessments. The letion of all patient-reported outcome	
It is important to note that PRO assess a different manner than observed or vol differences, no attempt will be made to discrepancies between observed or vol collected from subjects. Adverse even calculated from these solicited data but recorded by the investigator.	olunteered AEs. Given these o reconcile any apparent lunteered AEs and PRO data t incidence rates will not be	
Inflammatory Bowel Disease Questi	onnaire	
The Inflammatory Bowel Disease Que psychometrically validated PRO instru- disease-specific quality of life in subje- including ulcerative colitis and Crohn 32 items, which are grouped into 4 dim- status, systemic symptoms, and social 4 domains are scored as follows:	ument for measuring the ects with inflammatory bowel disease, a's disease. The IBDQ consists of mensions: bowel function, emotional	
• Bowel symptoms: 10 to 70		
• Systemic symptoms: 5 to 35		
• Emotional function: 12 to 84		
• Social function: 5 to 35.		
The total IBDQ score ranges from 32 domain, a higher score indicates better		

6	Protocol Amendment	1 Barris I
Summary of Change(s) Since Last Version of Approved Protocol		
Amendment Number 1	Amendment Date	Global/Country/Site Specific
-	18 Dec 2017	Global
Description of Cha	3	Section(s) Affected by Change
170 corresponds to clinical remission a considered to indicate a clinically mea		
The IBDQ is presented in Appendix 2.		
European Quality of Life 5 Dimensi	ons, 5 Levels questionnaire	
The European Quality of Life 5 Dimer patient completed instrument designed 5 domains: mobility, self-care, usual a anxiety/depression (Brooks et al., 1997 Additionally, scores from the 5 domain index value. The instrument provides a single index value for health status, an health conditions and treatments. The records the respondent's self-rated heat imaginable health state) to 100 (best in	I to assess impact on quality of life in ctivities, pain/discomfort, and I; Brooks, 2003; Kind, 1996). ns may be used to calculate a single a simple descriptive profile and a d is applicable to a wide range of EQ visual analog score (VAS) with on a scale from 0 (worst	
The EQ-5D-5L is presented in Append	lix 2.	
Patient Global Impression of Sever		
of Ch		
The Patient Global Impression of Seve	erity (PGIS) and Patient Global	
Impression of Change (PGIC) will cap		
of change and severity over the course		
used as exploratory measures and to en of other PROs in the proposed studies.		
The PGIS and PGIC are presented in .	· · · · · · · · · · · · · · · · · · ·	
Work Productivity and Activity Imp Col	pairment Questionnaire- Ulcerative	
The Work Productivity and Activity In Colitis (WPAI-UC) is a validated and that is used to assess the effect of UC perform regular activities. The WPAI:	self-administered 6-item instrument on the subject's ability to work and	
Work Productivity and Activity Imp Disease	pairment Questionnaire- Crohn's	
The Work Productivity and Activity Crohn's Disease (WPAI-CD) is a val 6-item instrument that is used to ass subject's ability to work and perform is presented in Appendix 2.	lidated and self-administered less the effect of CD on the	
Corrected of the number of samples to Year 2 and subsequent years, to align		Section 7.2.6, Volume of Blood to Be Drawn from Each Subject
Corrected the blood sample volumes for and in Table 8 (Treatment Year 1) and subsequent years) and the total blood v	Table 9 (Treatment Year 2 and	
Now reads:		
During this study, it is avaasted that a	pproximately 72-76 mL of blood will	

6	Protocol Amendment	nnuovad Pusta-al
Summary of Change(s) Since Last Version of Approved Protocol		
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Ch	ange and Rationale	Section(s) Affected by Change
be drawn from each subject in the first approximately 6354 mL of blood in e expected that an approximate total of from each subject at the EOT visit an 16 weeks following the last dose of in	ach year thereafter. Additionally, it is 28.5 30 mL of blood will be drawn d the safety follow-up visit at	
Added reference to CD studies SHP6 307.	47-305, SHP647-306, and SHP647-	Section 8.1, Definition of Adverse Events, Period of Observation,
Now reads:		Recording of Adverse Events
All AEs are collected from the time the defined follow-up period stated in Se diagnosis rather than a list of sympton considered to be significant by the im SHP647-301, SHP647-302, SHP647 - SHP647-303 307 will be captured as medical history, while ongoing AEs f SHP647-302, SHP647-303 , SHP647 307 will be captured as part of SHP64 throughout the SHP647-304 AEs in S not been made, then each symptom sh should be captured on the appropriate documents. In addition to untoward A investigational product indication sho source document.	ction 7.1.3. Where possible, a ms should be recorded. Resolved AEs vestigator that occurred in Studies 303, SHP647-305, SHP647-306, or part of the SHP647-304 baseline from Studies SHP647-301, -305, SHP647-306, or SHP647- 303 47 304 medical history followed Study SHP647-304 . If a diagnosis has nould be listed individually. All AEs e AE pages in the eCRF and in source AEs, unexpected benefits outside the	on it
Added definitions of unexpected adve serious adverse reaction.	erse event and suspected unexpected	Section 8.1.8, Unexpected Adverse Event
New sections added:	0	Section 8.1.9, Suspected Unexpected
8.1.8 Unexpected Adverse Event		Serious Adverse Reaction
An unexpected adverse event is an specificity, or outcome is not consis or description used in the Referenc "Unexpected" also refers to the AE occurring with a class of drugs or a pharmacological properties of the p mentioned as occurring with the pa investigation.	tent with the term, representation, e Safety Information (RSI). s that are mentioned in the IB as anticipated from the product, but are not specifically	
The expectedness of AEs will be det IB as the RSI. This determination v the number of AEs previously obse might be anticipated from the phar product.	vill include considerations such as rved, but not on the basis of what	
8.1.9 Suspected Unexpected Serious	s Adverse Reaction	
	dverse Reaction (SUSAR) is defined	53 I

	Protocol Amendment	
	Change(s) Since Last Version of App	
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Cha	nge and Rationale	Section(s) Affected by Change
as any suspected adverse reaction to active comparators) that is both seri The event(s) must meet all of the fol • Suspected adverse reac • Serious • Unexpected • Assessed as related to s	ious and unexpected. lowing: tion tudy treatment	Section 8.2.7 December Accord
Clarified that that related, unexpected Now reads: The sponsor or the CRO is responsible authorities, US central institutional rev ethics committees (ECs) of related, un In addition, the CRO is responsible for	e for notifying the relevant regulatory view boards (IRBs), and EU central expected SAEs (ie, SUSARs).	Section 8.2.7, Regulatory Agency, Institutional Review Board, Ethics Committee, and Site Reporting
across the SHP647 program. The investigator is responsible for not relevant local regulatory authority of a as required. Added text to clarify unblinding follow	Il SAEs that occur a this or her site	Section 9.5, Planned Interim
induction and maintenance studies. Now reads: Interim analyses may be conducted to during the program or for-submissions study. Such analyses would be conduc unblinding of the induction and mainte SHP647-302, and SHP647-303. in UC SHP647-303, and/or the induction a SHP647-305, SHP647-306, and SHP induction and maintenance studies of other, special care will be taken to n with ongoing induction and/or main analyses will be described in an SAF testing, these interim analyses have no	Defore the completion of this cted only after completion and enance studies <u>SHP647-301</u> , C, SHP647-301, SHP647-302, and nd maintenance studies in CD, 647-307. In the event that the of one indication finishes before the maintain the blind of the indication tenance studies. Any interim P. As there is no formal statistical	Analysis, Adaptive Design, and Data Monitoring Committee
Added projections for number of CD s Now reads: Approximately 11142453 subjects are No formal sample size estimation was It is estimated that approximately 440 respond to induction treatment will en SHP647-302. Approximately 284 subj SHP647-303 and 390 subjects who co enroll. Estimates are based on Studies	projected to enroll into this study. performed on this study. subjects with UC who did not roll from Studies SHP647-301 and jects who dropped out of study mpleted study SHP647-303 will	Section 9.6, Sample Size Calculation and Power Considerations

	Protocol Amendment	
	Change(s) Since Last Version of App	
Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
Description of Ch	ange and Rationale	Section(s) Affected by Change
rates from the literature (Loftus et al.,	2017).	
following induction treatment will o	the maintenance study SHP647-307 enroll from Studies SHP647-305 and objects who discontinued from study re and 433 subjects who completed nates are based on Studies	
Created new subsection heading 9.8.1 section applies to subjects with UC.	Efficacy Analyses to clarify that this	Section 9.8.1, Efficacy Analyses – Subjects with Ulcerative Colitis
Revised to clarify that efficacy analys analysis (not safety) set.	ses will be performed using the full	ll de la company
Removed "subjects with" and "propo efficacy endpoints for subjects with U		
Now reads:		
9.8.1 Efficacy Analyses – Subjects w	ith Ulcerative Colitis	
Efficacy analyses will be performed u	ising the safety-full analysis set.	
The exploratory efficacy endpoints an	e as follows:	
and at end of study. Remissi patient-reported symptoms u endoscopy as follows: stool least a 1-point change from i SHP647-302) baseline AND	d on composite score, assessed yearly on is defined as a composite score of using daily diary and locally read frequency subscore of 0 or 1 with at nduction study (SHP647-301 or rectal bleeding subscore of 0 AND score of 0 or 1 (modified, excludes	
assessed yearly and at end of Mayo score ≤ 2 with no indi	Remission, based on total Mayo score, f study. Remission is defined as a total vidual subscore (stool frequency, modified, excludes friability], and nt) exceeding 1.	
defined by stool frequency s 1-point change from induction	Clinical remission as defined by as ubscore of 0 or 1 with at least a on study (SHP647-301 or SHP647- ncy subscore, and rectal bleeding y and at end of study.	
	e Partial Mayo score of ≤2 with no time. The partial Mayo score does not ore.	
score, assessed yearly and at	Clinical response based on composite end of study. Clinical response is induction study (SHP647-301 or	

		Protocol Amendment	
	Summary of	Change(s) Since Last Version of App	proved Protocol
Ameno	dment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
	Description of Ch	ange and Rationale	Section(s) Affected by Change
symj 2 po subs blee	ptoms using daily diary ints and at least 30%, we core for rectal bleeding ding ≤ 1 .	e composite score of patient-reported and locally read endoscopy of at least ith an accompanying decrease in the ≥1 point or a subscore for rectal	
scor defin SHP and for r	e, assessed yearly and at ned as a decrease from in 647-302) baseline in the at least 30%, with an acc ectal bleeding ≥ 1 point of	Clinical response based on total Mayo end of study. Clinical response is aduction study (SHP647-301 or total Mayo score of at least 3 points companying decrease in the subscore or a subscore for rectal bleeding ≤ 1 .	
local		Endoscopic remission, as defined by core 0 or 1 (modified, excludes and at end of study.	
Added efficad	cy endpoints for subjects	with CD, in new subsection 9.82	Section 9.8.2, Efficacy Analyses -
Vew section 1	eads:	133	Subjects with Crohn's Disease
.8.2 Efficac	y Analyses – Subjects v	vith Crohn's Disease	
		l using the full analysis set.	
and the second second			
the explorat	ory efficacy endpoints		
	defined by 2-item PR average worst daily a 11-point NRS over th daily stool frequency	er time. Clinical remission is O CD daily e-diary subscore of abdominal pain ≤3 (based on te 7 most recent days) and average ≤2 of type 6/7 (very soft s shown in the BSFS over the	
•	end of study, as meas	c response, assessed yearly and at sured by a decrease in SES-CD of at ction study (SHP647-305 or e.	
•	Clinical remission ov	er time as measured by CDAI <150.	
•	CD daily e-diary sub abdominal pain ≤1 (h 7 most recent days an	er time as defined by the following: scores of average worst daily based on the 4-point scale) over the id average daily stool frequency ≤ 3 stools/liquid stools) as shown in the t recent days.	
•		on by 2-item PRO and enhanced over time (composite endpoint).	
•	Complete endoscopic SES-CD = 0-2.	healing at end of study, defined as	
	Change from inducti	on study (SHP647-305 or SHP647-	

CONFIDENTIAL

	Summary of (Change(s) Since Last Version of App	roved Protocol
Ameno	dment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global
	Description of Cha	nge and Rationale	Section(s) Affected by Change
	stool frequency, rectal vomiting, and incontin score based on subject rectal bleeding, stool f	own by type 6/7 on BSFS), total urgency, rectal bleeding, nausea, nence, and total sign/symptom t daily e-diary entries (sum of requency, abdominal pain, very and rectal urgency) over time.	
•		n study (SHP647-305 or SHP647- domains and total absolute scores	
•	306) baseline in SF-36	n study (SHP647-305 or SHP647- , version 2, acute (physical and nmary scores and individual me.	<i>M</i>
•	Incidence of hospitaliz during the study.	cations and total inpatient days	
•	Incidence of CD-relate procedures during the	ed surgeries and other surgical study.	
•		n study (SHP647-305 or SHP647- D VAS scores and the EQ-5D-5L	
٠		n study (SHP647-305 or SHP647- WPAI-CD questionnaire domains	
•	Subject TSQM total stime.	cores and 4 domain scores over	
•	Incidence of ED visits	during the entire study period.	
using descrip presented by nonresponde endpoints wi confidence in	otive statistics at each as the status at entry into er, maintenance SHP647 Il be summarized by des ntervals. For categorical	be summarized by treatment group sessment visit. Summaries may be the study (eg, induction completer, etc). Continuous scriptive statistics and 95% variables, statistical summaries percentages, and 95% confidence	
The detailed	analyses will be describ	ed in the SAP.	
Revised lang	uage for clarity.		Section 9.10.1, Pharmacokinetic
Now reads:			Analyses
	kinetic analyses will be p etie set PK population.	erformed using based on the	

		Protocol Amendment Change(s) Since Last Version of App	3 0		
A					
Amendr	nent Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global		
		ange and Rationale	Section(s) Affected by Change		
	ge for clarity. yses will be performed	lusing the pharmacodynamics	Section 9.10.2, Pharmacodynamic Analyses		
Added language requirements ar Development Sa		nsor will ensure that local regulatory , including annual safety reporting, ie,	Section 10.1.1, Good Clinical Practice Compliance		
Now reads:					
management or assigned roles for regulations, ICH	monitoring have been or this study in compli I GCP Guideline E6 (1	to whom aspects of the study delegated will undertake their ance with all applicable industry 1996) and E6 R2 (2017), EU pplicable national and local laws and			
the company or inspect study da with current GC regulations and	ganizing/managing the ata, subjects' medical r P and the respective lo	entatives of the study sponsor and/or e research on behalf of the sponsor to ecords, and eCRFs in accordance ocal and (inter)national government and data may additionally be reviewed es.			
before the start- safety reportin (or a nominated and confirmatio	of the study and durin g, ie, Development Sa designee) is responsib n of receipt of any reg	ory authority requirements are met ng the study (including annual afety Update Reports). The sponsor ble for the preparation, submission, ulatory authority approvals required act for shipment to the site.			
Added scales ar	nd assessments for sub	jects with Crohn's disease.	Appendix 2, Scales and Assessment		
Cover page now	v reads:				
Appendix 2 Sca	les and Assessments				
	. For questionnaires, l	be used in the study and are provided anguage-specific validated versions			
For subjects wi	th UC:				
Mayo scoring system					
• Pa		e Ulcerative Colitis (PRO-UC) daily			
• Work Productivity and Activity Impairment – Ulcerative Colitis (WPAI-UC)					
For subjects wi	th CD:				
			1		
• Si	mple Endoscopic Sco	re for Crohn's Disease (SES-CD)			

	Protocol Amendment	
	f Change(s) Since Last Version of A	
Amendment Number	Amendment Date	Global/Country/Site Specific
1	18 Dec 2017	Global
Description of Cl	hange and Rationale	Section(s) Affected by Change
 Patient-reported Out daily e-diary 	come Crohn's Disease (PRO-CD)	
 Work Productivity an Disease (WPAI-CD) 	nd Activity Impairment – Crohn's	
For all subjects:		
 Inflammatory Bowel 	Disease Questionnaire (IBDQ)	
• European Quality of questionnaire (EQ-5D	Life 5 Dimensions, 5 Levels)-5L)	
 Short Form-36 Health 	h Survey (SF-36)	
TSQM		
Made edits to the Mayo Scoring Sys Colitis Activity. <i>Now reads:</i> Mayo Scoring System for Assessm	50	Appendix 2, Scales and Assessments
most of the time 3 = Blood alone passes Subscore, 0 to 3	al non-com	
Findings on endoscopy ^c 0 = Normal or inactive disease 1 = Mild disease (erythema, decrease 2 = Moderate disease (marked erythe friability, erosions) 3 = Severe disease (spontaneous blee Subscore, 0 to 3	ema, lack of vascular pattern, any	
Physician's global assessment ^d 0 = Normal 1 = Mild disease 2 = Moderate disease 3 = Severe disease Subscore, 0 to 3		
The total Mayo score ranges from 0 more severe disease. Source: Sch		

		Protocol Amendment				
	Summary of Change(s) Since Last Version of Approved Protocol					
	Amendment Number 1	Amendment Date 18 Dec 2017	Global/Country/Site Specific Global			
	Description of Cha	inge and Rationale	Section(s) Affected by Change			
a	Each subject serves as his or her or abnormality of the stool frequency	wn control to establish the degree of				
b	The daily bleeding score represent	s the most severe bleeding of the day.				
c	Findings on endoscopy scoring r subscore (value of 1 does not incl	epresents the modified endoscopy lude friability).				
N	OTE: Data will be collected to cale both the modified endoscopy sub subscore (value of 1 including m analysis and to estimate the impa endoscopic subscore.	oscore and traditional endoscopy ild friability) as a sensitivity				
d	The physician's global assessment criteria, the subject's daily recolled general sense of wellbeing, and oth findings and the subject's performa-	ction of abdominal discomfort and her observations, such as physical				

Fornon-commercial

APPENDIX 2 SCALES AND ASSESSMENTS

The following scales/assessments will be used in the study after the implementation of Amendment 4 and are provided in this appendix.

For subjects with UC:

• Mayo scoring system

For subjects with CD:

- Simple Endoscopic Score for Crohn's Disease (SES-CD)
- Crohn's Disease Activity Index (CDAI)

For all subjects:

• Memory aid

Fornon-commercialuse only

Mayo Scoring System for Assessment of Ulcerative Colitis Activity

Stool frequency^a

0 = Normal number of stools for this subject 1 = 1 to 2 stools more than normal 2 = 3 to 4 stools more than normal 3 = 5 or more stools more than normal Subscore, 0 to 3

Rectal bleeding^b

- 0 = No blood seen
- 1 = Streaks of blood with stool less than half the time
- 2 =Obvious blood (more than just streaks) or streaks of blood with stool most of the time
- 3 = Blood alone passes

Subscore, 0 to 3

Findings on endoscopy^c

- 0 = Normal or inactive disease
- 1 = Mild disease (erythema, decreased vascular pattern)
- 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions)
- 3 = Severe disease (spontaneous bleeding, ulceration) For non-commer

Subscore, 0 to 3

Physician's global assessment^d

0 = Normal1 = Mild disease2 = Moderate disease3 = Severe disease

Subscore, 0 to 3

The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

Source: Schroeder et al., 1987

- Each subject serves as his or her own control to establish the degree of abnormality of the stool frequency.
- b The daily bleeding score represents the most severe bleeding of the day.
- Findings on endoscopy scoring represents the modified endoscopy subscore (value of 1 does not include friability).

Note: Data will be collected to calculate the total Mayo score using both the modified endoscopy subscore and traditional endoscopy subscore (value of 1 including mild friability) as a sensitivity analysis and to estimate the impact of the modification on the endoscopic subscore.

d The physician's global assessment acknowledges the three other criteria, the subject's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the subject's performance status.



Simple Endoscopic Score for Crohn's Disease (SES-CD)

Site # Investigator			Subject ID	-		/isit Date m dd yyyy)	
initions of	Simple Endoscopic S	Score for Croh	ın's Disease				
	1.1	Simple En	doscopic Score	for Crohn's Dise	ase values		
able							
of Ulcers	None		Apththous ulcers Large u (© 0.1 to 0.5 cm) (© 0.5 t			Very large ulcers (© >2 cm)	
rated surface	e None	<10%		10-30%		>30%	
cted surface	Unaffected segme	ent <50%		50-75%	1	>75%	
sence of rowing	None	Single passed	, can be 1	Multiple, can to passed	e)	Cannot be passed	
Ende	oscopy Finding	lleum	Right Colon	Transverse Colon	Left Colon	Rectum	
None Aptho Large Very la	ce and size of ulcers us ulcers (Ø 0.1 to0.5cm) ulcers (Ø 0.6to 2cm) arge ulcers (Ø > 2cm)	0000	20000	0000	0000		
Extent None < 10% 10 - 30 > 30%	of ulcerated surface	0000	0000	0000	0000		
	of affected surface ted segment %	0000	0000	0000	0000		
None Single, c	e and type of narrowings an be passed can be passed	0000	0000	0000	0000	0000	

SITE WORKSHEET: Simple Endoscopic Score for Crohn's Disease (SES-CD)

21 Sep 2020

Page 202

Crohn's Disease Activity Index (CDAI)

Crohn's Disease Activity Index (CDAI)

Variable No.	Variable Description	Multiplier	Total
1	No. of liquid or soft stools (each day for 7 days)	X 2	
2	Abdominal pain (0 = none, 1 = mild, 2 = moderate, 3 = severe)	X 5	
3	General well-being (0 = generally well, 1 = slightly under par, 2 = poor, 3 = very poor, 4 = terrible)	X 7	
4	Number of listed complications [arthritis or arthralgia, iritis or uveitis, erythema nodosum or pyoderma gangrenosum or aphthous stomatitis, anal fissure or fistula or abscess, other fistula, fever over 37.8°C (100°F)]	X 20	
5	Use of diphenoxylate or loperamide for diarrhea (0 = no, 1 = yes)	X 30	
6	Abdominal mass (0 = no, 2 = questionable, 5 = definite)	X 10	A
7	Hematocrit [Males: 47-Hct (%), Females: 42-Hct (%)]	X 6	
8	Body weight (1-weight/standard weight) X 100 (add or subtract according to sign)	SX1	
CDAI Score			

CDAI=Crohn's Disease Activity Index; ePRO=electronic patient-reported outcome; Hct=hematocrit.

Note: Variable 5: covers taking medication for symptomatic relief from diarrhoea, eg bulking agents, opiate, etc. Variable 7: Absolute deviation of hematocrit is the difference in hematocrit from standard. A male subject with a hematocrit of 40% has an absolute deviation of 7. Each percentage deviation has a value of 6 points. If hematocrit subtotal is <0, enter 0; Variable 8: is based on Metropolitan Life Tables (these are programmed into the ePRO device.

Percent deviation from standard weight is $(1 - \text{weight/standard weight}) \times 100$; therefore, positive percent deviation represents weight loss, which adds points to the CDAI. Percentage deviation from standard weight = 1 point for each percent deviation. If body weight subtotal is less than minus 10, enter -10.

CDAI Interpretation:

- 0-149 points: Asymptomatic remission (Note: subjects requiring steroids to remain asymptomatic are not considered to be in remission but are referred to as being "steroid dependent").
- 150-220 points: Mild to moderate active CD.
- 221-450 points: Moderate to severe active CD.
- >451 points: Severely active to fulminant disease.

CDAI online estimator: http://www.ibdjohn.com/cdai/ Sources: Best et al., 1976; Best et al., 1979.

CONFIDENTIAL

Memory Aid

Subject Reference Guide on "Memory Aid" Collection and Use

As you have noted in your consent, instead of a daily electronic diary, you may use a memory aid at each visit to track your clinical signs and symptoms for discussion with your study staff to assess your treatment response.

The memory aid can be in any form suitable to you and will not be collected by the study staff. This will assist you to verbally discuss the information about your daily disease activity for the week prior to your scheduled visit with your study staff. They will record it into your medical records/charts.

These written instructions will guide you on the needed information to be provided to your study doctor. For subjects with ulcerative colitis, the information recorded will consist of daily stool count and rectal bleeding as characterized by the Mayo subscore. For subjects with Crohn's disease, the information recorded will consist of the number of soft or loose stools, the level of abdominal pain, and sense of general well-being to calculate the CDAI (Crohn's Disease Activity Index) score.

"Memory Aid" Guidelines for Subjects with Ulcerative Colitis

Every day for the week (7 days) before each visit, you may use the memory aid to help you record the number of bowel movements you had that day and the WORST degree of blood you observed in your stool.

For the number of bowel movements: Every time you go to the toilet and pass liquid or solid material (blood, diarrhea, stool) will count as a bowel movement. You can write down the number of bowel movements you had that day. The day begins at 1 minute after midnight (12:01 AM) and ends at midnight (12:00 AM).

For blood in the stool: At the end of the day, think about the most blood you saw in any bowel movement and write down the number from the table below:

Observation	Number to Record
No blood seen	0
Streaks of blood with stool less than half of the time	1
Obvious blood (more than just streaks) or streaks of blood with stool most of	2
the time	
Blood alone passes	3

21 Sep 2020

You may have a separate entry each day for both number of stool and blood in stool; reporting in this manner helps you track your symptoms to discuss with your study staff at your next visit.

Example 1

October 21, 2020	
Number of bowel movements:	Number you had (for example, 3)
Blood in stool:	If "streaks of blood less than half of the time", write 1

5

October 22, 2020 Number of bowel movements: Blood in stool:

If "no blood seen", write **0**

USE ONLY


Example 2

Date	Bowel Movements	Blood		
October 21, 2020	3,0	1		
October 22, 2020	A CONTRACTOR OF	0		
	Fornoncoli			

"Memory Aid" Guidelines for Subjects with Crohn's Disease

Every day for the week (7 days) before each visit, you may use the memory aid to write down the number of very soft or liquid bowel movements you had that day (Type 6 or 7 from the Bristol Stool Chart), the level of abdominal pain, and your sense of general well-being.

For the number of soft or liquid bowel movements: Each time you go to the toilet and pass very soft or liquid material (Type 6 or 7 below) will count as a very soft or liquid bowel movement. Write down the number of such bowel movements you had that day. The day begins at 1 minute after midnight (12:01 AM) and ends at midnight (12:00 AM). ONLY COUNT very soft or liquid bowel movements that are Type 6 or 7 in the Bristol Stool chart:



Please rate your abdominal pain over the past 24 hours:	How would you rate your general well-being during the past 24 hours?
None	Generally well
Mild	Slightly below par
Moderate	Poor
Severe	Very poor
	Terrible

You may have a separate entry each day for level of abdominal pain, number of very soft/liquid stools, and sense of general well-being; reporting in this manner helps you track your symptoms to discuss with your study staff at your next visit.

Shire Ontamalimab	CONFIDENTIAL	Page 206
SHP647-304 Protocol Amendment 4		21 Sep 2020
Example 1		
October 21, 2020		
Number of very soft/liquid bowel mo	vements: Number you had (for	example, 3)
Abdominal pain:	Mild	
General well-being:	Slightly below par	

October 22, 2020	
Number of very soft/liquid bowel movements:	1
Abdominal pain:	Mild
General well-being:	Generally well

Example 2

Example 2		ce only	
Date	Very Soft/Liquid Bowel Movements	Abdominal Pain	General Well-being
October 21, 2020	3	Mild	Slightly below par
October 22, 2020	1	Mild	Generally well
	Fornonconni		

21 Sep 2020

APPENDIX 3 GLUCOCORTICOID EQUIVALENT DOSES

Glucocorticoid	Equivalent Dose (mg)	
Short Acting:		
Cortisone	25	
Hydrocortisone	20	
Intermediate Acting:		
Methylprednisolone	4	
Prednisolone	5	
Prednisone	5	
Triamcinolone	4	
Long Acting:		
Betamethasone	0.6	
Dexamethasone	0.75	


Reference: Lacy et al., 2001-2002.

Fornoncommercialuse only

APPENDIX 4 GUIDANCE FOR DIAGNOSIS AND TREATMENT OF INCREASED GASTROINTESTINAL SYMPTOMS

If, for any reason, the central laboratory is not available, the preferred diagnostic algorithm is to use the Alere Quik Chek card test (Figure A1).

Figure A1: Algorithm for *C. difficile* Diagnosis Using the Quick Check Card Test



If the Alere Quik Chek card test is not available, then a diagnosis may be established by following either of the algorithms shown in Figure A2 (using PCR for toxin), Figure A3 (using toxigenic culture) or Figure A4 (using toxigenic culture, followed by PCR). The rationale for the method in Figure A3 is that the majority of PCR tests are expected to be negative for toxin, thus obviating the need for the test at the central laboratory. The expected turnaround time at the central laboratory for a GDH card test is expected to be shorter than that for stool culture for *C. difficile* at the local laboratory. The details of the sensitivity and specificity of these tests were reported by Khanna (Khanna et al., 2017).

When medically reasonable, treatment decisions should be deferred until an etiology has been determined. When this is not feasible, management of symptoms should be dictated by the clinical situation.

Figure A2:Alternative 1 for C. difficile Testing Using Local Laboratory When No Alere
Quick Chek Card Test is Available




Figure A3: Alternative 2 for *C. difficile* Testing Using Local Laboratory When No Card Test is Available





Figure A4:Alternative 3 for C. difficile Testing Using Local Laboratory When No Alere
Quick Chek Card Test is Available



Treatment

When medically reasonable, treatment decisions should be deferred until an etiology has been determined. When this is not feasible, management of symptoms should be dictated by the clinical situation. If management requires a prohibited treatment (eg, intravenous glucocorticoids for induction or maintenance studies), the subject should be withdrawn from treatment.

If treatment has been deferred, once an etiology is determined (eg, *C. difficile*, disease exacerbation, Campylobacter), appropriate treatment should be promptly implemented without waiting for a scheduled visit. If the etiology is determined to be *C. difficile*, treatment guidelines conforming to the current IDSA recommendations for *C. difficile* infection (McDonald et al., 2018) or the recent expert review on *C. difficile* infection in IBD (Khanna et al., 2017) should be consulted.

If *C. difficile* infection was identified, clinical improvement should be noted within about 5 days after the start of treatment. If improvement does not occur, the etiology is most likely an IBD flare secondary to *C. difficile*, and treatment failure assessment should proceed per the protocol. Another possible explanation is primary failure of *C. difficile* therapy, which is unlikely.

If an infectious etiology other than *C difficile* is identified, it should be managed as appropriate, with reference to current clinical guidelines (Shane et al., 2017).

If any infectious etiology is determined, the site should contact the medical monitor to make him or her aware of the diagnosis and to discuss treatment and ongoing study participation.